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Summary
Diabetes mellitus is a chronic disease characterized by dysfunctions of the normal
regulation of glucose concentration in the blood. In Type 1 diabetes the pancreas is
unable to produce insulin, while in Type 2 diabetes derangements in insulin secretion and
action occur. As a consequence, glucose concentration often exceeds the normal range
(70-180 mg/dL), with short- and long-term complications. Hypoglycemia (glycemia below
70 mg/dL) can progress from measurable cognition impairment to aberrant behaviour,
seizure and coma. Hyperglycemia (glycemia above 180 mg/dL) predisposes to invalidating
pathologies, such as neuropathy, nephropathy, retinopathy and diabetic foot ulcers.
Conventional diabetes therapy aims at maintaining glycemia in the normal range by
tuning diet, insulin infusion and physical activity on the basis of 4-5 daily self-monitoring
of blood glucose (SMBG) measurements, obtained by the patient using portable minimally-
invasive lancing sensor devices. New scenarios in diabetes treatment have been opened in
the last 15 years, when minimally invasive continuous glucose monitoring (CGM) sensors,
able to monitor glucose concentration in the subcutis continuously (i.e. with a reading
every 1 to 5 min) over several days (7-10 consecutive days), entered clinical research.
CGM allows tracking glucose dynamics much more effectively than SMBG and glycemic
time-series can be used both retrospectively, e.g. to optimize metabolic control therapy,
and in real-time applications, e.g. to generate alerts when glucose concentration exceeds
the normal range thresholds or in the so-called “artificial pancreas”, as inputs of the
closed loop control algorithm. For what concerns real time applications, the possibility
of preventing critical events is, clearly, even more appealing than just detecting them
as they occur. This would be doable if glucose concentration were known in advance,
approximately 30-45 min ahead in time. The quasi continuous nature of the CGM
signal renders feasible the use of prediction algorithms which could allow the patient to
take therapeutic decisions on the basis of future instead of current glycemia, possibly
mitigating/ avoiding imminent critical events. Since the introduction of CGM devices,
various methods for short-time prediction of glucose concentration have been proposed in
the literature. They are mainly based on black box time series models and the majority
of them uses only the history of the CGM signal as input. However, glucose dynamics are
influenced by many factors, e.g. quantity of ingested carbohydrates, administration of
drugs including insulin, physical activity, stress, emotions and inter- and intra-individual
variability is high. For these reasons, prediction of glucose time course is a challenging
topic and results obtained so far may be improved.
The aim of this thesis is to investigate the possibility of predicting future glucose
concentration, in the short term, using new models based on neural networks (NN)
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exploiting, apart from CGM history, other available information. In particular, we first
develop an original model which uses, as inputs, the CGM signal and information on
timing and carbohydrate content of ingested meals. The prediction algorithm is based on
a feedforward NN in parallel with a linear predictor. Results are promising: the predictor
outperforms widely used state of art techniques and forecasts are accurate and allow
obtaining a satisfactory time anticipation. Then we propose a second model, which exploits
a different NN architecture, a jump NN, which combines benefits of both feedforward NN
and linear algorithm obtaining performance similar to the previously developed predictor,
although the simpler structure. To conclude the analysis, information on doses of injected
bolus of insulin are added as input of the jump NN and the relative importance of every
input signal in determining the NN output is investigated by developing an original
sensitivity analysis. All the proposed predictors are assessed on real data of Type 1
diabetics, collected during the European FP7 project DIAdvisor
TM
. To evaluate the
clinical usefulness of prediction in improving diabetes management we also propose a
new strategy to quantify, using an in silico environment, the reduction of hypoglycemia
when alerts and relative therapy are triggered on the basis of prediction, obtained with
our NN algorithm, instead of CGM. Finally, possible inclusion of additional pieces of
information such as physical activity is investigated, though at a preliminary level.
The thesis is organized as follows. Chapter 1 gives an introduction to the diabetes
disease and the current technologies for CGM, presents state of art techniques for short-
time prediction of glucose concentration of diabetics and states the aim and the novelty
of the thesis. Chapter 2 discusses NN paradigms from a theoretical point of view and
specifies technical details common to the design and implementation of all the NN
algorithms proposed in the following. Chapter 3 describes the first prediction model
we propose, based on a NN in parallel with a linear algorithm. Chapter 4 presents an
alternative simpler architecture, based on a jump NN, and demonstrates its equivalence,
in terms of performance, with the previously proposed algorithm. Chapter 5 further
improves the jump NN, by adding new inputs and investigating their effective utility
by a sensitivity analysis. Chapter 6 points out possible future developments, as the
possibility of exploiting information on physical activity, reporting also a preliminary
analysis. Finally, Chapter 7 describes the application of NN for generation of preventive
hypoglycemic alerts and evaluates improvement of diabetes management in a simulated
environment. Some concluding remarks end the thesis.
Sommario
Il diabete mellito e` una patologia cronica caratterizzata da disfunzioni della regolazione
della concentrazione di glucosio nel sangue. Nel diabete di Tipo 1 il pancreas non produce
l’ormone insulina, mentre nel diabete di Tipo 2 si verificano squilibri nella secrezione
e nell’azione dell’insulina. Di conseguenza, spesso la concentrazione glicemica eccede
le soglie di normalita` (70-180 mg/dL), con complicazioni a breve e lungo termine.
L’ipoglicemia (glicemia inferiore a 70 mg/dL) puo` risultare in alterazione delle capacita`
cognitive, cambiamenti d’umore, convulsioni e coma. L’iperglicemia (glicemia superiore
a 180 mg/dL) predispone, nel lungo termine, a patologie invalidanti, come neuropatie,
nefropatie, retinopatie e piede diabetico. L’obiettivo della terapia convenzionale del
diabete e` il mantenimento della glicemia nell’intervallo di normalita` regolando la dieta,
la terapia insulinica e l’esercizio fisico in base a 4-5 monitoraggi giornalieri della glicemia,
(Self-Monitoring of Blood Glucose, SMBG), effettuati dal paziente stesso usando un
dispositivo pungidito, portabile e minimamente invasivo. Negli ultimi 15 anni si sono
aperti nuovi orizzonti nel trattamento del diabete, grazie all’introduzione, nella ricerca
clinica, di sensori minimamente invasivi (Continuous Glucose Monitoring, CGM) capaci
di misurare la glicemia nel sottocute in modo quasi continuo (ovvero con una misurazione
ogni 1-5 min) per parecchi giorni consecutivi (dai 7 ai 10 giorni). I sensori CGM
permettono di monitorare le dinamiche glicemiche in modo piu` fine delle misurazioni
SMBG e le serie temporali di concentrazione glicemica possono essere utilizzate sia
retrospettivamente, per esempio per ottimizzare la terapia di controllo metabolico, sia
prospettivamente in tempo reale, per esempio per generare segnali di allarme quando
la concentrazione glicemica oltrepassa le soglie di normalita` o nel “pancreas artificiale”.
Per quanto concerne le applicazioni in tempo reale, poter prevenire gli eventi critici
sarebbe chiaramente piu` attraente che semplicemente individuarli, contestualmente al
loro verificarsi. Cio` sarebbe fattibile se si conoscesse la concentrazione glicemia futura con
circa 30-45 min di anticipo. La natura quasi continua del segnale CGM rende possibile
l’uso di algoritmi predittivi che possono, potenzialmente, permettere ai pazienti diabetici
di ottimizzare le decisioni terapeutiche sulla base della glicemia futura, invece che attuale,
dando loro l’oppurtunita` di limitare l’impatto di eventi pericolosi per la salute, se non
di evitarli. Dopo l’introduzione nella pratica clinica dei dispositivi CGM, in letteratura,
sono stati proposti vari metodi per la predizione a breve termine della glicemia. Si tratta
principalmente di algoritmi basati su modelli di serie temporali e la maggior parte di
essi utilizza solamente la storia del segnale CGM come ingresso. Tuttavia, le dinamiche
glicemiche sono determinate da molti fattori, come la quantita` di carboidrati ingeriti
durante i pasti, la somministrazione di farmaci, compresa l’insulina, l’attivita` fisica, lo
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stress, le emozioni. Inoltre, la variabilita` inter- e intra- individuale e` elevata. Per questi
motivi, predire l’andamento glicemico futuro e` difficile e stimolante e c’e` margine di
miglioramento dei risultati pubblicati finora in letteratura.
Lo scopo di questa tesi e` investigare la possibilita` di predire la concentrazione glicemica
futura, nel breve termine, utilizzando modelli basati su reti neurali (Neural Network,
NN) e sfruttando, oltre alla storia del segnale CGM, altre informazioni disponibili. Nel
dettaglio, inizialmente svilupperemo un nuovo modello che utilizza, come ingressi, il
segnale CGM e informazioni relative ai pasti ingeriti, (istante temporale e quantita`
di carboidrati). L’algoritmo predittivo sara` basato su una NN di tipo feedforward, in
parallelo ad un modello lineare. I risultati sono promettenti: il modello e` superiore ad
algoritmi stato dell’arte ampiamente utilizzati, la predizione e` accurata e il guadagno
temporale e` soddisfacente. Successivamente proporremo un nuovo modello basato su una
differente architettura di NN, ovvero una “jump NN”, che fonde i benefici di una NN di
tipo feedforward e di un algoritmo lineare, ottenendo risultati simili a quelli del modello
precedentemente proposto, nonostante la sua struttura notevolmente piu` semplice. Per
completare l’analisi, valuteremo l’inclusione, tra gli ingressi della jump NN, di segnali
ottenuti sfruttando informazioni sulla terapia insulinica (istante temporale e dose dei
boli iniettati) e valuteremo l’importanza e l’influenza relativa di ogni ingresso nella
determinazione del valore glicemico predetto dalla NN, sviluppando un’originale analisi
di sensitivita`. Tutti i modelli proposti saranno valutati su dati reali di pazienti diabetici
di Tipo 1, raccolti durante il progetto Europeo FP7 (7th Framework Programme, Settimo
Programma Quadro) DIAdvisor
TM
. Per valutare l’utilita` clinica della predizione e il
miglioramento della gestione della terapia diabetica proporremo una nuova strategia per
la quantificazione, in simulazione, della riduzione del numero e della gravita` degli eventi
ipoglicemici nel caso gli allarmi, e la relativa terapia, siano determinati sulla base della
concentrazione glicemica predetta, utilizzando il nostro algoritmo basato su NN, invece
che su quella misurata dal sensore CGM. Infine, investigheremo, in modo preliminare, la
possibilita` di includere, tra gli ingressi della NN, ulteriori informazioni, come l’attivita`
fisica.
La tesi e` organizzata come descritto in seguito. Il Capitolo 1 introduce la patologia
diabetica e le attuali tecnologie CGM, presenta le tecniche stato dell’arte utilizzate per
la predizione a breve termine della glicemia di pazienti diabetici e specifica gli scopi e le
innovazioni della presente tesi. Il Capitolo 2 introduce le basi teoriche delle NN e specifica
i dettagli tecnici che abbiamo scelto di adottare per lo sviluppo e l’implementazione di
tutte le NN proposte in seguito. Il Capitolo 3 descrive il primo modello proposto, basato
su una NN in parallelo a un algoritmo lineare. Il Capitolo 4 presenta una struttura
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alternativa piu` semplice, basata su una jump NN, e dimostra la sua equivalenza, in
termini di prestazioni, con il modello precedentemente proposto. Il Capitolo 5 apporta
ulteriori miglioramenti alla jump NN, aggiungendo nuovi ingressi e investigando la loro
utilita` effettiva attraverso un’analisi di sensitivita`. Il Capitolo 6 indica possibili sviluppi
futuri, come l’inclusione di informazioni sull’attivita` fisica, presentando anche un’analisi
preliminare. Infine, il Capitolo 7 applica la NN per la generazione di allarmi preventivi
per l’ipoglicemia, valutando, in simulazione, il miglioramento della gestione del diabete.
Alcuni commenti e osservazioni concludono la tesi.
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1
Diabetes and Continuous Glucose Monitoring
(CGM)
According to the World Health Organization (WHO) 347 million people worldwide have
diabetes [1]. In 2004, an estimated 3.4 million people died from consequences of high
fasting blood sugar (more than 80% in low- and middle-income countries) and WHO
projects that diabetes will be the 7th leading cause of death in 2030. From an economic
point of view, diabetes costs were estimated in $ 245 billion in 2012 in the US [2], while
they ranges from 6 to 14% of the total health expenditure in EU countries [3]. This
explains why diabetes is considered one of the most challenging socio-health emergencies
of the 3rd millennium [4] and also why the impact of innovative methodologies and
technologies for diabetes monitoring and treatment can be extremely high. This chapter
gives an overview of the diabetes disease and of its therapy. In this context, the potential
clinical importance of the Continuous Glucose Monitoring (CGM) sensors, appeared
in the market in the early 2000s, is highlighted, together with a short description of
minimally invasive and non invasive CGM devices.
2 Diabetes and Continuous Glucose Monitoring (CGM)
1.1 The diabetes mellitus disease
1.1.1 Glucose-insulin regulatory system
In human beings, glucose represents the basic nutrition factor for the muscles and the only
energy source for the brain. Glucose reaches the blood stream via several mechanisms
(released by the intestine after a meal, or produced by the liver and, in small part, by the
kidneys in fasting conditions) and is then absorbed by tissues either via hormone-mediated
mechanisms (e.g. by the muscles) or via non-mediated transportation (e.g. by the brain).
Thanks to a complex hormonal regulatory mechanism, glucose concentration in blood
of healthy subjects is tightly kept in a limited rage, i.e. 70-180 mg/dL, although it
fluctuates due to utilization and production processes. Different hormones are involved in
this regulation: the most important is insulin, which is produced by the beta-cells of the
pancreas, and is responsible for lowering glucose concentration in blood after a meal by
facilitating the uptake of glucose by the muscles, by suppressing the hepatic production of
glucose by the liver and by controlling the conversion of glucose into glycogen for internal
storage in the liver [5]. If the glycemia decreases and sufficient nutrients delivery to the
tissues is not guaranteed, counter-regulatory hormones, such as glucagon, are secreted
and stimulate the conversion of glycogen to glucose, allowing to keep the concentration
of glucose in the safety range [6].
Figure 1.1 shows a rough description of glucose-insulin regulatory system. Glucose
is used by many organs, tissues and cells. Some, like brain or red blood cells, consume
glucose continuously and independently of insulin and the interruption of this supplying
may cause severe damages. For muscles, fatty tissue and liver the absorption of glucose
is proportional to insulin concentration. Glucose in blood derives both from intestinal
absorption of Carbohydrate (CHO) (not shown in Figure 1.1) and from internal production.
In particular, the latter consists in the conversion to glucose of glycogen stored in the
liver or in the so-called gluconeogenesis (the “re-construction” of glucose using substrate
derived from glucose degradation). An increase in blood glucose concentration causes an
increase in insulin secretion. Glucose and insulin concentration have the same effect on
the glucose production and utilization: an increase in insulin (or glucose) concentration
causes a decrease of glucose production and an increase of glucose utilization by muscle,
while there is no influence on glucose utilization by brain.
1.1.2 Types of diabetes mellitus
The term diabetes mellitus describes a metabolic disorder of multiple aetiology charac-
terized by chronic hyperglycemia with disturbances of CHO, fat and protein metabolism
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Figure 1.1: Scheme of the glucose-insulin regulatory system. Continuous arrows represent
fluxes. In particular, brown ones are referred to glucose, while black ones to insulin. Dashed
arrows represent the positive and negative control, indicated with “+” and “-” respectively.
The green dotted arrows highlight the self-control employed by a substance, while red dotted
arrows indicate the control of a substance over the other one.
resulting from defects in insulin secretion, insulin action, or both. Diabetes mellitus is
diagnosed, according to the WHO, by the classic symptoms of polyuria, polydipsia and
unexplained weight loss, and/or a hyperglycemia (≥200 mg/dL) in a random sample,
or fasting (no caloric intake for 8 h) plasma glucose higher than 126 mg/dL, and/or
postprandial value higher than 200 mg/dL. (2 h plasma glucose level during an oral
glucose tolerance test) [7]. Two major types of diabetes, requiring distinct therapy, can
be distinguished.
1.1.2.1 Type 1 Diabetes (T1D)
Type 1 Diabetes (T1D), or Insulin Dependent Diabetes Mellitus (IDDM), is characterized
by loss of insulin production by the pancreatic beta cells, leading to total insulin deficiency.
Only approximately 5% of people with diabetes have this form of the disease [8]. In
most cases, T1D has an autoimmune origin and various factors may contribute to its
onset, including genetics and exposure to certain viruses. T1D typically appears during
childhood or adolescence, thus it is also called “juvenile diabetes”, however, it also can
develop in adults. Despite active research, T1D has no cure, although it can be managed.
The therapy of T1D consists in exogenous injections of insulin to compensate for
missing secretion from the pancreas. Before each meal, the patient decides the insulin
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bolus to be injected to allow the tissues to uptake the glucose that will reach the
bloodstream. Such bolus is defined according to tables designed by the physician and
tuned on the patient’s history. Moreover, either slow-acting insulin or a continuous
infusion of insulin are administered to mimic the so called insulin basal rate, which allows
the body to continuously absorb the glucose which is produced mostly by the liver.
1.1.2.2 Type 2 Diabetes (T2D)
Type 2 Diabetes (T2D), or Non-Insulin Dependent Diabetes Mellitus (NIDDM), is a
chronic condition that affects the way the body metabolizes glucose. In T2D, the organism
either resists the effects of insulin or does not produce enough insulin to maintain a
normal glucose level. It is frequently associated with obesity and a sedentary lifestyle.
T2D is the most common diabetes type, accounting for about 90% to 95% of all diagnosed
cases [9] and mostly affects adult people, however, it increasingly affects children as
childhood obesity increases [10].
There’s no cure for T2D, but it can be managed by tuning appropriately Physi-
cal Activity (PA) and diet. In some T2D subjects, after years of overproduction of
insulin, the pancreas may cease to secrete insulin and exogenous insulin infusions become
necessary [11].
1.1.3 Diabetes-Related Complications
In diabetes, the concentration of glucose in blood, referred in the following as Blood
Glucose (BG), often exceeds the euglycemic range. Hypoglycemia and hyperglycemia
might lead to short and long term complications. Hypoglycemia affects mostly the brain,
given its continuous glucose demand and it can progress from measurable cognition
impairment to aberrant behaviour, seizure and coma [12]. Several factors can cause
hypoglycemia in people with diabetes, including taking too much insulin or other diabetes
medications, skipping a meal, or exercising harder than usual. Hyperglycemia, if left
untreated, can become severe and lead to serious complications requiring emergency care,
such as diabetic coma. In the long term, persistent hyperglycemia, even if not severe,
can lead to several invalidating complications, including micro-vascular complications
(involving small blood vessels) and macro-vascular complications (involving large blood
vessels) [13]. The former, like neuropathy, nephropathy and retinopathy can lead to nerves
damage, renal failure and blindness respectively. The latter to coronary heart disease,
strokes and peripheral vascular disease. Several factors can contribute to hyperglycemia
in people with diabetes, including food and PA choices, illness, or not taking enough
glucose-lowering medication.
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In order to prevent the onset of these complications, diabetes therapy attempts to
keep BG within the euglycemic range. As said in Subsection 1.1.2, this is usually done
tuning diet, PA and use of appropriate medications, like insulin injections before meals
and to mimic the basal insulin rate, in T1D. However, insulin dosing is a difficult task and,
often, patients are not able to maintain their glucose concentration “in target” because of
insulin under/overdosing. It is very important to keep the glycemic concentration in blood
monitored in order to effectively tune the insulin bolus and basal rate. Patients with
diabetes are thus required to monitor their blood glucose levels frequently, as explained
in the following section.
1.2 Technologies for glucose monitoring in diabetes
therapy
1.2.1 Self-Monitoring Blood Glucose (SMBG)
The most established and used technique to monitor glucose concentration is SMBG.
Devices for SMBG have become available in the early seventies, and have now become a
pocket tool that any diabetic uses daily. The most common test for measuring BG involves
pricking a finger with a lancet device to obtain a small blood sample, applying a drop of
blood onto a reagent test-strip, and determining the glucose concentration by inserting the
strip into a measurement device. Different manufacturers use different technologies, but
most systems measure an electrical characteristic proportional to the amount of glucose
in the blood sample [14]. Examples of commercially available glucometers are shown
in Figure 1.2. While the firs two are standalone devices (One TouchR©UltraMiniR© [15]
and Accu-ChekR©Aviva-Plus [16]) and only need to be fed with a measurement strip, the
third device (iBGstar
TM
marketed by sanofi-aventis [17]) can be connected to an Apple
iPhone or iPod touch to register all the information that a patient needs, and can be
interfaced with pieces of software that run on the smartphone.
In the majority of cases, SMBG time-series are analyzed and interpreted by the
Figure 1.2: Commercial SMBG devices. From lef to right: One TouchR©Ultra MiniR© [15],
Accu-CheckR©Aviva-Plus [16] and iBGstar
TM
[17].
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physician during periodic visits, e.g. every two/four months and the individual therapeutic
plan is revised accordingly. SMBG samples can also be used in real-time by the patient
to assess somewhat the current effectiveness of glucose control. However, the sampling
procedure cannot be repeated more than 5-6 times a day, indeed, the finger prick is
painful for the patient, who needs to collect a drop of blood from the fingertips at each
measurement. Thus, due to their sparseness, SMBGs cannot give complete information
of glycemic excursions and dynamics and it may happen that glucose subtly exceeds the
safe euglycemic range without the patient’s awareness [18]. To overcome the limitations
of SMBG monitoring, in the last 15 years devices able to measure glucose concentration
almost continuously, the so called CGM sensors, have been developed and commercialized
and are becoming even more popular and widely adopted by diabetic patients.
1.2.2 CGM
To overcome SMBG limits, during the last 15 years, CGM sensors have been developed.
CGM devices measure the glycemic level in the interstitial fluid in place of the blood
compartment, as done instead by SMBG, thus their invasiveness is minimal and glucose
concentration can be measured in real time with a 1-5 min sampling period and for up
to 7-10 consecutive days (with the perspective of increasing the duration of their life up
to 14 days in the next few years).
CGM sensors can essentially be divided into two categories: implantable needle-type
enzyme sensors, and systems based on the use of a micro-dialysis probe coupled with a
glucose biosensor. In the rest of this section we will give a brief overview of some popular
commercial sensors. Reviews of how these sensors work at the biochemistry level, with a
critical discussion of pros, cons and perspectives and a comprehensive bibliography are
reported in [19–22].
1.2.2.1 Subcutaneous needle-based enzyme sensors
Needle-type enzyme sensors exploit glucose-oxidation reaction and measure the current
flowing from the working to the counter electrode. The glucose-oxidase measurement
principle is based on the generation of hydrogen peroxide via the enzyme glucose oxidase.
After this step, a mediator conveys the electrons to the working electrode, where a potential
is applied to oxidize the mediator itself. Since the sensor is implanted, enzyme and
mediator should be immobilized onto the electrode surface to avoid them to dissolve in the
interstitial fluid. A popular mediator is oxygen, because it is available in the interstitial
fluid without requiring immobilization [20]. However, since oxygen concentration in
interstitial fluid can be several hundred times smaller than the glucose concentration,
1.2 Technologies for glucose monitoring in diabetes therapy 7
techniques to limit glucose concentration should be adopted [23, 24]. The reaction,
considering oxygen as a mediator, is the following:
glucose +O2
glucose oxidase−−−−−−−−−→ H2O2 + gluconic acid
H2O2
∼700mV−−−−−→ O2 + 2H+ + 2e−
(1.1)
Some examples of commercially available subcutaneous sensors include the FreeStyle
NavigatorR©(Abbott Laboratories, Alameda, CA, USA), the Dexcom SEVENR©PLUS and
Dexcom G4R©PLATINUM (Dexcom Inc., San Diego, CA, USA), the MiniMed Guardian
Real-Time (Medtronic MiniMed, Northridge, CA, USA), to mention a few.
The FreeStyle NavigatorR©CGM System consists of four components (see Figure 1.3):
a miniature electrochemical sensor placed in the subcutaneous adipose tissue, a disposable
sensor delivery unit, a radiofrequency transmitter connected to the sensor, and a hand-
held receiver to display continuous glucose values [25]. The sensor can be used for 5 days,
the glucose data on the receiver are updated once a minute1 and include a trend arrow
to indicate the direction and rate of change averaged over the preceding 15 min. The
user interface of the receiver allows the threshold alarms to be set at different glucose
levels. The receiver contains a built-in Free-Style blood glucose meter for calibration of
the sensor as well as for confirmatory blood glucose measurements. It was approved by
Food and Drug Administration (FDA) in 2008 [26,27].
Figure 1.3: FreeStyle NavigatorR©CGM System [27]. From left to right: miniature electro-
chemical sensor placed in the subcutaneous adipose tissue, sensor delivery unit, radiofrequency
transmitter connected to the sensor and hand-held receiver to display continuous glucose
values.
The Dexcom SEVENR©PLUS sensor consists of three parts (see Figure 1.4(a)): a
small sensor placed in the subcutaneous adipose tissue, a wireless transmitter, which has
approximately the same size of a quarter coin, and a receiver [28]. It performs a new
1The FreeStyle Navigator sensor used during the DIAdvisor
TM
DAQ trial (see Appendix B) returned
raw current data with a sampling time of 1 min and glucose concentration data every 10 min. SMBG
used for calibration were also rendered available, thus, once the data had been downloaded, the raw
current data could be calibrated to obtain glycemic data every minute for testing prediction algorithms.
Nevertheless, some of the literature models discussed in Section 1.5 use FreeStyle Navigator glucose data
with a sampling period of 10 min.
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measure every 5 minutes for 7 days. The receiver displays the sensor glucose value along
with a graph showing glucose trend of the last 1, 3 or 9 h. The receiver contains memory
up to 30 days of continuous glucose information and has programmable high and low
glucose alerts and a non-changeable low glucose alarm set at 55 mg/dL. It was approved
by FDA in 2009 [29]. An improvement of this sensor is the recently commercialized
Dexcom G4R©PLATINUM, approved by FDA in 2012 [30], whose performance are notably
better than those of the SEVENR©PLUS, as reported in [30,31].
(a) Dexcom SEVENR©PLUS sensor.
From left to right: the sensor, the trans-
mitter and the receiver [28].
(b) Dexcom G4R©PLATINUM sensor.
From left to right: the sensor, the receiver
and the transmitter [30].
Figure 1.4: Dexcom SEVENR©PLUS and Dexcom G4R©PLATINUM sensors.
The Guardian Real-Time device consists of the GuardianR©REAL-Time CGM System
monitor (Figure 1.5, left), the MiniLink REAL-Time Transmitter and the glucose sensor
inserted in the subcutis (Figure 1.5, right). This sensor performs a new measure every
5 minutes for 3 days [32]. The receiver contains memory up to 21 days of continuous
glucose information and has alerts if a glucose level falls below or rises above pre-set
values. It was approved by FDA in 2005. This sensor is usually integrated with an
insulin pump to provide the MiniMed Paradigm Real-Time Insulin Pump and Glucose
Monitoring System [33].
Figure 1.5: The GuardianR©REAL-Time [32]. REAL-Time CGM System monitor (left), the
MiniLink REAL-Time Transmitter together with the glucose sensor inserted in the subcutis
(right).
1.2.2.2 Microdialysis sensors
Another type of minimally invasive subcutaneous CGM sensor is based on a microdialysis
system, which exploits a hollow fiber, permeable to glucose and other small molecules
and impermeable to larger molecular species, inserted subcutaneously. A fluid isotonic to
the interstitial fluid, but containing no glucose, is pumped through the membrane fibers,
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so that the glucose in the interstitial fluid, driven by osmotic forces, diffuses through
the membrane into the fluid stream, and the glucose concentration in the pumped fluid
reaches an equilibrium with the glucose concentration in the interstitial fluid. The fluid
flowing through the microdialysis membrane is then pumped to a glucose detector, which
usually measure glucose with the amperometric approach, exploiting glucose oxidase
and oxygen. The major advantages of microdialysis are the possibility of exposing the
detector to atmospheric oxygen, (avoiding the deficit that characterizes glucose oxidase
electrochemical sensors using O2/H2O2 as mediator), and the fact that the measurement
is not affected by biofouling mechanisms, since the sensor is outside the body. However,
new issues are represented by the necessity of a biocompatible microdialysis membrane,
and by the time lag due to the pipe between the microdialysis membrane and the glucose
sensor.
The GlucoDayR©by Menarini Diagnostics (Florence, Italy) is a microdialysis-based
glucose monitoring system [34, 35], based on enzymatic-amperometric measurement
analyzing the fluid coming from the subcutis of the abdominal region. The system,
shown in Figure 1.6, comprises an apparatus with dimension comparable to a walkman,
a sensor fibre no thicker than a hair as well as two plastic bags (one for the buffer
solution, one for the waste products) as disposables. The apparatus contains also a
measurement cell and a peristaltic pump. The buffer solution is pumped from a bag
into the subcutaneous tissue through the microfibre and rinses the interstitial fluid,
from which the measurements are obtained every 3 min and stored in memory. Data
are downloaded after monitoring (maximum monitoring time, 48 h). It incorporates
safety alarms for hypo- or hyperglycemia events. Recently, the same company launched
the GlucoMenR©Day (currently waiting the Conformite´ Europe´enne (CE) mark), which
overcomes various shortcomings of its predecessor [36]. It is smaller and more compact,
and has a longer lifetime (100 h), is more stable and embeds different algorithms for
signal processing and data management [37,38].
Figure 1.6: GlucoDayR©S device: receiver (left) and transmitter (right) attached to the
inserted sensor [35].
Another sensor based on a microdialyses principle is the SCGM 1 sensor (Roche
Diagnostics, Mannheim, Germany) [39,40].
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1.2.2.3 Other techniques for CGM
As alternative to subcutaneous sensors based on the glucose-oxydase enzyme and to
sensors based on microdialysis, other systems and prototypes have been proposed for
CGM monitoring. We cite some of them for sake of completeness.
• Iontophoresis and Sonophoresis. These techniques require the stimulation
of the skin from outside, in order to extract glucose from the skin for its direct
measure. The iontophoresis is based on the extraction of glucose associated with
the application of an electrical potential, causing the migration of ions from beneath
the skin. In particular, sodium and chloride are pulled towards the cathode and
anode respectively. The ion flow also causes neutral molecules like glucose to
migrate across the skin along with the water hydrating the ions. Glucose is then
detected with the enzymatic reaction reported in eq 1.1. The GlucoWatch G2
Biographer (Cygnus Inc., Redwood City, CA, not on the market any more because
it caused skin irritation in users), is an example of device which used the reverse
iontophoresis. Sonophoresis uses low-frequency ultrasounds to create an array of
microscopic holes on human skin, which increase its permeability, allowing glucose
to trespass the skin to be directly measured. The SonoPrep (Echo Therapeutics
Inc., Philadelphia, PA [41]) is a device which exploits this technology.
• Micropores and Microneedles Techniques. Micropores techniques perforate
the stratum corneum without perforating the full thickness of the skin with the aid
of pulsed laser or local heat. Interstitial fluid is then collected applying vacuum
and a direct measure of glucose is obtained.
• Noninvasive CGM. Non-invasive CGM sensors measure glucose concentration
through the skin without extracting blood or interstitial fluid or without a needle
penetrating the skin for reaching these fluids. Hence, these sensors are more comfort-
able for the patient than the previously described sensors and do not cause adverse
physiological reactions. These sensors measure different physical properties of the
skin and underlying tissues which are modulated by glucose concentration changes.
Among the physical principles exploited for this scope, we can list optical techniques,
e.g. based on absorption phenomena (Near InfraRed Spectroscopy, Mid InfraRed
Spectroscopy), on scattering (Raman Spectroscopy, Occlusion Spectroscopy), on
Optical Coherence Tomography, on Fluorescence Technologies; Photoacoustic Spec-
troscopy; Impedance Spectroscopy; Electromagnetic Sensing; Thermal Emission
Spectroscopy. A general idea is to combine several of these techniques to obtain
signals which are correlated to the concentration of glucose in blood (multisensor
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concept). Although non-invasive CGM are attractive from a user’s point of view,
they do not offer the same accuracy of subcutaneous sensors yet. In particular they
are difficult to calibrate, and they are not yet usable to extract reliable information
on glucose dynamics [42].
In this thesis, only subcutaneous minimally invasive CGM will be considered, hence
the acronym CGM will be always referred to these kind of devices.
1.2.3 Offline and online use of CGM time series
Diabetic patients who monitor themselves via SMBGs and CGM can gather a lot of
information regarding their pathology. In particular, patients can exploit such information
in several ways, e.g. to tune their insulin therapy. Moreover, the advent of CGM devices
offers a richer insight of glucose dynamics and their relation with exogenous events.
CGM time series can be analyzed retrospectively to evaluate glucose variability,
e.g. [43] and to suggest the refinement of the patient individual therapy. In clinical
practice, it is today largely accepted that CGM sensors can significantly improve diabetes
control and reduce HbA1c [44–46]. Furthermore, CGM has been recommended, possibly
integrated in the so called sensor-augmented pump, for the treatment of subjects prone
to hypoglycemia, e.g. [47, 48].
Apart from offline analysis of quasi continuous glucose recordings, CGM sensors allow
interesting online applications, as the generation of hypo and hyperglycemic alerts as soon
as interstitial glucose exceeds those critical thresholds, with the possibility for the patient
of timely treating/mitigating the event (by a sugar ingestion to compensate a hypo or
an insulin administration to tackle a hyper), see [49] for a review. Moreover, a research
community of applied mathematicians and biomedical engineers is active to improve
CGM sensor outcomes and strengthen the impact of applications by developing real-time
algorithms for denoising, signal enhancement, prediction of glucose time course and alert
generation, see e.g. [50,51] for reviews and [52] for the recently proposed “algorithmically
smart sensor” concept. In addition, the CGM sensor is crucial in the development of the
Artificial Pancreas (AP), a minimally-invasive pump which subcutaneously administers
insulin according to a temporal profile determined in real-time by a sophisticated closed-
loop control algorithm that has CGM measurements as one of its key inputs, see e.g [53,54]
for recent perspectives.
Of particular interest in the present thesis is the possibility of predicting glucose
concentration in the short term (approximately 30-60 min in advance), allowing the
patient to take therapeutic decisions on the basis of future instead of current glycemia,
possibly mitigating/ avoiding imminent critical events.
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1.3 Short-term prediction of glucose concentration from
CGM sensor data
Glucose dynamics are influenced by many factors, e.g. CHO intake, administration of
drugs including insulin, PA, stress, emotions. Furthermore, inter- and intra-individual
variability is high. For these reasons, prediction of future glucose levels poses several
challenges. To better highlight glucose prediction issues, in Figure 1.7 we show the
time-course of glucose concentration (black dots linearly interpolated to facilitate the
visualization of the time series) measured during the day of a T1D subject by the
Dexcom SEVEN PLUS CGM sensor, together with information on insulin injections
(green stems) and on CHO ingested during meals (blue stems). Hypo- and hyperglycemic
thresholds are also reported (thin horizontal lines). As we can note, during the first night
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Figure 1.7: Representative CGM signal (black dots linearly interpolated to facilitate the
visualization of the time series) measured by the SEVEN PLUS device and information on
insulin doses (green stems) and CHO content of meals (blue stems) of a T1D.
glucose concentration was in the euglycemic range, but fell below 70 mg/dL around time
07:30. The subject had breakfast around 8:00 but did not inject any insulin bolus in
concomitance to the meal. During the morning, around 09:00, glucose concentration
reached hyperglycemic values and the subject injected a correction bolus of insulin
around time 10:00 and re-entered the euglycemic range around time 12:00. At time
13:00 and 19:00 the subject ate and injected insulin to counterbalance the effects of
CHO. Notably, around time 17:00 the CGM signal fell in the hypoglycemic range and
the subject promptly ingested 10 g of sugar to increase his glycemia and re-enter the safe
range. After dinner, around time 20:00, glycemia crossed the hyperglycemic threshold
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and re-entered the safe range only around time 01:00. The subject also experienced a
hypoglycemic event during the second night, at time 04:00 and he medicated it by timely
ingesting 10 g of sugar. This example confirms that, in principle, forecasting glucose
concentration should use several inputs: certainly glucose concentration measured by the
CGM sensor, but also ingested CHO and injected insulin play a major role. However,
accounting for all these inputs, formalizing them in mathematical terms and extracting
useful signals from them is not easy. For these reasons, as better discussed in Section 1.4,
the majority of published glucose prediction methods solely use the CGM signal as input.
While we refer the reader to [50, 51] for comprehensive reviews on algorithms for
prediction of glucose concentration, in the rest of this chapter we will shortly describe
some class of widely used prediction models, paying particular attention to Neural
Network (NN)-based algorithms. Section 1.4 reviews approaches based only on past
CGM data. Section 1.5 presents algorithms proposed in the last five years, able to exploit
not only CGM, but also information on insulin therapy, ingestion of CHO and PA, which
are known from physiology to influence glucose concentration dynamics. Section 1.6
summarizes contributions demonstrating the clinical utility of prediction for reducing
hypoglycemia. Section 1.7 states the aim of the present thesis and, finally, Section 1.8
gives an outline of the thesis.
1.4 Prediction methods based only on CGM information
1.4.1 AR and ARMA models
Two popular time-series modelling approaches adopted for short-time prediction are
based on Auto-Regressive (AR) and Auto-Regressive with Moving Average (ARMA)
models. These techniques assume that future glucose concentration can be expressed as a
linear function of previous glucose measurements and do not use neither prior information
nor meal or insulin information.
In [55] a time invariant AR model of order 10 was proposed. The model was identified
on data of 9 T1D subjects, monitored for approximately 5 consecutive days with the
iSense CGM device [56], with a sampling time of 1 min. Parameters were optimized
using regularized Least Squares (LS) and the models were assessed in terms of Root
Mean Square Error (RMSE) and Error Grid Analysis (EGA) [57], considering Prediction
Horizon (PH) of 30, 60 and 120 min. Both subject specific and subject invariant models
were evaluated obtaining comparable results. In [58] Gani and colleagues proposed an
AR(30) time invariant subject specific model. The models were optimized and assessed
on data of 9 T1D subjects, monitored for approximately 5 consecutive days with the
14 Diabetes and Continuous Glucose Monitoring (CGM)
iSense CGM device (sampling time of 1 min). The first 2000 min of every time series
were used for optimizing the AR model parameters and the remaining 2000 min were
used as test data. Three cases were considered: scenario 1, in which raw glucose data
were used; scenario 2, in which glucose data where smoothed before computing AR
coefficients and scenario 3, in which smoothing and regularization were used. Parameters
were determined via LS and the models were assessed on PH of 30, 60 and 90 min in
terms of RMSE and time anticipation. Only scenario 3 guaranteed accurate predictions
and a clinically acceptable time lag for PHs of 30 and 60 min.
In several contributions, to cope with the non-stationarity due to intra-subject
variability characterizing glucose dynamics, the authors adopt time variant AR and
ARMA models, identified recursively every time a new glucose measurement becomes
available, using a forgetting factor to assign a relative weight to past data and a finite
memory to the system. In [59] Sparacino and colleagues proposed a first order AR
model with time-varying parameter. The model was identified on CGM data of 28 T1D
volunteers monitored for 48 consecutive hours by the GlucoDay CGM system (sampling
time of 3 min), in normal daily life conditions. Parameters were estimated at each time
step using Recursive Least Squares (RLS). Various values of the forgetting factor were
tested with PH of 30 and 45 min. Prediction was assessed computing Mean Square
Error (MSE), Energy of Second Order Derivative (ESOD) and time anticipation. Results
were accurate and time anticipation was sufficient to potentially avoid or mitigate several
critical hypo- and hyperglycemic events. In [60] an ARMA(2,1) model with time-varying
parameters was investigated. The model parameters were estimated with RLS at each
time step, using a change detection method to enable dynamic adaptation of the model
to intra-subject variability and dynamic disturbances. The models were identified and
tested on denoised data monitored with the Gold
TM
CGMSR©system (Medtronic MiniMed)
for 48 consecutive hours, with a sampling time of 5 min. Two distinct databases were
used: one formed by 22 healthy hospitalized individuals, the other one constituted by
14 T2D subjects in free daily life conditions. Models were evaluated in terms of Sum
of Squared Errors (SSE), Relative Absolute Difference (RAD) and EGA for PHs up to
30 min. Results proved that recursive identification of the model parameters allowed
improving accuracy, with respect to time-invariant models.
1.4.2 Polynomial models
In [59] a time-varying first order polynomial (i.e. linear) model was identified with
weighted RLS on CGM data of 28 T1D subjects, monitored for 48 consecutive hours by
the GlucoDay CGM system (sampling time of 3 min). The quality of prediction was
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quantified in terms of MSE, ESOD and time anticipation, considering PHs of 30 and
45 min. Results were comparable to those obtained with the AR(1) [59] predictor on the
same data.
1.4.3 Kalman filter
A Kalman filtering methodology was proposed in [61,62], which only uses information
on past CGM readings by assuming a double integrated random walk as prior for
glucose dynamics. In [61] the authors used simulated data to demonstrate the effects of
measurement sampling frequency, prediction threshold level for hypoglycemia detection
and PH on sensitivity and specificity of hypoglycemia prediction. In [62] the approach was
used on 13 time series relative to hypoglycemic clamps, in which glucose concentration
was measured with the Medtronic CGMS sensor (sampling period of 5 min). Over all
the dataset, the sensitivity and specificity of hypoglycemia (defined as glucose lower than
70 mg/dL) prediction were calculated, for different PHs ranging from 5 to 30 min and
different prediction thresholds, from 60 to 90 mg/dL, for hypoglycemia detection.
1.4.4 Kernel-based regularization strategies
In [63] a kernel-based regularization learning algorithm was proposed. The authors
adopted a meta-learning approach, in which the kernel and the regularization parameter
are adaptively chosen on the basis of previous similar learning tasks, using past glucose
information. The algorithm was trained on data of one diabetic patient, monitored for
24 h with an Abbott FreeStyle Navigator CGM sensor (sampling time 10 min). The
predictor was then tested, without any re-adjustment, on other 10 diabetic patients,
monitored with the Abbott CGM sensor and on 6 diabetic subjects, monitored with the
SEVEN PLUS CGM system (sampling time 5 min). Results were computed in terms of
EGA and Prediction EGA (PEGA) [64] for PHs of 30 and 60 min.
1.4.5 Hybrid strategies
In [65] the authors proposed a combination of multiple models for hypoglycemia prediction.
Going into details, their system consisted in a linear projection based on the trend on the
previous 15 min, a Kalman filtering in line with that presented in [62], a hybrid infinite
impulse response filter, statistical models and numerical logical algorithms. A voting
system processed the output of the five algorithms and determined if a hypoglycemic alert
was generated. The method was developed using data of 21 T1D children, monitored with
the FreeStyle Navigator CGM sensor (sampling time 1 min) and tested using a separate
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dataset of 18 subjects, monitored with the same sensor. Low glucose concentration was
induced by gradual increases in basal insulin infusion rate up to 180% from the subject’s
own baseline infusion rate. The algorithm was assessed, retrospectively, on the basis of
the number of hypo events correctly forecasted, evaluating and comparing performance
obtained with different voting thresholds, PHs ranging from 35 to 55 min and alarm
thresholds equal to 70, 80 and 90 mg/dL.
1.4.6 Neural Networks (NN)
In the last few years, the possibility of using NNs for short-time glucose prediction has
been investigated. In particular, in [66] Pe´rez-Gand´ıa et al. proposed a NN whose inputs
were CGM samples in the previous 20 min and the current time instant, and whose output
was glucose concentration after PH ranging from 15 up to 45 min. The proposed NN is
feedforward with 2 hidden layers with 10 and 5 neurons, respectively. The model was
trained with Levenberg-Marqardt backpropagation and tested on two distinct datasets:
one constituted by 9 subjects monitored using the Guardian CGM sensor (sampling
period of 5 min) and the other one formed by 6 subjects monitored with the Navigator
CGM system (sampling time of 1 min). Results, quantified in terms of RMSE and time
anticipation, were comparable to those obtained with the AR(1) and the linear model
of [59] on the same dataset.
1.5 Prediction methods based on CGM and other
available information
1.5.1 ARX and ARMAX models
A natural approach to exploit CGM and other available information is to extend AR and
ARMA models by adding a term related to exogenous signals among their inputs.
A first attempt of exploiting information on CHO and insulin therapy by Auto-
Regressive with eXogenous Inputs (ARX) models was made in [67] by Finan and colleagues.
Both a time-invariant and a time variant approach were assessed in terms of FIT and
RMSE for PHs ranging from 30 to 90 min. The models were tested on two datasets,
collected on the same patients under different conditions. The dataset consisted in several
time series measured in normal ambulatory conditions in 9 T1D adults monitored with
the CGMS (sampling period of 5 min). Insulin pump records of basal rates, bolus amounts
and time, and subject recorded estimates of time and CHO quantity of meals were also
collected. Each dataset spanned 2 to 8 days. Third order batch ARX models were
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identified from the first half of the dataset and were used to predict the second half of the
dataset. In a second portion of the study, 6 of the 9 subjects were administered prednisone,
(an insulin sensitivity lowering drug), for 3 consecutive days. For these datasets batch
ARX models identified from normal data were used to predict prednisone data. In
addition, time variant ARX models were identified recursively to predict prednisone data.
PHs of 30, 45, 60 and 90 min were investigated. The batch ARX method produced
prediction as accurate or slightly more accurate than the recursive ARX method.
In [68] a time-varying ARX model using meal and insulin information preprocessed
to generate, respectively, CHO rate of appearance in the blood and plasma insulin was
proposed. Model parameters were estimated recursively using the normalized least mean
square algorithm and exploiting a physiological gain adaptation rule. The model was
used for prediction of future glucose concentration up to 50 min ahead in time and tested
on data of 15 hospitalized T1D subjects, monitored for 76 h with the FreeStyle Navigator
CGM device (sampling time 10 min). Results were quantified in terms of FIT and
Continuous Glucose - Error Grid Analysis (CG-EGA) [69] and defined satisfactory.
In [70] a time-varying multivariate subject specific Auto-Regressive with Moving
Average and eXogenous Inputs (ARMAX) model, with exogenous inputs including food
intake, PA, emotional stimuli and lifestyle was investigated. Parameters were identified
online using the weighted RLS method coupled with a change detection strategy for
a faster adaptation in case of drastic glycemic disturbance. Data used in this study
were relative to 5 T2D subjects under free living conditions, monitored for about 24
days. Glucose concentration was monitored with the MMT-7012 Medtronic CGM sensor
(sampling time 5 min) and physiological signals were measured with the SenseWear
Pro3 (BodyMedia Inc., Pittsburgh, PA) armband body monitoring system. Prediction
performance was numerically evaluated computing the RAD and the SSE of Glucose
Prediction, investigating a PH of 30 min. Results showed that prediction accuracy was
improved and error metrics were reduced using the multivariate model, with respect to
an univariate model based solely on CGM data. The authors also preliminarily evaluated
the ability of the multivariate ARMAX algorithm of predicting hypoglycemia, reporting
acceptable sensitivity and false alarm rate.
Recently, Turskoy and colleagues [71] proposed a subject specific recursive ARMAX
model for prediction of glucose concentration exploiting insulin on board and PA infor-
mation. In their implementation, the ARMAX model was converted to its state-space
form, to develop a simpler stability criterion and simplify the set of equations. Moreover,
a constraint to guarantee that insulin had a negative effect on the predicted signal
was introduced. The model was tested on data of 14 T1D subjects, smoothed both,
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non-casually using a Savitzky-Golais filter and casually, with a Kalman filter. Glucose
concentration was measured with the iPro CGM device (sampling period 5 min), while
metabolic, PA and emotional state were monitored with the SenseWear Pro3 armband
system. PHs ranging from 5 to 60 min were considered. Assessment criteria included
the accuracy of the forecasted profile, measured with RMSE and SSE and the model
ability of predicting hypoglycemia, quantified in terms of sensitivity, false alarm ratio
and average detection time. Results suggested that when PA information was added to
the ARMAX model the prediction error decreased significantly. Moreover, the model was
able to predict accurately almost all the hypoglycemic events with an average anticipation
of 28 min.
1.5.2 Machine learning strategies
In [72] Daskalaki and colleagues compared, on a simulated dataset, the performance
of an AR, an ARX and a NN model exploiting, respectively, only CGM history, CGM
and insulin and CGM, insulin and meal information. The AR and ARX models have
time-varying parameters updated at each time step using RLS algorithms. The NN model
has feedback connections for better learning glucose nonlinear time-varying dynamics.
The three models were optimized and evaluated on a virtual population of 30 T1D
subjects, extracted from [73], simulated for 8 consecutive days with a sampling period of
5 min. PHs of 30 and 45 min were considered and goodnes of prediction was quantified
computing RMSE, RAD, time lag and correlation coefficient. The NN resulted to be the
most appropriate algorithm for prediction of glucose profile based on glucose, insulin
and meal data and outperformed the other models for all patients and for both PHs.
However, no comparison with an ARX model using both insulin and meal information
was reported.
In [74] Zaho et al. used CGM, meal and insulin information as inputs of a latent
variable based predictor, optimized via partial least square and canonical correlation
analysis. Impulsive information on insulin therapy and meal were preprocessed with a
second order transfer function model to obtain time-smoothed inputs. The proposed
approach was compared with time-invariant AR and ARX models and with a latent
variable algorithm based solely on CGM data. The algorithm was assessed on 10 virtual
datasets [73] simulated for 7 days with a sampling time of 5 min. The first 2 days were
used for optimizing and validating the algorithm, while the following 5 days were used
for testing it. Furthermore, the strategy was also applied to clinical data of 7 ambulatory
T1D subjects, monitored with the SEVEN PLUS CGM sensor (5 min sampling time).
In this case, the first day of data was used for model identification and the rest of the
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time series was used for testing the algorithm. Results were quantified in terms of RMSE
and CG-EGA. On simulated data, the latent variable algorithm using CGM, meal and
insulin outperformed the other reference methods. However, on real data performance
was comparable.
In [75, 76] Georga and colleagues proposed, respectively, a random forest and a
support vector based algorithm to predict glucose concentration. In both contributions
the authors analyzed PHs of 15, 30, 60 and 120 min. The inputs of both predictors include
CGM, the rate of appearance of meal and the cumulative amount of glucose appeared
in the blood, plasma insulin concentration generated with a model of the absorption of
exogenous insulin, the hour of the day and the cumulative amount of energy expended
during PA. Both algorithms were optimized and tested on data of 27 T1D patients,
monitored for 5 to 22 days with the Guardian Real-Time CGM system (sampling time
5 min). Information on PA was registered with the SenseWear armband system, while
information on food intake and insulin therapy was recorded manually by the patients.
Results, computed in terms of RMSE and correlation coefficient, suggested that the best
accuracy was obtained when all the exogenous inputs were used. No comparison with
other predictors was reported.
In [77] Pappada and colleagues developed a feedforward NN incorporating, in addition
to CGM data, other inputs such as SMBG readings, impulsive information on insulin and
meal, information on hypo- and hyperglycemic symptoms, lifestyle, activity and emotions.
Their NN model predicts a complete vector of future glucose values across the model
PH of 75 min. The database used for optimizing and testing the NN was constituted
by 27 insulin dependent diabetic patients; glucose concentration was measured by the
CGMS Gold device (sampling time of 5 min) and documentation of other information
was done by the patients using an electronic diary. The predictor was trained on data
of 17 patients and assessed on data of the remaining 10 subjects in terms of RMSE,
percentage Mean Absolute Error (MAE) and EGA. The model accuracy was satisfactory
but hypoglycemia resulted routinely overestimated.
Recently, Wang and colleagues [78] combined several prediction algorithms (AR,
extreme learning machine and support vector regression) using adaptive weights inversely
proportional to each model’s prediction error. The models were optimized and tested
on data of 10 T1D subjects monitored either with the SEVEN PLUS, either with a
Medtronic CGM device (both with a sampling time of 5 min). The first half of each time
series was used for optimizing the models and the second half for testing the algorithm.
Prediction quality was assessed computing the RMSE, the relative error, the EGA and the
J index [79]. Results showed that the model ensemble performed better than the singular
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algorithms and was more robust with respect to variations on data characteristics.
1.6 Quantification of the clinical usefulness of glucose
prediction for hypoglycemia reduction
One of the most appealing application of glucose prediction is the generation of hypo-
glycemic alerts based on the predicted glucose value, potentially allowing the patient to
take adequate therapeutic decisions in advance, possibly avoiding or at least mitigating
the risky event. So far, some proof of concept applications on the possibility of limiting
induced hypoglycemia have been described in the literature.
In Buckingham et al. [80,81], nocturnal hypoglycemia was induced in 15 hospitalized
subjects increasing basal insulin infusion. Five different literature glucose prediction
techniques (all based solely on past glycemic data measured by CGM) were simultaneously
used to forecast future hypoglycemia, and hypo-alerts were generated on the basis of a
predefined voting scheme. The triggering of a hypoglycemic alarm involved the suspension
of basal insulin infusion, until recovering of blood glucose concentration to a safe value,
either for a maximum of 90 min. This strategy allowed preventing the majority of the
nocturnal induced hypo crisis. In [82] the same paradigm was tested outpatients, however,
the authors’ objective was the assessment only of the safety, not of the effectiveness, of
the system.
A different strategy was employed by Hughes et al. in [83]. In this work, the
authors presented a method to detect/predict the risk of hypoglycemia and to perform a
gradual attenuation of insulin delivery on the basis of risk factors, instead of immediate
pump shutoff. The aim was to create a safety module to be used especially in AP
applications. The method was assessed on data simulated through the FDA approved
T1D simulator [73] in presence of hypoglycemic conditions induced by elevated basal rate
and overbolus of insulin. Results indicated that attenuating insulin delivery reduced,
or at least delayed the onset of hypoglycemia, especially if the rescue CHO dose was
delivered sufficiently ahead-in-time.
1.7 Aim of the thesis
As described in Section 1.4 the majority of glucose prediction strategies proposed in
the literature does not extensively exploit all the relevant available information. In
particular, besides CGM history, information on ingested CHO, insulin therapy and PA
could improve prediction accuracy. Indeed, from physiology, meal, insulin and exercise are
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known to act like disturbances for glucose homeostasis, influencing its dynamics. The first
aim of this thesis is thus to develop a NN based prediction model exploiting, apart from
CGM, other available information. This task will be tackled in Chapters 3, 4 and 5, where
two NN algorithms will be proposed and the benefits of adding inputs other than CGM
will be evaluated. NN algorithms can easily exploits, as inputs, signals with different
nature and characteristics and are naturally able to learn complex nonlinear functions,
thus they are promising models for glucose concentration prediction, potentially more
powerful than linear ARX and ARMAX algorithms. In the glucose prediction literature,
only a few NN strategies have been proposed so far and they did not significantly
outperformed linear time series models. We will overcome this limitation by optimizing
the NN structure to better exploit its ability of learning complicated nonlinear functions.
Furthermore, we will preprocess exogenous information to obtain input signals that result
more informative for prediction purposes. The proposed NN models will be optimized
and tested, considering several merit indexes, using simulated CGM profiles and real data
of T1D subjects in free life conditions and results will be compared with those obtained
by state of art algorithms, implemented on the same data.
As described in Section 1.6 a few literature contributions assessed the benefit deriving
from prediction methods to prevent/mitigate hypoglycemia on real data. However, state
of art analysis are mainly qualitative and a comprehensive objective assessment is missing.
Indeed, a drawback of clinical studies is that, once a patient takes an action (e.g., eating
sugar at time t1), there is no way of coming back to time t1 and evaluating what would
have happened if different actions were adopted (e.g., administration of sugar at time
t1+τ or no administration at all). Thus, the second aim of this thesis is the comprehensive
conceptual investigation of benefits in diabetes management that could be obtained if
hypoglycemic alerts were generated on the basis of prediction. This will be addressed
in Chapter 7 on a simulated database. Using the simulation environment will allow us
to overcome limitations of literature approaches because, for the same subject and the
same hypoglycemic event, we will be able to run different simulations (corresponding to
parallel alternative and mutually exclusive scenarios) and fairly compare the effect of
different actions, starting from the very same initial patient conditions. Moreover, the
simulation analysis is also a powerful tool to optimize the design of expensive clinical
trials for quantifying, as objectively as possible, the clinical usefulness of prediction.
Both simulated and real data will be used in this thesis. Simulated T1D glycemic
profiles are obtained using the UVA/Padova diabetic simulator, a system shown to
represent adequate glucose fluctuations in T1D observed during meal challenges and
accepted by FDA as a substitute to animal trials in preclinical testing of closed-loop
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control strategies [73, 84]. Real data consists in signals collected during the FP7 EU
project DIAdvisor
TM
[85], which involved our research group in the past.
1.8 Thesis outline
The thesis is organized as follows. Chapter 2 introduces the fundamental theory of NN
and describes our implementation choices, common to all the proposed models. Chapter 3
describes the first predictor we developed, which is based on a NN in parallel with a time
varying linear model and uses information on CGM and CHO content and timing of meals.
Results obtained on simulated and real data and comparison with state of the art methods
are also reported. Chapter 4 presents a new prediction model based on a jump NN that
overcomes some limitations of the previous structure and obtains statistically comparable
results. Chapter 5 further investigates the jump NN predictor by adding information
relative to insulin therapy as input of the model and quantifying the relative contribution
of each input signal in determining the predicted time series. Chapter 6 presents a
quantification of short-term effects of mild PA on glucose concentration dynamics and
discusses future perspectives, as the inclusion of signals related to PA as additional
inputs of the NN. Chapter 7 describes a practical application of prediction for generation
of hypoglycemic alerts. The reduction of hypoglycemia obtained using prediction is
extensively evaluated on a simulated dataset and the design of a clinical trial, to confirm
results obtained in simulation, is also briefly discussed. Finally, Chapter 8 concludes the
thesis summarizing the original results obtained in our research and discussing possible
future works.
2
Fundamentals of Neural Network (NN) modelling
2.1 General features of NN
A NN is a mathematical model that aims to mimic the functioning of the brain and is
motivated by the recognition that the human brain computes entirely differently from
conventional digital computers. Indeed the brain can be thought as a highly complex,
nonlinear and parallel computer able to organize its structural units, called neurons, so
as to perform certain computations (e.g. perception, pattern recognition, etc) faster than
modern digital computers. Analogously, an artificial NN is a massively parallel distributed
model constituted by interconnection of simple processing units, called neurons, which has
a natural propensity for storing knowledge and making it available for use. It resembles
the brain because:
1. knowledge is acquired by the network environment through a learning process;
2. synaptic weights, i.e. inter-neuron connection strengths, store the acquired knowl-
edge.
NN are characterized by the following useful properties:
1. Nonlinearity. Artificial neurons can be both linear or nonlinear and the network
resulting from their interconnection is itself nonlinear if nonlinear units exist.
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Furthermore this nonlinearity is distributed through the system. Nonlinearity is an
important property if the process to learn is itself nonlinear.
2. Input-output mapping. The most popular learning paradigm is called supervised
learning and consists in the optimization of synaptic weights by applying a set of
labelled training samples, each one consisting in a input signal and relative target.
The samples are presented to the network and the weights are modified so as to
minimize the distance between the target and the actual NN output. Thus the
network, from examples, constructs an input-output map of the given problem.
Such an approach belongs to the field of nonparametric statistical inference, since
no prior assumptions are made on statistical models for the data.
3. Adaptivity. A NN trained to work in a specific environment can be easily retrained
to deal with minor changes in the environmental conditions. In addition, when
operating in a nonstationary context, the network could be designed to change
its synaptic weights in real time. However, it should be emphasized that adap-
tivity might lead to non-robustness: indeed an adaptive system with short time
constants may change rapidly and, therefore, respond to spurious disturbances
with a degradation of performance. An adaptive system should be chosen only if
the principal time constant of the process is long enough for the system to ignore
spurious disturbances, but short enough to respond to meaningful environmental
changes. This problem is referred to as the stability-plasticity dilemma [86].
2.2 NN architecture
2.2.1 Artificial neuron model
The neuron is the information processing unit fundamental to the operation of a NN.
The block diagram of Figure 2.1 represents the model of a neuron, which is constituted
by three basic elements:
1. A set of synapses, characterized by their own weight. Going into details, a signal xj
at the input of synapses j connected to neuron k is multiplied by the weight wkj .
It is worth making a note on how the subscripts of synaptic weight wkj are written:
the first subscript refers to the neuron to which the synapses leads, while the second
subscript refers to the neuron from which the synapses originates. Weights can
be positive as well as negative. The neuronal model also includes a bias bk = wk0
(associated to the fixed input x0 = 1), whose effect is increasing (if positive) or
decreasing (if negative) the net input of the activation function.
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2. An adder that sums the weighted input signals.
3. An activation function for processing the input of the neuron and, usually, limiting
the amplitude of the output.
Figure 2.1: Model of an artificial neuron [87].
The neuron can be described mathematically by
yk = ϕ
 p∑
j=0
xjwkj
 (2.1)
where x1, . . . , xp are the input signals, wk1, . . . , wkp are the synaptic weights of neuron k,
wk0 is the weight connected with the input x0 = 1, thus it represents the bias, ϕ(·) is the
activation function and yk is the output of neuron k.
2.2.1.1 Neuron activation function
The activation function ϕ(v) defines the neuron output in terms of the weighted sum of
its inputs. Figure 2.2 shows the three basic types of activation function:
1. Threshold function, mainly used for classification, which can be the Heaviside
function (Figure 2.2(a))
ϕ(v) =
{
1 if v ≥ 0
0 if v < 0
(2.2)
or the sign function (Figure 2.2(b)), if an antisymmetric function with respect to
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the origin is desirable
ϕ(v) =

1 if v > 0
0 if v = 0
−1 if v < 0
(2.3)
2. Linear function (Figure 2.2(c))
ϕ(v) = v (2.4)
commonly used as activation function of the output neuron when the network is
used for function approximation and prediction.
3. Sigmoid function, which is the most common form of activation function used for
hidden layers of NN. This is usually a sigmoid logistic function (Figure 2.2(d))
ϕ(v) =
1
1 + e−2v
(2.5)
or a sigmoid tangent hyperbolic function (Figure 2.2(e)), if we prefer a function
antisymmetric with respect to the origin
ϕ(v) =
1− e−2v
1 + e−2v
(2.6)
(a) Heaviside function. (b) Sign function. (c) Linear function.
(d) Sigmoidal logistic function. (e) Tangent hyperbolic function.
Figure 2.2: Neural activation functions.
2.2 NN architecture 27
2.2.2 Multilayer FeedForward Neural Network (FFNN)
In a multilayer FeedForward Neural Network (FFNN) (commonly referred also as multi-
layer perceptron) the neurons are organized in layers and each layer projects only onto
the following layer, but not vice versa, thus no feedback loops exist. The function of
hidden neurons is to intervene between external inputs and network output, enabling the
network to extract high order statistics [87].
The source nodes in the input layer supply the elements of the input vector, which
constitute the inputs of the first hidden layer. The output signals of the first hidden
layer are used as inputs of the second hidden layer and so on for the rest of the network.
Typically, the neurons in each layer of the network have as inputs the output signals
of the preceding layers only. The set of output signals of the neurons in the final layer
of the network constitutes the NN response to the input activation pattern. The graph
in Figure 2.3(a) illustrates a FFNN with 3 inputs, one hidden layer of 5 neurons and
an output layer with 2 neurons. For brevity, such a structure is shortly referred as
3-5-2 and, generally, a FFNN with m input nodes, h1 neurons in the first hidden layer,
h2 neurons in the secon hidden layer and q neurons in the output layer is referred as
m− h1 − h2 − q network. The architecture in Figure 2.3(b) represents a FFNN with two
hidden layers and an unspecified number of neurons in each layer. The NNs of Figure 2.3
(a) Fully connected FFNN with one hidden
layer.
(b) Fully connected FFNN with two hid-
den layers.
Figure 2.3: Fully connected FFNNs.
are fully connected since each node in every layer is connected to every node of the
adjacent forward layer. If some links were missing, the network would have been partially
connected.
A multilayer perceptron has three characteristics:
1. Each hidden neuron is characterized by a nonlinear differentiable activation function,
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commonly the logistic function or the tangent hyperbolic function. The presence
of nonlinearities is essential for the NN ability of learning nonlinear relationships
between inputs and target. The output neurons are usually characterized by a
linear function.
2. The NN contains one or more hidden layers, which enable it to learn complex task
by extracting, progressively, features from the input patterns.
3. The NN has a high degree of connectivity.
The computing power of multilayer FFNN derives from these characteristics and from
the ability of learning from experience through training.
Let us define: yk the k
th output of the NN; ml the number of neurons of the l
th layer,
with l = 0, . . . , L, thus m0 is the number of inputs, m1 the size of the first hidden layer
and mL the number of outputs; w
n−m
ji the weight connecting the i
th neuron of the mth
layer to the jth neuron of the nth layer, with n,m = 0, . . . , O, thus n = 0 is the input
layer, n = 1 the first hidden layer and n = O the output layer, and the same for m;
finally, wlk0 the bias of the k
th neuron of the lth layer and, with an abuse of notation, for
simplifying equations, wl−mk0 also represents the bias of the k
th neuron of the lth layer.
The mathematical representation of the FFNN of Figure 2.3(a) is
yk = w
2
k0 +
m1∑
j=1
w2−1kj ϕ
(
m0∑
i=0
w1−0ji xi
)
(2.7)
and the mathematical representation of the FFNN of Figure 2.3(b) is
yl = w
3
l0 +
m2∑
k=1
w3−2lk ϕ
w2k0 + m1∑
j=1
w2−1kj ϕ
(
m0∑
i=0
w0−1ji xi
) (2.8)
Comparing equations (2.7) and (2.8) it is clear that adding one hidden layer increases the
number of parameters to be estimated by the factor (m1+1)(m2-1)+(m2+1). Adding
hidden layers adds complexity, but also increases the number of parameters to estimate,
thus increasing the training time, the number of training examples necessary for robustly
training the NN and, last but not least important, the risk that the optimization procedure
may converge to a local, rather than a global, optimum.
2.2.3 Jump NN
An alternative to a pure FFNN is a jump NN, i.e. a FFNN in which the inputs xi
have direct linear links, called jump connections, to the output, as well as to the output
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through the hidden layers [88]. Figure 2.4 shows a FFNN with jump connections (in dark
red) with 4 inputs, one hidden layer with 5 neurons and one output neuron. Using the
Figure 2.4: Block scheme of a jump NN (jump connections are in dark red).
same symbols introduced in Subsection 2.2.2 the jump NN of Figure 2.4 is represented,
mathematically, as
yk =
m1∑
j=1
w2−1kj ϕ
(
m0∑
i=0
w1−0ji xi
)
+
m0∑
i=0
w2−0ki xi (2.9)
whose first term coincides with equation (2.7) and the second term is relative to the
direct connections between inputs and output.
An advantage of a jump NN is that it nests the pure linear model and the FFNN
model and allows the possibility that a function may have both, a linear and a nonlinear
component. As a consequence, such an architecture is particularly appropriate when the
function to be learned has linear and nonlinear relationships with the regressors.
2.2.4 Recurrent NN
A recurrent NN, differently from a FFNN, has at least one feedback loop. There might
be both, self-feedback loops, if the output of a neuron is fed back into its own input and
non self-feedback loops, if the output of a neuron is fed back as input of neurons of the
previous layers. Figure 2.5(a) shows a recurrent NN with one hidden layer and feedback,
with two delay elements, from the output to the inputs. Figure 2.5(b) shows a recurrent
NN with self feedback loops in the neurons of the hidden layer and feedback connections
from the output to the hidden layer.
Let us define y(t− 1) the output of the recurrent NN of Figure 2.5(a) at time t− 1,
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(a) Recurrent NN with one hidden layer and one out-
put neuron, with recursion (with two delay elements
z−1 from output to inputs).
(b) Recurrent NN with one hidden layer,
with self feedback connections and two
output neurons, whose output is fed back
into hidden neurons [89].
Figure 2.5: Two examples of recurrent NNs.
the following equation represents the system schematized in Figure 2.5(a)
y(t) = w20 +
m1∑
j=1
w2−1j ϕ
(
NI∑
i=0
w1−0ji xi + w
z−1
j y(t− 1) + wz
−2
j y(t− 2)
)
(2.10)
where w20 represents the bias relative to the output neuron and w
z−k
j is the weight
connecting the output, delayed of k-steps, to the jth hidden neuron.
As we can deduce from equation (2.10), the presence of feedback loops introduces a
memory in the evolution of the neurons, profoundly changing the learning ability and
the performance of the NN and requiring the use of delay elements, which result in a
dynamical nonlinear behavior.
2.3 NN training
One of the most important properties of a NN is its ability of learning from the environ-
ment, adjusting properly its synaptic weights. In line with a definition of Mendel and
McClaren [90], learning may be defined as [87]
Learning is a process by which the free parameters of a neural network are
adapted through a process of stimulation by the environment in which the
network is embedded. The type of learning is determined by the manner in
which the parameters changes take place.
This definition implies three fundamental steps:
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1. The NN is stimulated by an environment.
2. The NN undergoes changes in its weights as a result of this stimulation.
3. The NN responds in a new way to the environment because of the changes occurred
in its free parameters.
There are several learning algorithms, mainly differing in the way in which the synaptic
weights are adjusted. In Subsection 2.3.3 we will describe in details the backpropagation
learning paradigm, which is one of the most widely used in the literature and, further-
more, is the technique adopted for training the NNs presented in this thesis. For more
information on learning algorithms we refer the reader to [87].
2.3.1 Learning paradigms
We can distinguish between two learning paradigms: supervised and unsupervised
training.
2.3.1.1 Supervised training
In supervised training, the knowledge of the environment is represented by a set of input-
output examples, which constitute the training set. The NN is exposed to a training
vector and its parameters are adjusted on the basis of the error signal, i.e. the distance
between the NN output and the desired response. The adjustment continues iteratively
step-by-step, with the final goal of making the NN respond as accurately as possible to
all the training examples.
2.3.1.2 Unsupervised training
In unsupervised training there are no labelled examples of the function to be learned.
Two paradigms are possible.
Reinforcement learning/ Neurodynamic programming: the input-output map-
ping is learned through continuous interaction with the environment to minimize a scalar
index of performance. The goal is the minimization of a cost-to-go function, i.e. the
expectation of the cumulative cost of actions, taken over a sequence of steps, instead
of the immediate cost. The delay in generating the reinforcement signal implies that
the NN must assign credit and blame individually to each action that led to the final
outcome, while the primary reinforcement may only evaluate the outcome.
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Unsupervised learning: the NN should learn autonomously a representation of the
environment, by extracting the statistical regularities of the input data and forming
internal representations for encoding features of the input, creating automatically classes.
2.3.2 Learning task
The choice of a learning strategy is determined by the learning task that a NN is required
to perform. These tasks might be, for example: pattern association, pattern recognition,
function approximation, control, filtering. In this thesis NN will be used for prediction,
thus, below, we will shortly introduce the task of function approximation.
In function approximation, given an unknown functional relationship
y = f(x) (2.11)
with x input and y output and a set of N labelled examples
T = {(xi,yi)}Ni=1 (2.12)
the task is to design a NN able to approximate the unknown function f(·) such that the
actual network output function F(·) is close enough to the target over all inputs. Usually,
the Euclidean distance is used to measure the goodness of the approximation and the
NN weights are chosen to minimize
‖F(x)− f(x)‖ < ε for all x (2.13)
with ε small positive number. If the size N of the training set is large enough and the
NN has enough free parameters, the approximation error ε can be small enough for the
task. The approximation problem is an ideal candidate for supervised learning.
2.3.3 Learning algorithm
The most commonly used learning algorithm for FFNN (and jump NN), trained for
function approximation is the backpropagation algorithm. To ease its derivation, which
is rather complex, we summarize the notation used in the following paragraph.
2.3.3.1 Notation
• Indexes i, j and k refers to different neurons; with signals propagating through the
NN strictly from left to right, neuron j lies in a layer to the right of neuron i and
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neuron k lies in a layer to the right of neuron j (following the alphabetical order of
the indexes).
• During the nth iteration the nth training example is presented to the network.
• E(n) is the sum of error squares at iteration n. Eav is the average error over all the
training examples.
• dj(n) is the desired response for neuron j.
• yj(n) is the output of neuron j.
• ej(n) is the error at the output of neuron j at iteration n, thus ej(n) = dj(n)−yj(n).
• wji(n) is the weight connecting neuron i to neuron j at iteration n.
• ∆wji(n) is the correction applied to the weight wji at iteration n.
• vj(n) is the the weighted sum of all synaptic inputs plus bias of neuron j at iteration
n.
• ϕj(·) is the activation function describing the input-output nonlinear relationship
between input and output of neuron j.
• wj0 = bj is a weight associating a fixed input equal to 1 to neuron j and represents
the bias applied to neuron j.
• xi(n) is the ith element of the nth input vector.
• ok(n) is the kth element of the nth output vector.
• η is the learning rate.
• ml is the number of neurons in layer l, with l = 0, . . . , L. Thus m0 is the size of
the input layer, m1 is the size of the first hidden layer and mL is the number of
outputs.
2.3.3.2 Backpropagation algorithm
The backpropagation algorithm is the most common routine for training FFNN. There
are many variants of this algorithm, to optimize its speed and to minimize the risk of
getting trapped in local minima. There is also a dynamic version, namely backpropagation
through time, proposed for training recurrent NNs. However, it is less efficient than the
original algorithm both, in terms of speed and performance of the trained network.
The algorithm consists in two steps: a forward pass and a backward pass.
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• In the forward pass, a training input is presented to the NN and the corresponding
output values are computed. Each output is compared with the corresponding
target and the error committed by every output neuron is computed.
• In the backward pass, the synaptic weights are modified applying the error-correction
rule. The error is backpropagated through the network, from the output to the
input, trying to infer the error committed by every hidden neuron (of which both,
target and actual output are unknown), modifying the weights to minimize the
error.
The error relative to the output neuron j at iteration n is
ej(n) = dj(n)− yj(n) (2.14)
The instantaneous value of the error energy for neuron j is defined as 12e
2
j (n). The value
E(n) of the total error energy is obtained summing 12e
2
j (n) over all the neurons of the
output layer, i.e. over all the neurons for which the error signal can be calculated directly,
E(n) =
1
2
∑
j∈C
e2j (n) (2.15)
where C is the set including all the neurons of the output layer. Let N denote the number
of examples in the training set. The average squared error energy is obtained as
Eav =
1
N
N∑
n=1
E(n) =
1
2N
N∑
n=1
∑
j∈C
e2j (n)
=
1
2N
N∑
n=1
∑
j∈C
(dj(n)− yj(n))2 (2.16)
Both, E(n) and Eav are functions of the NN weights and biases. For a given training
set, Eav represents the cost function that should be minimized by adjusting the free
parameters of the NN.
The NN training can be performed:
• online, modifying the weights after each example of the training set, i.e. minimizing
at each iteration E(n);
• in batch mode, modifying the weights on the basis of the error computed on the
entire training set, i.e. minimizing Eav.
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In the rest of the paragraph we will consider the case in which weights are updated
online.
Let us define the input of neuron j as
vj(n) =
m∑
i=0
wji(n)yi(n) (2.17)
with m total number of inputs applied to neuron j and wj0 (corresponding to the fixed
input y0 = 1) weight associated with the bias bj . The output of neuron j is
yj(n) = ϕj(vj(n)) (2.18)
The backpropagation algorithm applies a correction ∆wji(n) to the weight wji, propor-
tional to the partial derivative of the error ∂E(n)/∂wji(n) (or of the average error, in
batch mode ∂Eav/∂wji). Using the chain rule the gradient can be expressed as
∂E(n)
∂wji(n)
=
∂E(n)
∂ej(n)
∂ej(n)
∂yj(n)
∂yj(n)
∂vj(n)
∂vj(n)
∂wji(n)
(2.19)
Differentiating both sides of (2.15) we obtain
∂E(n)
∂ej(n)
= ej(n) (2.20)
Differentiating both sides of (2.14) we obtain
∂ej(n)
∂yj(n)
= −1 (2.21)
Differentiating (2.18) with respect to vj(n) we obtain
∂yi(n)
∂vj(n)
= ϕ′j(vj(n)) (2.22)
where ϕ′j(·) is the derivative of ϕj(·) with respect to its argument. Finally, differentiating
(2.17) with respect to wji(n) we have
∂vj(n)
∂wji(n)
= yi(n). (2.23)
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Substituting equations from (2.20) to (2.23) in (2.19) yields
∂E(n)
∂wji(n)
= −ej(n)ϕ′j(vj(n))yi(n) (2.24)
The correction ∆wji(n) applied to wji(n), is defined as
∆wji(n) = −η ∂E(n)
∂wji(n)
=
∂E(n)
∂ej(n)
∂ej(n)
∂yj(n)
∂yj(n)
∂vj(n)
∂vj(n)
∂wji(n)
= ηδj(n)yi(n) (2.25)
with η learning rate and δj(n) local gradient defined as
δj(n) = − ∂E(n)
∂ej(n)
∂ej(n)
∂yj(n)
∂yj(n)
∂vj(n)
= ej(n)ϕ
′
j(vj(n)) (2.26)
From equations (2.25) and (2.26) we note that ej(n) is key factor in computing the
weight adjustment ∆wji(n). Depending on the position of neuron j in the network we
may distinguish two cases: if j is an output neuron computing its error is trivial, if j is
a hidden neuron its output and its error are not directly accessible. The problem is to
know how to penalize hidden neurons for their responsibility in determining the output
errors. This issue is solved by backpropagating the error signals through the NN.
Case 1: neuron j is an output node. In this case we know the target signal, thus
we can use equation (2.14) to compute the error ej(n) and then compute the local
gradient δj(n) using equation (2.26).
Case 2: neuron j is a hidden node.
From (2.26) we may redefine the local gradient of a hidden neuron j as
δj(n) = − ∂E(n)
∂yj(n)
∂yj(n)
∂vj(n)
= − ∂E(n)
∂yj(n)
ϕ′j(vj(n)) (2.27)
where we used (2.22) in the second line. As seen in (2.15), if k is an output node its error
2.3 NN training 37
is
E(n) =
1
2
∑
k∈C
e2k(n) (2.28)
which corresponds to (2.15), with k used instead of j for avoiding confusion, since j refers
to a hidden neuron under case 2. Differentiating (2.28) with respect to yj(n) we get
∂E(n)
∂yj(n)
=
∑
k∈C
ek
∂ek(n)
∂yj(n)
=
∑
k∈C
ek
∂ek(n)
∂vk(n)
∂vk(n)
∂yj(n)
(2.29)
where we applied the chain rule in the second row. From (2.14) and (2.18) we know that
ek(n) = dk(n)− yk(n)
= dk(n)− ϕk(vk(n)) (2.30)
thus
∂ek(n)
∂vk(n)
= −ϕ′k(vk(n)) (2.31)
From (2.17) we also note that the input of neuron k is
vk(n) =
m∑
j=0
wkj(n)yj(n) (2.32)
and differentiating with respect to yj(n)
∂vk(n)
∂yj(n)
= wkj(n) (2.33)
Using (2.31) and (2.33) in (2.29) we obtain the desired partial derivative
∂E(n)
∂yj(n)
= −
∑
k∈C
ek(n)ϕ
′
k(vk(n))wkj(n)
= −
∑
k∈C
δk(n)wkj(n) (2.34)
Finally, using (2.34) in (2.27) we get the backpropagation formula for the local gradient
δj(n) relative to a hidden neuron
δj(n) = ϕ
′
j(vj(n))
∑
k∈C
δk(n)wkj(n) (2.35)
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For what concerns the factors involved in the computation of the local gradient:
• ϕ′j(vj(n)) depends solely on the activation function of neuron j;
• δk(n), with k ∈ C, require knowledge of the error ek(n) for all neurons that lie in
the layer to the immediate right of hidden neuron j and that are directly connected
to neuron j;
• wkj(n) are the synaptic weights associated with these connections, i.e. the connec-
tions between neuron j and the neurons in the layer to its immediate right.
Summarizing, in the backpropagation algorithm:
1. Input n is presented to the NN and the error committed by the network is computed.
2. The correction ∆wji(n) is computed as Weightcorrection
∆wji(n)
 =
 learningrate
η
 ·
 localgradient
δj(n)
 ·
 input signalof neuron j
yi(n)

The local gradient δj(n) depends on whether neuron j is an output node or a hidden
node. If neuron j is an output node δj(n) = ϕ
′
j(vj(n))ej(n). If neuron j is a hidden
node δj(n) is obtained by the product of ϕ
′
j(vj(n)) and the weighted sum of the δs
computed for the neurons in the next layer that are connected with neuron j.
3. Iterations continue until a minimum of E(n) is reached.
In the batch learning case Eav is minimized instead of E(n). Thus, equation (2.19)
becomes
∂Eav
∂wji
=
1
N
N∑
n=1
∂E(n)
∂ej(n)
∂ej(n)
∂yj(n)
∂yj(n)
∂vj(n)
∂vj(n)
∂wji(n)
(2.36)
Apart from the introduction of the sum over all the elements of the training set, the
procedure corresponds to that previously presented and ∆wji is given by
∆wji = η
1
N
N∑
n=1
δj(n)yi(n) (2.37)
It is worth stressing that with batch learning the NN weights remain constant and all
the elements of the training set are presented to the network. Then the average error is
computed and the weights are updated along the delta-rule, to minimize the error.
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Generally, the backpropagation algorithm cannot be shown to converge and there are
no well defined criteria to stop it. Reasonable criteria derive from the characterization
of a global or local minimum in the error surface. Let the weight vector w∗ denote a
minimum. A necessary condition is that the gradient vector of the error surface with
respect to the weight w is zero at w = w∗. Thus a convergence criterion might be a
sufficiently small Euclidean norm of the gradient vector. Alternatively, we might define a
criterion exploiting the fact that the cost function Eav is stationary at w = w∗. Thus
the backpropagation algorithm may be considered to have converged when the absolute
rate of change in the average square error per epoch is sufficiently close to zero. Another
criterion usually adopted is based on the generalization ability of the trained NN and is
discussed in Subsection 2.3.4.
2.3.4 Generalization in NN
In backpropagation the synaptic weights of the FFNN are computed by learning the
training examples as accurately as possible. The hope is that the trained NN will
generalize well on test data, similar to those seen during the training procedure, but
never used to optimize the weights. In fact, one of the problems that may occur during
NN training is overfitting, i.e. the network memorizes the training data and finds feature
that are due to noise, but not informative of the function to be modelled.
One method for improving network generalization is to keep the complexity of the
NN low and using a number of neurons just large enough to adequately fit the target
function [91]. In addition, increasing the size of the training set is another good option
to prevent overtraining. However, often a huge training set is not available and a NN
with a few neurons might not be adequate for learning the function of interest. Thus,
two techniques commonly used are early stopping and regularization.
2.3.4.1 Early stopping
Ordinarily, a FFNN learns in stages, increasing the performance in the training set as
the training session progresses, towards a local minimum of the error surface. However,
the NN might end up overfitting the training data and generalizing poorly. The onset of
overfitting can be identified using cross-validation: the training data are split into an
effective training set, used for computing the error and its gradient and updating the
network weights and a validation set, used for monitoring the error during training. The
training session is stopped periodically and the error on the validation set is computed.
The validation error normally decreases during the initial phase of training, however,
when the network begins to overfit the data, the error on the validation set begins to rise.
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When the error increases for a specified number of consecutive iterations the training
is stopped and the weights at the minimum of the validation error are returned. This
procedure is referred to as early stopping and was presented in [92].
2.3.4.2 Regularization
Another method for improving generalization is using regularization. This involves
modifying the performance function and minimizing
R(w) = Es(w) + λEc(w) (2.38)
The first term, Es(w), is the standard performance measure, depending on the network
weights and the input data. The second term, Ec(w), is the model complexity penalty and
λ is a regularization parameter, representing the relative importance of the complexity
penalty term with respect to the performance measure term.
A popular choice for regularization is the weight decay procedure, proposed in [93].
The complexity penalty term is defined as
Ec(w) = ‖w‖2
=
∑
i∈Ctotal
w2i (2.39)
with Ctotal set of all the synaptic weights in the network. This procedure forces some of
the weights to take values close to zero. Accordingly, the network weights are grouped
into two categories: those having a great influence in the model performance and those
having almost no influence on it. The latter are likely to take completely arbitrary values
and might lead to poor generalization performance.
2.4 NN structure optimization
The NN architecture defines its structure, including the number of hidden layers and of
neurons in each layer. The number of input and output neurons is easy to determine,
since it corresponds to the the number of input and output variables, respectively. On
the contrary, the determination of the appropriate number of hidden layers and hidden
neurons is a critical task, since no prior knowledge are usually available, nor statistic or
theoretical rules. A NN with one hidden layer and an appropriate number of hidden nodes
should be able of approximating any function (see Section 2.6 for details). In practice,
NN with one or two hidden layers are commonly used with satisfactory performance.
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Analogously, there is no formula to select the number of hidden neurons, thus this choice
involves experimentation and simulation. A network with too few hidden nodes would
not be able to learn accurately enough the training data. On the other side, a network
with too many hidden nodes is likely to overfit the data. Three methods are commonly
used for optimizing the number of hidden neurons: fixed approach, network growing or
constructive approach, and network pruning or destructive approach [94,95].
In the fixed approach several NNs are trained and each is evaluated. Usually, N -
fold-cross-validation is adopted: the training set is divided into N subsets, each network
is trained on N − 1 subsets and tested on the remaining subset and the procedure is
repeated N times, leaving out each time a different subset for testing the models. The
performance of each NN is the average obtained on the N experiments. The increment in
the number of hidden neurons might be one, two or more (or logarithmic). The network
with the smallest error is selected because it is able to generalize best.
The constructive and destructive approaches involve changing the number of hidden
neurons during training and this functionality is not supported by the majority of
commercial NN software packages. The constructive approach starts with the smallest
possible architecture and continues adding hidden neurons until the network performance
is stable or begins deteriorating. The destructive approach starts with a big network and
continues removing neurons until the performance begins deteriorating.
Regardless of the method chosen for optimizing the NN architecture, the rule is
to choose the NN that performs best on a validation set, with the smallest number of
neurons.
2.5 Data preprocessing
Several preprocessing techniques are commonly applied before the data are used for
training the NN to accelerate convergence and to ease the problem to be learned [95]. The
most common are noise removal, input dimensionality reduction and feature extraction,
data transformation, data inspection with outliers deletion.
An essential operation is scaling data so that all the regressors have similar variance
and span the same range of values. This is usually done by applying a linear mapping of
the training set in the range [−1, 1], i.e. the interval of input values in which the sigmoid
functions (both hyperbolic tangent and logistic) have a linear behaviour. Thus a signal x
assuming values in the range [xmin, xmax] is mapped in the set [ymin, ymax] by applying
y = (ymax − ymin) x− xmin
xmax − xmin + ymin (2.40)
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Alternatively, the signal is mapped to have zero mean and unitary standard deviation,
by applying
y =
x− xmean
xsd
(2.41)
where xmean is the average of the values assumed by the signal x, on the training set and
xsd is its standard deviation. Data normalization is essential to prevent larger numbers
from overriding smaller ones and to prevent premature saturation of hidden nodes, which
would deteriorate the learning process.
In practice data preprocessing involves trial and error: one method to select appro-
priate input variables is to test various combinations, however, it might be not possible
to do it exhaustively. Other alternative methods include [96]:
1. Methods that use a priori knowledge of the system being modelled. A priori
knowledge and a good understanding of the system to be modelled are essential
for selecting a set of candidate inputs, however, this method should, possibly, be
combined with other analytical approaches.
2. Methods based on cross-correlation. This is one of the most popular analytical
techniques for inputs selection. The major disadvantage of this technique is the fact
that it captures only linear dependence between two variables, while it is unable to
detect any nonlinear dependence.
3. Methods using heuristic approaches. These methods comprise step-wise addition
of variable to the set of inputs, backward elimination of inputs and comparison of
different networks trained with different subsets of inputs. Since these approaches
are based on trial-and-error, there is no guarantee that they will find the globally
best subset. Moreover, they are computationally expensive.
4. Methods extracting knowledge from trained NN. These methods rely on the
computation of sensitivity of the output with respect to each input to choose
which inputs should be removed. The difficulty of this approach is selecting the
appropriate cut-off point for input significance and choosing an appropriate method
for computing sensitivity.
5. Methods combining the above four approaches.
2.6 NN for function approximation
A multilayer perceptron trained with backpropagation (see Subsection 2.3.3) can perform
a nonlinear input-output mapping, as stated in the
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Theorem 2.6.1. Universal Approximation Theorem
Let ϕ(·) be a non-constant, bounded and monotone-increasing function. Let Im0 denote
the m0 dimensional hypercube [0, 1]
m0. The space of continuous functions on Im0 is
denoted by C(Im0). Then, given any function f ∈ C(Im0) and ε > 0, there exist an
integer M and sets of real constants αi, θi, e wij, where i = 1, . . . ,m1 and j = 1, . . . ,m0
so that we may define
F (x1, . . . , xm0) =
m1∑
i=1
αiϕ
m0∑
j=1
wijxj + bi
 (2.42)
as an approximate realization of the function f(·), that is
| F (x1, . . . , xm0)− f(x1, . . . , xm0) |< ε
for all {x1, . . . , xm0} ∈ Im0.
The universal approximation theorem is directly applicable to FFNN: the logistic and
the tangent hyperbolic function (ϕ(v) = 1/(1 + e−2v) and ϕ(v) = (1 + e−2v)/(1 + e−2v)
respectively), used as activation function of hidden neurons of a multilayer perceptron
are both non-constant, bounded and monotone increasing function and, thus, satisfy the
requirements for ϕ(·). Furthermore, equation (2.42) represents the output of a FFNN
with m0 inputs, denoted as x1, . . . , xm0 , and a unique hidden layer with m1 neurons.
Hidden neuron i has synaptic weights wi1 , . . . , wim0 and bias bi and the network output
is a linear combination of the hidden layer outputs weighted with α1, . . . , αm1 . The
universal approximation theorem guarantees that a FFNN with a single hidden layer
can approximate a given training set represented by the set of inputs x1, . . . , xm0 and a
target output f(x1, . . . , xm0).
This theorem is important from a theoretical point of view, however, it does not
specify how to determine the multilayer perceptron architecture. Furthermore, it assumes
that the target function is known (without errors) and that a hidden layer, potentially of
unlimited size, could be used. Both these assumptions are usually violated and in several
applications more than one hidden layer is used.
In the context of function approximation, the use of backpropagation offers another
useful property. A FFNN with smooth activation functions should have output function
derivatives that can approximate the derivative of the unknown input-output mapping.
A theoretical proof of this statement is presented in [97] where it is shown that multilayer
perceptrons can approximate functions not differentiable in the classical sense, but with
generalized derivatives, as in the case of piecewise differentiable functions. This theorem
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justifies the use of FFNN in applications that require the approximation of both, a
function end its derivative.
2.7 NN models for glucose prediction: the chosen design
and implementation strategy
In NN theory there is no clear mathematically proven formula for successful network
modelling. Thus several popular rule of thumbs are normally adopted. In this section
we will describe our design choices, adopted for implementing and optimizing the NN
models described in Chapters 3, 4 and 5.
2.7.1 Input signals selection
The inputs of all the NN models were chosen using a mixed approach, exploiting a priori
knowledge, cross-correlation results and N-fold-cross-validation analysis. Indeed we used
prior knowledge from physiology to select available information which are known to
influence glucose concentration dynamics and generate (preprocessing this information)
a set of possible input signals. Afterwards we performed a cross-correlation analysis, on
the training set, between the target glucose concentration and every candidate input and
we repeated this analysis for various time lags of the candidate input. In this way we
determined if, effectively, a significant correlation between target and candidate input
exists and we also established whether a time lag should be applied to the candidate
input signal. Finally, in case there were multiple signals, relative to the same piece of
information, significantly correlated with future glycemia and in case the same signal
was significantly correlated for different time lags we used N-fold-cross-validation on the
training set, to test all the possible combination of inputs and select the best one.
It is worth noting that, before training the NN, all the selected input signals were
mapped to assume values merely in the range [−1, 1].
2.7.2 Structure optimization
The method we adopted for optimizing the NN structure is based on N-fold-cross-
validation, applied on the training set. For every developed NN model, we started with a
unique hidden layer with one neuron and we increased the number of neurons one by one,
testing the performance of every model using the three metrics described in Appendix C.
Increasing the number of hidden neurons initially improves the NN performance, however,
from a certain point inwards, results begin to worsen or the improvement is close to zero.
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Thus we selected the model that obtained acceptable performance with as few neurons
as possible. The selection was done primarily on the basis of the RMSE, however Time
Gain (TG) and ESOD were also used in case multiple models could be selected on the
basis of the RMSE.
A preliminary analysis showed that NN models with two hidden layers did not perform
better than NNs with a unique hidden layer. For this reason we concentrated on structures
with only one hidden layer of neurons.
2.7.3 NN training
All the proposed NN models were trained with backpropagation implemented in the
Levenberg-Marquardt variant, applied in batch mode [98,99]. The Levenberg-Marquardt
algorithm, like the quasi-Newton methods, was designed to approach second-order training
speed without having to compute the Hessian matrix. When the performance function
has the form of a sum of squares (as is typical in training FFNN), then the Hessian
matrix can be approximated as
H = JTJ (2.43)
and the gradient can be computed as
g = JTe (2.44)
where J is the Jacobian matrix that contains first derivative of the network errors with
respect to the weights and biases, and e is a vector of network errors. The Jacobian
matrix can be computed through a standard backpropagation technique [99] that is much
less complex than computing the Hessian matrix.
The Levenberg-Marquardt algorithm uses this approximation to the Hessian matrix
in the following Newton-like update:
wk+1 = wk −
(
JTJ + µI
)−1
JTe (2.45)
When the scalar µ is zero, this is just Newton’s method, using the approximate Hessian
matrix. When µ is large, this becomes gradient descent with a small step size. Newton’s
method is faster and more accurate near an error minimum, so the aim is to shift toward
Newton’s method as quickly as possible. Thus, µ is decreased after each successful step
(reduction in performance function) and is increased only when a tentative step would
increase the performance function. In this way, the performance function is always
reduced at each iteration of the algorithm.
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The original description of the Levenberg-Marquardt algorithm is given in [98] and
its application to neural network training is described in [99]. This algorithm appears to
be the fastest method for training moderate-size FFNNs (up to several hundred weights)
and has an efficient implementation in MatlabR©.
Early stopping was used for terminating the training routine. Thus, for every NN
model developed the training and validation set was randomly split into the effective
training set constituted by 70% of the data and the validation set formed by the remaining
30% of data. After every iteration on the whole training set the NN weights were updated
and the algorithm was tested on the validation set, to check if over-fitting was occurring.
Training was stopped when, for 100 consecutive times, the validation performance had
not increased and the weights of the last successful validation test were kept.
We also tested the backpropagation with Bayesian regularization training algorithm.
This technique updates the weight and bias values according to Levenberg-Marquardt
optimization, minimizing a combination of squared errors and squared weight values so
that, at the end of training, the resulting network has good generalization without using
early stopping. In addition, the unnecessary weights should assume values close or equal
to zero at the end of the training and should, potentially, be eliminated by the NN without
compromising its performance. This training procedure gave results comparable to those
obtained with the classical backpropagation, however it was considerably more time
consuming, thus the classical Levenberg-Marquardt algorithm was adopted. Furthermore,
using Bayesian regularization all the weights resulted significant at the end of the training,
confirming also that the chosen NN architecture was parsimonious.
One of the limitations of Levenberg-Marquardt backpropagation derives from the use
of the Jacobian for calculations, which assumes that performance is a mean or sum of
squared errors. Therefore the objective function minimized during training must be the
MSE or the SSE. Despite MSE and its variants (e.g. SSE, RMSE, etc) are widely used for
assessing the performance of glucose concentration prediction algorithms, these metrics
are suboptimal, as discussed in Appendix C. Indeed during training we might want to take
into account also the time anticipation of prediction, the adherence of the derivative of the
predicted time series to the derivative of the target signal and we might aim to assign a
higher penalty to overestimation of hypoglycemia and underestimation of hyperglycemia,
than to underestimation of hypoglycemia and overestimation of hyperglycemia. This
is not possible if the NN is trained using functions implemented in the Matlab Neural
Network toolbox.
We performed a preliminary analysis training the NN using a Genetic Algorithm (GA)
followed by a gradient descent method with initial parameters equal to the best solution
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found by the GA. As possible objective function we considered:
• A regularized MSE for limiting spurious oscillations due to noise amplification in
the predicted time series. Thus the objective function minimized was:
J = ‖yˆ − y‖2 + γ‖¨ˆy‖2 (2.46)
where ¨ˆy represents the second order time derivative of yˆ.
• A function penalizing both, deviation of prediction and of prediction derivative
from target and target derivative, respectively
J = ‖yˆ − y‖2 + γ‖ ˙ˆy − y˙‖2 (2.47)
where y˙ represents the first order time derivative of y.
• The gluco-specific MSE proposed in [100], which modifies MSE with a Clark error
grid inspired penalty function, which penalizes overestimation in hypoglycemia and
underestimation in hyperglycemia.
This training routine required a considerably higher time than Levenberg-Marqardt
backpropagation and gave no global improvement of prediction performance. For these
reasons all the proposed NN models described in the next Chapters will be trained with
the standard Levenberg-Marqardt backpropagation algorithm implemented in the Matlab
Neural Network toolbox.
However, as future work it might be worth investigating objective functions more
adequate for quantifying the goodness of glucose prediction.
2.8 Concluding remarks
As discussed in Section 1.4, the majority of algorithms for glucose concentration prediction
uses past CGM readings only as input and does not exploit available information on meal
and insulin therapy. One of the reasons is the difficulty of formalizing such information
in mathematical terms and of incorporating, among the inputs of the predictor, signals
with different characteristics, e.g. glucose concentration, meal and insulin. As we have
seen in this chapter, NNs allow the creation of empirical models using heterogeneous
information and are thus promising candidates for forecasting CGM utilizing, potentially,
all the available information. Moreover, their intrinsically non linear behaviour is an
appealing feature for accomplishing the task of learning a complex function as glucose
concentration time course.
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Our first aim will be the development of a short time (PH = 30 min) NN-based
predictor able to exploit information on CGM as well as on time and dose of CHO
ingested during meals. This will be accomplished in Chapters 3 and 4.
3
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3.1 Rationale
Rather surprisingly, complex prediction techniques based on NNs, as [66, 77] did not
significantly outperform the much simpler strategies based on time-series modelling. For
instance, in [66] results obtained, for the same dataset, with the NN strategy are similar
to those obtained with the AR(1) algorithm of [59]. Results of [77] indicate that the
NN described therein does not outperform the NN of [66], even if the first embeds also
information on meal intake, insulin medications, emotions and physical exercise.
A possible justification of this disappointing performance of NNs lies in the way NNs
have been used in [66, 77]. The following example motivates this assertion. Figure 3.1
displays a CGM time series (black dotted line) of a representative real subject. The plot
also shows the profile predicted by a simple linear strategy, the first order polynomial
algorithm of [59] (referred as poly(1) hereafter), with PH = 30 min (gray line). The plot
is restricted to a 8 h time interval to allow to better capture, visually, differences between
the different profiles. The prediction error of poly(1) is particularly low in the time
interval 11:00-14:30 h, where the target time series exhibits limited variability. Conversely,
the poly(1) prediction shows an evident loss of accuracy after meals. In fact, CHO intake
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can be thought as an exogenous disturbance that introduce a new component in glucose
dynamics that the linear poly(1) algorithm is not able to track promptly. Since FFNN
with nonlinear activation functions in their hidden layers have an intrinsically nonlinear
behavior, it would be natural to expect them to significantly improve on the simple
poly(1) prediction strategy. On the contrary, as shown in Figure 3.1, the NN (cyan line)
prediction of [66] behaves similarly to poly(1) and results inaccurate in correspondence
of the meal.
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Figure 3.1: Real CGM profile (black dotted line), the prediction with PH=30 min obtained
with poly(1) (gray line), and with the NN of [66] (cyan line). Plot taken from [66], (Fig.4).
The blue stem denotes CHO intake.
The theoretical potentialities of FFNNs in learning nonlinear relationships appear to
be not fully exploited when they have to model both linear and nonlinear components of
glucose dynamics. In [101] it has been suggested that when data show a relevant linear
pattern, in addition to a minor, but essential nonlinear component, the network could be
used in parallel with a linear model. The advantage of this approach is that the linear
model extrapolates the slope of the signal, while the NN learns only nonlinear dynamics.
Two alternative strategies can be used for identifying the complete model:
• The linear model parameters can be estimated in a first step and, successively, the
NN can be trained on the error of the linear model, keeping the linear model fixed.
• The linear model and the NN can be trained together.
The second strategy is more flexible, but the linear model is identified only in combination
with the nonlinear NN, thus it might not be a good representation of the process on its
own and may result unstable on its own.
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We adopt a similar approach for determining the glucose predictor: the NN we design
is trained to describe the nonlinear components in glucose dynamics that poly(1) is
not able to predict [102]. Indeed the NN model is in parallel with the linear prediction
algorithm. For this reason this architecture will be referred as NN-LPA from now inward.
This is a first major novelty of this approach, with respect to NNs proposed so far in
the literature. A second novelty is that the NN embeds, among its inputs, information
on ingested CHO, preprocessed with the physiological model proposed in [103], using
population parameters estimated in [104].
3.2 Architecture of the prediction algorithm
In order to ease the explanation of the methodology, in Figure 3.2 we report a block
diagram of the glucose predictor.
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D) NN MODEL
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Figure 3.2: Block scheme of the glucose predictor architecture. The model is composed by a
NN in parallel with a linear prediction algorithm and is called, for this reason, NN-LPA. In
our implementation Tm=15 time steps (i.e. 15 min), and Ta=10 time steps (i.e. 10 min).
Let us introduce the symbol x(t) to indicate the signal x measured at time step t;
the symbol xˆ(t2|t1) to indicate the signal x at time step t2, predicted using data until
time step t1, N is the PH in number of steps (thus, if the sampling period is of Ts min,
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N = PH/Ts), while z
−kx(t) = x(t− k), i.e. z−k indicates the k step delay operator.
As anticipated in the previous paragraph, yˆ(t+N |t), i.e. glucose concentration at
time step t+N , predicted from data available until time step t, results from the sum of
two components, yˆP (t+N |t) and eˆ(t+N |t). The first term yˆP (t+N |t) is the glucose
prediction obtained through a first order polynomial (thus, linear) algorithm (block
labelled as “A” in Figure 3.2), on the basis of the past CGM readings. Here the poly(1)
method of [59] is used. The calculation of the second term, eˆ(t + N |t), which is the
estimation of the error committed by the linear predictor, is more complex. A memory
block (denoted by “B” in Figure 3.2) stores yˆP (t+N |t) for N steps and, every time a
new glucose level y(t) is provided by the CGM sensor, the error e(t) = y(t)− yˆP (t|t−N)
is computed. The error e(t) and other inputs, which will be described in detail in
Subsection 3.2.1, feed a NN which is trained to predict e(t+N), i.e. the error affecting
yˆP (t+N |t) (block “D” in Figure 3.2, details reported in Section 3.3). Finally eˆ(t+N |t)
is summed to yˆP (t+N |t), to obtain a better estimate of y(t+N).
3.2.1 Description of the neural network model
The architecture of the network is schematized in block “D” in Figure 3.2. Inputs and
outputs are described below. Regarding the NN structure, it presents one hidden layer
with 8 neurons, each one with tangent hyperbolic activation function, and an output
layer with one neuron with linear transfer function. The network is totally connected
and feedforward.
The output of the NN is eˆ(t+N |t), i.e. the unknown error affecting yˆP (t+N |t) (the
present poly(1) prediction of y(t+N)).
As shown in block “D” of Figure 3.2, the first four inputs are:
• the current prediction error e(t) = y(t) − yˆP (t|t − N), where yˆP (t|t − N) is the
glycemia predicted N steps before by the linear model, and y(t) is the current
glycemia measured by the sensor;
• the trend of the prediction error, in the last Tm steps, (1− z−Tm)e(t).
• the current glucose concentration measured by the CGM sensor y(t);
• the glycemic trend in the last Tm steps (1− z−Tm)y(t), (with Tm = 15 steps, i.e.
15 min in our implementation).
Four other inputs are present in block “D” of Figure 3.2. They all depend on the
amount of ingested CHO. Information on ingested CHO provided by the patients is
impulsive, however, CHO effects on glycemia are neither impulsive, nor instantaneous,
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nor constant over time. For this reason, to exploit at best the available meal information
we preprocessed this input with a physiological model of oral glucose absorption (block
labelled as “C” in Figure 3.2). In particular, we used the model proposed in [103],
completed with the population parameters obtained in [104] (some details are reported
in Appendix A.1). Precisely, the NN uses:
• the glucose rate of appearance, i.e. the output of the glucose absorption simulation
model, predicted at time t+N , RaG(t+N);
• three differences of the predicted rate of appearance of ingested CHO:
1. (1− z−Ta)RaG(t+N),
2. (z−Ta − z−2Ta)RaG(t+N),
3. (z−2Ta − z−PH)RaG(t+N).
In our implementation on the data later described in Section 3.4, we will consider
Ta=N/3=10 steps (i.e. 10 min). This value of 10 steps was chosen because it captures
adequately the future dynamics of RaG in the time interval [t, t+N ]. Anyway, it should
be re-adjusted if different PHs or different sampling rates were considered.
The above network structure and inputs were determined, using the Matlab R2010a
Neural Networks Toolbox [91], exploiting a priori physiological knowledge and through a
10-fold-cross-validation strategy applied on the training set.
Remark: to correctly compute the future rate of appearance of ingested CHO, the
patient should announce the meal PH minutes in advance. However, in the absence of
meal announcement, the effect of ingested CHO could be computed retroactively when
the meal occurs, the only observed effect being a limited loss of prediction accuracy
during the PH minutes preceding the meal.
3.2.2 Mathematical representation of the NN model
Predicted glucose concentration is obtained as
yˆ(t+N |t) = yˆP (t+N |t) + eˆ(t+N |t) (3.1)
In particular, the first term in the right side of (3.1) is
yˆP (t+N |t) = θ1N + θ0 (3.2)
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where the parameters θ0 and θ1 are updated at each time step, (using a forgetting factor
µ chosen in (0,1)), by the equations
θ0 = y(t) (3.3)
θ1 = arg min
θ1
1
2
t∑
i=1
µt−i(y˜(i)− θ1(i− t))2 (3.4)
with
y˜ = y − y(t) (3.5)
For what concerns the NN prediction
eˆ(t+N |t) = Ψ · Φ(Γ ·X(t)) (3.6)
= ψ0 +
Nhn∑
j=1
ψjϕ
(
Nin∑
i=0
λjixi(t)
)
(3.7)
where X(t) indicates the [Nin+1] column vector of Nin input signals plus the input equal
to 1 associated with the weights representing the bias terms, i.e.
X(t) =
[
1, y(t), (1− z−Tm)y(t), e(t), (1− z−Tm)e(t), RaG(t+N), . . .
. . . (1− z−Ta)RaG(t+N), (z−Ta − z−2Ta)RaG(t+N), (z−2Ta − z−N )RaG(t+N)
]T
(3.8)
where the inputs correspond to the signals described in Section 3.2.1. Ψ represents the
[Nhn+1] row vector of weights connecting the L hidden neurons to the output neuron,
including also the bias term, (Ψ(k) = ψk is the weight connecting the k
th hidden neuron
to the output). Γ is the [Nhn x Nin+1] matrix of weights connecting inputs and hidden
neurons (Γ(ji) = γji represents the weight connecting the i
th input to the jth hidden
neuron). Φ is the tangent-sigmoid function, computed element-wise on the values of the
vector Γ ·X(t). By substituting (3.2), (3.3), (3.4) and (3.7) into (3.1) we obtain
yˆ(t+N |t) =
(
arg min
θ1
1
2
t∑
i=1
µt−i((y(i)− y(t))− θ1(i− t))2
)
N + y(t) + · · ·
· · ·+ ψ0 +
Nhn∑
j=1
ψjϕ
(
Nin∑
i=0
λjixi(t)
)
(3.9)
which is the explicit formula of the prediction schematized in Figure 3.2.
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3.3.1 Inputs and output preprocessing
The NN inputs and output were scaled, so that, at the beginning of the training procedure,
all the signals had potentially the same weight, and they all belonged to the linear range
of the tangent sigmoid activation function of the neurons of the hidden layer.
In particular, e(t) and its difference (1 − z−Tm)e(t), y(t) and its difference (1 −
z−Tm)y(t), and the target e(t + N) were mapped so that they had zero mean and
standard deviation equal to 0.5.
The signal RaG(t+N) was scaled in the range [0, 3] and its differences were mapped
so that they had zero mean and standard deviation equal to 0.25.
The rationale was obtaining mapped values mainly distributed in the range [−1, 1],
apart from RaG(t + N), whose mapped values were mainly concentrated in [0, 1], (in
fact RaG is a non-negative biological signal whose mean value is close to 0 and whose
statistical distribution is not symmetric).
3.3.2 Structure and weights optimization
The number of hidden neurons was chosen with 10-fold-cross-validation on the training
set and results equal to 8, thus, since the NN has 8 inputs, the number of free parameters
to be optimized during training is equal to 81. Network weights were randomly initialized
and optimized through a backpropagation Levenberg-Marquardt training algorithm,
applied in a batch mode. The training procedure was stopped, using cross-validation,
after 100 consecutive worsenings of the NN performance on the validation set, to avoid
overfitting.
3.4 Test-bed
3.4.1 Simulated data
Twenty virtual patients were extracted from the UVA/Padova T1D Simulator [73,84].
For each subject the simulation scenario consisted of 11 consecutive days of monitoring,
with 3 meals per day. Breakfast was randomly located in the time interval 06:00-08:00 h,
and consisted of 45+u g of CHO, where u is a random variable drawn from the uniform
distribution u ∼ U(−10, 10)g which is used to have more realistic simulations and to
account for variability in CHO intake. Lunch was randomly located in the time interval
12:00-14:00 h, and consisted of 75+u g of CHO; finally, dinner was randomly located
in the time interval 19:00-21:00 h, and consisted of 85+u g of CHO, with u defined as
56
New glucose prediction method by NN plus linear prediction algorithm
(NN-LPA)
specified above. In order to obtain a significant number of hypo and hyperglycemic events,
in 50% of cases the nominal insulin dosage in correspondence to meals was randomly
modified by adding a quantity sampled from a uniform distribution between -3 and +3 U.
Finally, realistic CGM time series were obtained by adding a noise sequence generated
by an AR first order model (with pole in 0.95) driven by white Gaussian noise with
zero mean and variance equal to 2. Such a noise sequence proved more realistic than
that obtained with the noise model embedded in the simulator, which had already been
demonstrated to be suboptimal [105].
Each of the 20 simulated profiles was divided in three subseries of 3 days, obtaining 60
CGM profiles, that were randomly divided into a training and validation set (40 profiles)
and a test set (20 series). 70% of the data in the training set was used to optimize the
NN weights’ values, while the remaining 30% of the data was used to stop the training
algorithm by cross-validation (see Subsection 3.3.2). Profiles in the test set did not take
part in the NN architecture optimization, neither in its training nor validation.
3.4.2 Real data
The real data available when we implemented this algorithm were those collected during
the first year of the DIAdvisor project [85], during the DAQ trial (see Appendix B for
details). 15 T1D patients were monitored for 7 consecutive days with the FreeStyle
NavigatorR©CGM system, that returns a glucose value every minute. The patients were
not hospitalized, and neither insulin nor meal were programmed and thus assumed not to
have fixed schedule. Since the NN requires, among its inputs, the estimation of the future
RaG, PH minutes in advance, it is assumed that patients announce meal information (i.e.
time and amount of CHO) at least PH minutes ahead in time.
The NN was trained and validated on 25 time series, each one of 3 days, selected so
as to ensure a wide variety of glycemic dynamics. Nine daily profiles, containing several
hypo and hyperglycemic events, were used to test the NN.
3.5 Results
The proposed NN was assessed in term of RMSE, TG and ESODnorm (see details in
Appendix C) and compared with the NN developed by Pe´rez Gand´ıa et al. [66] and the
AR(1) model of Sparacino et al. [59], implemented on the same dataset.
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3.5.1 Simulated data
NN-LPA and the NN of Pe´rez Gand´ıa et al. [66], (hereafter referred as NNPG), were
both trained on the training set and tested on the independent test set. Consistently, the
forgetting factor of the AR(1) model was tuned on the training set, and the predictor
performance was assessed on the test set. Data did not undergo any preprocessing (e.g.
digital filtering).
An example of the application of the three prediction algorithms with PH = 30 min
is displayed in Figure 3.3. A short time window (06:30-16:00 h) is reported, in order to
allow the reader to better capture differences among the behavior of the three predictions.
Anyway we would like to stress that numerical results were calculated on the whole
3-days test series. The figure compares the prediction obtained with NN-LPA (orange
line) with those of NNPG (cyan line) and AR(1) (gray line). The target signal, i.e. the
original CGM recording, is also reported (black dotted line). It is worth clarifying that
the predicted signal is plotted at the time instant to which it refers, i.e. the value plotted
at a certain time is obtained N time steps earlier, using only data available until N time
steps earlier.
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Figure 3.3: A synthetic CGM profile (black dotted line), and the predictions (PH=30 min)
obtained with NN-LPA (orange line), NNPG (cyan line), and AR(1) (gray line). CHO ingestion
is evidenced by blue stems.
As seen by inspection, NN-LPA performs better than NNPG and AR(1). The
prediction obtained by NN-LPA is more adherent to the target profile than NNPG and
AR(1), as confirmed by the lower RMSE equal to 9.0 mg/dL for NN-LPA and 11.1 mg/dL
and 20.45 mg/dL for NNPG and AR(1), respectively. Furthermore, prediction obtained
with NN-LPA has less spurious oscillations than NNPG prediction, as confirmed by
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ESODnorm equal to 2.12 for NN-LPA, 3.5 for AR(1) and 37.9 for NNPG. The most
significant improvement can be found after CHO ingestion, i.e. when the performance of
NNPG was already observed to be suboptimal (see Figure 3.1). Indeed, in these intervals
NN-LPA detects the changes in the sign of the CGM derivative more quickly. This is
confirmed also by the higher TG, equal to 27.0 min for NN-LPA, 17.0 min for NNPG
and 21.0 min for AR(1). Performance obtained for the other subjects are similar.
Table 3.1 reports a summary of the average results obtained by the three prediction
algorithms on all the 20 simulated CGM time series of the test set, and p-values returned
by the non-parametric Mann-Whitney U test1 [106].
Table 3.1: Summary of performance indexes (Mean ± SD) on the 20 simulated datasets (with
PH=30min). Asterisk (∗) indicates statistically significant difference at the 5% confidence
level. p-values are also reported. The lower the RMSE, the higher the TG, the closer to 1
ESODnorm the better the quality of the predicted profiles.
NN-LPA NNPG AR(1)
RMSE [mg/dL] 9.4± 1.5 10.7± 1.9∗ 17.5± 6.4∗
p-value 0.0275 1.6 · 10−5
TG [min] 24.9± 4.4 16.5± 3.6∗ 21.5± 2.9∗
p-value 0 0.0156
ESODnorm [-] 1.9± 0.2 39.3± 4.7∗ 3.39± 0.2∗
p-value 6.8 · 10−8 6.8 · 10−8
The RMSE is satisfactory for both NNs, and significantly lower than for AR(1).
Moreover NN-LPA is slightly but significantly more accurate than NNPG in predicting
the future glycemia, with a PH of 30 min. As far as TG is concerned, NN-LPA ensures
almost 25 minutes of net anticipation. This would be a major improvement over NNPG
(+8.3 min greater), and over AR(1) (+4.5 min greater) since such a large margin of time
would allow patients to take more effective countermeasures to e.g. avoid (or at least
mitigate the effect of) dangerous hypoglycemic events. ESODnorm is significantly lower
for NN-LPA (1.9) than for NNPG (39.3), and for AR(1) (3.4) indicating that NN-LPA
predicted profiles exhibit fewer spurious oscillations. From a patient perspective, the
smoothness of the predicted time series is crucial, since oscillations can facilitate the
generation of false hypo and hyper-alerts, lowering the predictor reliability. Remarkably,
1The Mann-Whitney U test is a statistic non-parametric test of the null hypothesis that two populations
are the same against an alternative hypothesis. It has greater efficiency than the t-test on non-normal
distributions, and it is nearly as efficient as the t-test on normal distributions.
3.5 Results 59
NN-LPA significantly outperforms AR(1), in addition, even though the RMSE appears
similar for NN-LPA and for NNPG, the profiles predicted by NN-LPA are definitely more
“usable”, than the time series predicted by NNPG, as confirmed by the other indexes.
The non-parametric Mann-Whitney U test confirms that all the differences observed
between the numeric values of the indexes are significant (see p-values in Table 3.1).
3.5.1.1 Robustness to errors in meal information
A robustness analysis to assess the impact of errors in meal timing and CHO size estimates
was also performed. Two major scenarios, each one with four different subcases, were
created. In the first, all meal timings were anticipated or delayed by -10, -5, +5, and
+10 minutes, respectively. In the second, errors of -20%, -10%, +10%, and +20% on
all meal sizes were introduced. Note that all these scenarios correspond to a worst-case
evaluation of NN-LPA behavior in the presence of inaccurate meal data, since, in each
subcase, all meals were shifted/ wrongly estimated by the considered time/ amount.
Average results are reported in Table 3.2, where p-values refer to the comparison to the
reference case, (no errors on meal information). As we can observe, NN-LPA is robust
on both errors. In fact, all indexes do not significantly change from the reference results,
except RMSE when meal timing is delayed by 10 min, TG when a 20% reduction of
CHO amount is applied, and ESODnorm in the 20% CHO amount increase scenario. The
Mann-Whitney U test confirms that results obtained with slightly inaccurate meal data
are, in the majority of cases, not statistically different from those obtained with perfect
meal data.
3.5.2 Real data
Figure 3.4 shows the result of the application of the three prediction algorithms to
two different real CGM (Abbott FreeStyle NavigatorR©) profiles. To better appreciate
differences among predictions the displayed interval is restricted to a 8 h time window.
As for simulated data, numerical results refer to the whole 1 day time series, and we chose
to plot time windows containing at least one meal, to better show the advantage given by
NN-LPA over reference methods. In fact, glucose dynamics are faster and more difficult
to predict after a meal than during the night, when glucose concentration behavior is
more regular because of the absence of exogenous inputs.
As already observed in simulation, NN-LPA outperforms NNPG and AR(1). In
particular, NN-LPA detects changes in the sign of CGM derivative more quickly. This
results evident in Figure 3.4(a) around 13:00 h and 18:00 h and in Figure 3.4(b) around
09:00 h and 14:00 h. The greater “usability” of the forecasted profile obtained by
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(a) Subject 1.
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Figure 3.4: Two representative real CGM profiles (black dotted line), and the predictions
(PH=30 min) obtained with NN-LPA (orange line), NNPG (cyan line) and AR(1) (gray line).
CHO ingestion is evidenced by blue stems.
NN-LPA, with respect to the time series predicted by NNPG, can be appreciated in
Figure 3.4(b), where due to the noise affecting the CGM values measured by the sensor,
NNPG predictions exhibit non-physiological oscillations, and, occasionally, cross the hypo
and hyperglycemic thresholds, even when the true glucose stays in the euglycemic range,
potentially generating three false hypo-alerts at 12:00 h, 13:20 h, and 13:25 h. Regarding
quantitative indexes relative to Figure 3.4(a):
• RMSE is 20.7 mg/dL for NN-LPA, 23.5 mg/dL for NNPG and 31.9 mg/dL for
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AR(1);
• TG is 16.0 min for NN-LPA and 13.0 min for both NNPG and AR(1);
• ESODnorm is 4.4 for NN-LPA, 62.6 for NNPG and 5.5 for AR(1).
Regarding quantitative indexes relative to Figure 3.4(b):
• RMSE is 13.5 mg/dL for NN-LPA, 15.5 mg/dL for NNPG and 23.8 mg/dL for
AR(1);
• TG is 16.0 min for NN-LPA, 13.0 min for NNPG and 17.0 min for AR(1);
• ESODnorm is 1.0 for NN-LPA, 99.9 for NNPG and 3.2 for AR(1).
Table 3.3 reports the average results for the indexes obtained in the 9 real CGM test
series, and the p-values obtained with the non-parametric Mann-Whitney U test.
Table 3.3: Summary of performance indexes (Mean ± SD) on the 9 real datasets (with
PH=30min). Asterisk (∗) indicates statistically significant difference.
NN-LPA NNPG AR(1)
RMSE [mg/dL] 14.0± 4.1 14.2± 4.5 19.6± 7.2*
p-value 1 0.0625
TG [min] 16.2± 3.7 12.8± 1.6∗ 16.7± 4.2
p-value 0.0153 0.776
ESODnorm [-] 2.7± 1.6 105.3± 52.8∗ 3.9± 0.8
p-value 4.11 · 10−5 0.077
In accordance with what is observed on the simulated data, the RMSE is almost
identical for the two NNs, and better than for AR(1), indicating that the accuracy of
the predictions is comparable or improved. The TG achieved by NN-LPA is better than
the one obtained with NNPG (+3.5 min), and is comparable with the TG of AR(1).
It is worth noting that a TG of 16 min is sufficient to mitigate the effects of a hypo
or hyperglycemic event, increasing the utility of the proposed prediction algorithm in
a therapeutic perspective. As far as ESODnorm is concerned, the value obtained by
NN-LPA is markedly lower than the value achieved by NNPG, and slightly lower than
the value obtained by AR(1). This means that NN-LPA forecasts are much more regular
than those of NNPG, without spikes and with far fewer spurious oscillations, possibly
leading to false crossings of the euglycemic thresholds.
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The results obtained on real test data support quantitatively what already observed
on simulated data. Not only NN-LPA predicts the future glycemia with a high accuracy,
especially during and after meals, but it also achieves a TG large enough to mitigate, or
even totally avoid, future glucose excursions out of the euglycemic range. An exhaustive
quantification of the potential reduction of hypoglycemia that could be obtained using
NN-LPA’s predicted profiles is reported in Chapter 7.
3.6 Conclusions and margins for further improvement
NN-LPA combines a NN model with a first-order polynomial predictor and uses them in
parallel to forecast, respectively, the nonlinear and linear components of glucose dynamics.
In this way the prediction algorithm takes advantage of the ability of poly(1) to predict
linear components of glucose dynamics and of the ability of NN to track the nonlinear
components (e.g. after meals). The NN also uses available information on CHO intake,
preprocessed with a literature physiological model [103,104].
Results both on 20 simulated and 9 FreeStyle NavigatorR©real datasets demonstrated
that this approach improves on the recent NNPG approach [66], and over the AR(1)
model proposed in [59]. In particular, on simulated data the RMSE achieved by NN-LPA
is significantly lower than NNPG, (-2.09 mg/dL), and than AR(1) (-8.1 mg/dL) with
a simultaneous increase of the average TG (+10 min and +3.5 min with respect to
NNPG and AR(1) respectively). Similar results were obtained also on the 9 real datasets.
Thanks to the information on CHO intake, the proposed algorithm is highly accurate
especially during and after meals. In particular, it is faster than the reference NNPG and
AR(1) methods in detecting upward changes in the glycemic trend due to CHO ingestion.
These results have been published in [102].
The proposed method is totally causal and, once trained, the parameters of the
NN are fixed and its real-time implementation is computationally light; however, the
poly(1) model is time-varying, thus its parameter should be re-optimized at each time
step using RLS and past CGM values, weighted by a forgetting factor µ. The algorithm
is almost completely autonomous in computing its inputs, the only burden for the patient
would be to provide information on CHO content of meals PH minutes in advance. This
requirement might be an issue, since in real life it is not always possible to estimate
roughly, with an anticipation of 30 min, the amount of CHO of the future meal.
These limitations, i.e. the necessity of updating the parameters of the linear model at
each time step and the requirement of announcing the meal at least 30 min in advance
will be overcome by the NN predictor presented in Chapter 4.
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4
Further development of glucose prediction
methods by jump NN
4.1 Rationale
In this chapter we will describe a novel NN architecture we proposed to overcome the
three major limitations of NN-LPA, i.e.:
1. the need of a time-varying linear model in parallel with the NN structure;
2. the necessity of announcing the meal PH min in advance;
3. the fact that the NN models the nonlinear relation between past and future CGM
and both, linear and nonlinear effects of glucose rate of appearance in the blood,
on future glucose concentration.
As pointed out in Subsection 2.2.3 of this thesis, jump NNs are particularly suitable
for fitting and predicting time series characterized by the presence of both linear and
nonlinear dynamics. This is the case of glucose signals, where we may assume that
each input is able to influence future blood glucose concentration with both linear and
nonlinear effects.
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Thus our aim is to implement a predictor based on a jump NN and evaluate if it is
able to obtain results comparable to, or better of, those of NN-LPA, despite the simpler
structure and without announcing the meal ahead in time [107].
4.2 Architecture of the Jump NN
The architecture of the proposed jump NN is schematized in Figure 4.1.
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x3(t)
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Figure 4.1: Block scheme of the proposed jump NN model for glucose prediction.
As we can note, the main differences with respect to Figure 3.2 are the absence of
the polynomial model and the presence of weights connecting each input also to the
target. Inputs and output are similar to those of NN-LPA: the NN output is the future
CGM signal, with a PH of 30 min, and the 4 NN inputs are the glycemic concentration
value, currently measured by the CGM sensor, the current trend of the CGM signal,
the glucose rate of appearance, simulated with the model of [103], using as parameters
the population values estimated in [104] and its derivative. To face ill-conditioning, the
trend of the CGM signal is computed using a Bayesian smoothing approach [108]. For
what concerns meal-related information, no meal announcement is required. Indeed, a
cross-correlation analysis between the estimated RaG obtained with [103] and glucose
concentration, considering various time shifts, confirmed that correlation between the
current RaG and glucose concentration observed 30 min in the future assumes a value
comparable to that of the correlation between future RaG and future glycemia.
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The jump NN predicts a signal that may be expressed as:
yˆ(t+N |t) = Ω ·X(t) + Ψ · Φ(Γ ·X(t)) (4.1)
=
Nin∑
i=0
ωixi(t) +
Nhn∑
j=1
ψjϕ
(
Nin∑
i=0
λjixi(t)
)
(4.2)
where X(t) indicates the [Nin+1] column vector of Nin input signals at time step t, plus
an input equal to 1 associated with the weights accounting for the bias terms,
X(t) =
[
1, y(t), ∆BSy(t), RaG(t), (1− z−N )RaG(t)
]T
, (4.3)
Ω is the [Nin+1] row vector of weights connecting every input directly to the output
neuron, thus Ω(i) = ωi indicates the weight connecting the i
th input to the output
neuron. ∆BS indicate the Bayesian smoothing paradigm adopted for computing the
signal derivative. Ψ is the [Nhn] row vector of weights connecting every hidden neuron
to the output neuron, thus Ψ(j) = ψj is the weight connecting the j
th hidden neuron
to the output neuron. Γ is the [Nhn x Nin] matrix of weights connecting every input to
every hidden neuron, thus Γ(ji) = γji indicates the weight connecting the i
th input to
the jth hidden neuron. Notably, the second addendum of the right hand side of equation
(4.2) coincides with the last term of equation (3.9), (apart from differences in some input
signals of the NN). The first addendum of equation (4.2) can be developed as
Ω ·X(t) =
Nin∑
i=0
ωixi(t) =
= ω0 + ω1y(t) + ω2 (∆BSy(t)) + ω3RaG(t) + ω4
(
(1− z−N )RaG(t)
)
(4.4)
By comparing equation (4.4) and the first two terms of equation (3.9) we note that the
term ω1y(t) + ω2 (∆BSy(t)) gives a contribution similar to that of the polynomial model
(i.e. θN1 N + y(t)). Moreover, the term ω3RaG(t) + ω4
(
(1− z−N )RaG(t)
)
accounting for
the linear effect of ingested CHO on future glycemia has no counterpart in (3.9). This
comparison confirms that the absence of the polynomial model is fulfilled by the weights
directly connecting y(t) and ∆BSy(t) to the output and that, in addition, the jump NN
also takes into account the linear effects of CHO on future glycemia.
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4.3 Jump NN training
4.3.1 Inputs and output preprocessing
Before training the jump NN, inputs and outputs were normalized, so that they had
zero mean and standard deviation equal to 1 so that, at the beginning of the training
procedure, all the signals had, potentially, the same importance and they all belonged
to the input range in which the tangent sigmoidal activation functions have a linear
behavior.
4.3.2 Structure and weights optimization
The jump NN structure was optimized and trained following a procedure analogous to
that used for NN-LPA (see Chapter 3, Subsection 3.3.2). The number of hidden neurons
was chosen with 10-fold-cross-validation on the training set and is equal to 5 neurons,
with tangent sigmoidal activation function. Thus, since the number of input signals
is equal to 4, plus the bias-related term, there are 35 free parameters to tune during
training. This is considerably lower than the number of weights of NN-LPA, which, after
having re-optimized its structure on data sampled every 5 min, is equal to 65 (see Remark
in Section 4.4 for details).
The jump NN parameters were randomly initialized and optimized with the back-
propagation Levenberg-Marquardt training algorithm, applied in batch mode. The
training procedure was stopped using cross-validation, after 100 consecutive worsening of
the performance of the algorithm on the validation set. The above NN structure was
optimized with the Matlab 2011b Neural Network toolbox [91].
4.4 Test-bed
Data collected during the second session of the DIAdvisor [85] project were used to
optimize and train the jump NN. In particular data of 20 type 1 diabetic patients,
monitored for 2 or 3 consecutive days in real-life conditions were considered. CGM
was measured by the Dexcom SEVEN PLUS CGM sensor, which has a sampling time
of 5 min. We chose to implement the algorithm on the new available data, instead of
using the same database of NN-LPA, because SEVEN PLUS data were less noisy and
information on meals and insulin therapy was more reliable. Furthermore, developing
the algorithm on data of a widely used commercial device, as the SEVEN PLUS CGM
sensor, characterized by a sampling period of 5 min, as the vast majority of CGM devices,
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rendered results potentially more appealing in light of possible effective implementation
in commercial sensors.
The database was divided into a training and validation set, constituted by 10 time
series and a test set, formed by the other 10 time series. During training, the training
and validation set was further randomly divided into the training set constituted by 70%
of the data, used for minimizing the prediction error and the validation set constituted
by the remaining 30% of data, used for stopping the training procedure.
Remark: The NN-LPA of the previous chapter was developed not on SEVEN PLUS
data, (sampling time 5 min), but on FreeStyle NavigatorR©data (sampling time 1 min),
which was the CGM sensor used during the DAQ trial of the DIAdvisor project. For a
fair comparison, NN-LPA inputs and structure were re-optimized on the new dataset.
The updated NN-LPA has 6 inputs instead of 8, since only one derivative of RaG was
selected (at time t the selected signal was (1− z−N )RaG(t+N)), while the number of
hidden neurons was unchanged, thus equal to 8, leading to 65 free parameters.
4.5 Results
The 3 panels of Figure 4.2 show approximately one day of monitoring of 3 representative
subjects. The black dotted line is the target signal, measured by the sensor, the orange
line is the prediction obtained with NN-LPA, described in Chapter 3, used as reference,
and the blue line is the signal predicted by the jump NN. The two horizontal thin lines
correspond to the hypo- and the hyper-glycemic threshold, while the stems represent
CHO ingestion. Figure 4.2(a) shows a representative example where the performance of
the jump NN and of NN-LPA are very similar, as confirmed also by numerical results
reported in the first row of Table 4.1. Indeed, even from visual inspection, we can note
that both predictions are close to target (RMSE=17.6 mg/dL for the jump NN, and
RMSE=22.9 mg/dL for NN-LPA) and both NNs forecast with a minimum time lag
changes in the trend and in the dynamics of the CGM signal (TG=15 min for both
models). Furthermore, spurious oscillations are limited (ESODnorm equals 9.9 for the
jump NN and 13.5 for NN-LPA). This suggests that the predicted profile could be useful
for generating preventive alerts in case of impending hypo- and hyper-glycemia, with
a low risk of generating false alerts. Figure 4.2(b) shows an example where the jump
NN outperforms NN-LPA in terms of RMSE and TG (see fourth row of Table 4.1). The
lower RMSE corresponds to the lower over-estimation of the target in correspondence
of hyperglycemic picks, around time 14:20 h and 20:20 h, while for what concerns the
TG, the jump NN predicts the downward trends from time 21:00 h to 00:00 h and from
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(a) Subject 1. NN-LPA and the jump NN show very similar performance.
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(b) Subject 4. The jump NN outperforms NN-LPA in terms of RMSE and TG.
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(c) Subject 10. The jump NN has a TG slightly worse than NN-LPA.
Figure 4.2: CGM profile (black dotted line) and prediction obtained with NN-LPA (orange
line) and with the new jump NN (blue line). Stems indicate CHO ingestion, horizontal thin
lines represent the hypo- and the hyperglycemic threshold.
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09:00 h to 10:30 h better than NN-LPA. Finally, Figure 4.2(c) shows a case where the
jump NN has a TG slightly worse than NN-LPA, as confirmed by its visible greater
delay in forecasting the signal downward trend in the time interval 16:00-18:00. Results
obtained on the 10 time series are shown in Table 4.1, where also average results and the
p-values obtained with the non-parametric Mann-Whitney U test are reported.
Table 4.1: Results obtained on the 10 test subjects (with PH=30 min), average (mean±sd)
values and p-values computed with the non-parametric Mann-Whitney U test.
RMSE [mg/dL] TG [min] ESODnorm [-]
Jump NN NN-LPA Jump NN NN-LPA Jump NN NN-LPA
subj 1 17.6 22.9 15 15 9.9 13.5
subj 2 20.3 21.2 15 20 10.0 7.4
subj 3 13.1 15.9 20 20 8.7 7.1
subj 4 12.0 15.9 25 20 7.4 7.5
subj 5 15.6 21.2 20 20 8.5 8.5
subj 6 15.9 20.1 20 20 12.6 23.7
subj 7 13.7 15.1 20 20 9.4 10.0
subj 8 17.8 18.7 15 20 8.1 7.4
subj 9 18.2 22.8 20 20 12.0 9.9
subj 10 21.3 23.2 15 20 9.8 9.6
mean±sd 16.6±3.1 19.7±3.1 18.5 ± 3.4 19.5±1.6 9.6±1.6 10.5±5.0
p-value p=0.08 p=0.35 p=0.38
Average results confirm what observed on the 3 subjects plotted on the 3 panels of
Figure 4.2: predicted CGM profiles are close to the target time series measured by the
CGM sensor, as we can infer from the RMSE that, in every subject, is lower for the jump
NN than for NN-LPA. In addition, the jump NN predictions are characterized by a TG
ranging from 15 min to 25 min, with an average value of 18.5 min. Furthermore, the
presence of spurious oscillations, due to measurement noise, is limited, as confirmed by
the low values of ESODnorm obtained in all subjects. p-values confirm that no statistically
significant difference exists between the two NNs.
4.6 Conclusions and margins for further improvement
Results reported in Section 4.5 allow us to conclude that the jump NN predicts satis-
factorily future glycemia, giving results statistically comparable to those of NN-LPA. It
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is worth stressing that the jump NN has a simpler structure, indeed once trained, it is
time-invariant and, differently from NN-LPA, does not need a time-varying polynomial
model in parallel with it. Remarkably, while the reduction of operations needed for
predicting future glucose concentration is irrelevant in a personal computer, it can be of
great impact if implemented in the chip of a CGM sensor, where computational power and
memory are limited and shared between various simultaneous processes and algorithms.
Moreover, the jump NN does not need meal announcement, since it uses information
on quantity of ingested CHO until the current time instant, thus the subject simply
has to enter this information at the same time of the meal. Differently, NN-LPA needs
information on future ingestion of CHO, with an anticipation of PH min, thus the subject
should announce the correct quantity of CHO he/she will ingest PH min in advance,
which is often unlikely to be doable in every-day life conditions. These results have been
published in [107].
A further improvement of the jump NN model will be the inclusion of information on
insulin therapy, which we will investigate in Chapter 5.
5
Inclusion of insulin information
5.1 Rationale
As discussed in Chapter 4 the jump NN using information on past CGM and on timing
and CHO content of meals resulted equivalent, in terms of performance, to NN-LPA,
which is constituted by a feedforward NN in parallel with a time-varying first order
polynomial model, whose parameters need to be re-adjusted at each time step and requires
meal announcement PH minutes in advance. Given the simpler structure of the jump NN
predictor, we decided to adopt this model and try to further improve its performance, by
adding, to CGM and CHO related inputs, signals derived from information on timing
and dose of insulin therapy [109,110]. In particular, we analyzed PHs of 15, 30, 45 and
60 min and we compared the performance of four NN predictors using different input
combinations:
1. NN CGM using CGM;
2. NN I using CGM and insulin (timing and dose of bolus);
3. NN M using CGM and meal (timing and CHO content);
4. NN I+M using CGM, insulin (timing and dose of bolus) and meal (timing and
CHO content).
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5.2 Architecture of the jump NN-based predictors
The structure of the chosen predictor is similar to that of the jump NN described in
Section 4.2 of this thesis and is schematized in Figure 5.1.
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Figure 5.1: Block scheme of the jump NN prediction model.
For what concerns the mathematical representation of the predictor, it is analogous
to equation (4.1), apart from the input vector X. For easing the reader, we report the
equations and the meaning of symbols. The predicted signal at time t is
yˆ(t+N |t) = ΩX(t)T + ΨΦ (ΓX(t)) (5.1)
where X(t) is the [Nin + 1]-size column vector of inputs at time instant t, including an
entry equal to 1 accounting for the bias term; Ω is the row vector of length Nin + 1 of
weights connecting the inputs directly to the output neuron; Ψ is the row vector of size
Nhn of weights connecting the hidden neurons to the output neuron; Γ is the matrix of
size [Nhn ×Nin + 1] of weights connecting the inputs to the hidden neurons and Φ is the
hyperbolic tangent activation function of the hidden neurons, computed element-wise on
the elements of the matrix ΓX(t); Nin is the number of inputs and Nhn indicates the
number of hidden neurons. Thus, yˆ(t+N |t), i.e. prediction obtained at time instant t,
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and relative to t+N , can be expressed, explicitly, as
yˆ(t+N |t) =
Nin∑
i=0
ωixi(t) +
Nhn∑
j=1
ψjϕ
(
Nin∑
i=0
γjixi(t)
)
(5.2)
where xi(t) is the i
th input at time t; ωi is the weight connecting the i
th input to the
output neuron; ψj is the weight connecting the j
th hidden neuron to the output neuron;
γji is the weight connecting the i
th input to the jth hidden neuron and ϕ(·) is the tangent
hyperbolic activation function. The vector of inputs, for model 4, (i.e. NN I+M), is
X(t) =
[
1, y(t), ∆BSy(t),
t+N∑
i=t
RaG(i),
t+N∑
i=t
RaI(i)
]T
, (5.3)
with ∆BS indicating the Bayesian smoothing approach for computing glucose concentra-
tion first-order time derivative. Details on the procedure adopted for choosing the input
signals are reported in the next section.
5.3 NN inputs
When dealing with insulin information, we had to face three major issues:
1. insulin information is impulsive, while insulin effects last several hours and are not
constant over time;
2. insulin injection and CHO ingestion are almost always concomitant and proportional
to each other, thus the signals are highly correlated;
3. insulin action is affected by physiological delays and inter- and intra-subject vari-
ability is high.
To cope with the first problem we adopted a solution analogous to that used for CHO
information. Indeed insulin was preprocessed with a state-of-art physiological model [103],
completed with population parameters estimated in [104] to generate insulin rate of
appearance (RaI) in the blood. This signal is an estimate of the velocity with which
insulin enters the blood stream after injection. Details are reported in Appendix A.2
Since insulin injection and CHO ingestion are usually concomitant and proportional
to each other, RaI and RaG signals are highly correlated. Thus, to solve issues 2 and 3
we delayed the input related to insulin of 60 min, in line with results obtained in [111],
where the average physiological delays in insulin action was estimated to be equal to
60 min.
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It is worth noting that we used only information relative to insulin bolus therapy (for
patients using insulin pumps) or to fast-acting insulin bolus therapy (for patients using
fast and slow insulin). The rationale for discarding information on basal or slow insulin
is that those inputs have slow effects, quasi constant over the whole day, thus they do
not relevantly affect glucose dynamics during the PHs we considered in our analysis.
For choosing the effective NN inputs, we adopted a mixed strategy based on a priori
physiological knowledge, correlation analysis and 10-fold-cross-validation results.
For what concerns the input signals relative to CGM history, in line with the jump
NN described in Chapter 4 and the NN-LPA described in Chapter 3, we used the
current glucose concentration, measured by the sensor and its first-order time derivative,
computed using a Bayesian smoothing approach [112]. Parameters of the Bayesian filter
were fixed to render it computationally light and potentially implementable in real time,
even on a CGM device.
For what concerns meal and insulin related inputs, we considered various signals
related to RaG and RaI , e.g. their past, current and future (predicted using only
current information) values, their first-order time derivatives and their cumulative sum
calculated on a sliding window. We computed the correlation between these signals and
the target glucose concentration, for every PH we wanted to predict (i.e. 15, 30, 45 and
60 min) and we choose the signals whose correlation with future glucose concentration
was higher, possibly for all the PHs. Two signals relative to meal and two signals relative
to insulin had a pretty high correlation with future glucose, for every PHs: the current
rate of appearance and the cumulative amount of insulin/ glucose, computed summing,
respectively, the values of RaI and RaG between the current and the predicted time
instant. However, a 10-fold-cross-validation analysis on the training set showed that if
both the inputs relative to CHO and both the inputs relative to insulin were used, the
NN converged prematurely and had poor performance. The best results were obtained
when the cumulative amount of insulin and glucose were used as inputs.
5.4 NN training
Each NN structure was optimized, for each PH, via 10-fold-cross-validation on the training
set. All the NNs have a single hidden layer with a number of neurons ranging from 4 to
5 and one output neuron.
Before training the NN, inputs and output were normalized, so that they had zero
mean and standard deviation equal to 1. Network parameters were randomly initialized
and optimized through a backpropagation Levenberg-Marquardt training algorithm,
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applied in a batch mode. The training procedure was stopped using cross-validation,
after 100 consecutive worsening of the performance of the algorithm on the validation set.
From a preliminary analysis we noted that the NN was particularly inaccurate in
predicting hypoglycemia, especially for PHs longer than 30 min. This is likely due to
the fact that low glucose concentration values are a small percentage of the data, thus
their impact on the MSE objective function minimized during training is minimal. To
improve the NN performance in the hypoglycemic range, weights proportional to the
risk of hypoglycemia [113] were used during training to increase the weight of prediction
errors when the target glucose concentration is below 100 mg/dL.
5.5 Test-bed
The algorithms are optimized and tested on data collected during the project DIAdvisor
[85]. In particular data of 15 type 1 diabetic patients, monitored for 3 consecutive real-life
days are considered. Part of this dataset coincides with that used for the jump NN
described in Chapter 4. Some new time series, rendered available only at the end of the
project, were included while some of the time series used previously had to be discarded,
because insulin information was missing. CGM was measured by the SEVEN PLUS
CGM sensor, (TS=5 min).
The dataset was divided into a training and validation set (including the first day
of monitoring of every subject) and a test set (containing the following two days of
monitoring of every subject). The training and validation set was further randomly
divided into a training set (containing the 70% of data) and a validation set (formed by
the remaining 30% of data).
Remark: Since the NN predictors we consider will be intended as “population” models,
every NN is optimized on the whole training and validation set and then assessed on
every profile of the test set.
5.6 Results
5.6.1 Assessment on the entire time window
Figure 5.2 shows glucose concentration during a 7 h time window of a representative
subject together with the prediction obtained by the four NNs for PH=15 min (upper
panel), PH=30 min (second panel), PH=45 min (third panel) and PH=60 min (bottom
panel). The black dotted line is the target signal, as measured by the CGM sensor, the
gray line is prediction obtained with NN CGM (using only CGM information), the green
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Figure 5.2: Representative CGM profile (black dotted line) and prediction obtained with
the four NNs for PH=15, 30, 45 and 60 min (from top to bottom).
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line is prediction obtained with NN I (using CGM and insulin information), the blue line
is prediction obtained with NN M (using CGM and CHO information) and the red line
is prediction obtained with NN I+M (using CGM, insulin and CHO information). The
green and red stems represent, respectively, insulin injection and CHO ingestion. Adding
to CGM information on CHO and insulin (red line) or information on CHO only (blue
line) visually improves the prediction over the 2 h time window following CHO ingestion
and insulin injection. If we concentrate on the time frame 19:00-21:00, we note that
for all PH but 15 min NN I+M and NN M forecast with a minimum delay the upward
trend following the ingestion of CHO, while NN I and NN CGM have a delay almost
comparable to PH. On the contrary, in the rest of the profile all the NNs show similar
performance and the predicted profiles almost coincide.
From numerical results computed on the entire monitoring, reported in Table 5.1
and in the boxplots of Figure 5.3, we can note that there is no evident difference among
the four NNs. This is expected since ingestion of CHO and injection of insulin largely
Table 5.1: Average results (mean±sd) for the 15 test time series computed on the entire test
time series.
PH NN CGM NN I NN M NN I+M
RMSE [mg/dL]
15 min 13.6±3.5 13.6±3.3 13.6±3.6 13.9±3.7
30 min 26.0±4.9 25.8±4.6 26.0±5.0 26.4±5.8
45 min 37.0±5.6 37.1±5.8 37.2±5.5 35.1±6.4
60 min 47.4±7.2 48.0±7.2 46.1±7.5 44.2±8.2
TGnorm [-]
15 min 0.44±0.1 0.36±0.09 0.42±0.15 0.42±0.15 6
30 min 0.30±0.07 0.30±0.07 0.34±0.08 0.42±0.11
45 min 0.26±0.07 0.24±0.06 0.27±0.07 0.31±0.10
60 min 0.19±0.04 0.17±0.04 0.26±0.07 0.26±0.10
ESODnorm [-]
15 min 4.2±1.0 3.7±0.7 3.4±0.9 3.1±0.6
30 min 8.0±2.5 6.5±1.8 7.0±2.1 7.0±2.0
45 min 11.2±4.9 9.4±4.2 10.7±3.7 7.6±2.4
60 min 13.5±6.0 7.6±3.2 13.9±5.4 10.5±4.6
influence glucose time course mostly during the 2 h following the events. Therefore, we
expect insulin and/ or CHO information to improve prediction during those limited time
intervals, which constitute approximately the 25% of the test time series. For this reason,
in Subsection 5.6.2 we evaluate the four predictors separately, on the 2 h time window
following CHO ingestion and insulin injection and during the night.
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Figure 5.3: Boxplots summarizing the performance of the proposed models in terms of RMSE,
average TGnorm and ESODnorm on the entire test time series. For each box the horizontal
lines represent, from bottom to top, the 25th, the 50th and the 75th percentile respectively,
the whiskers extend until the most extreme values, the red crosses represent outliers and the
circle corresponds to the average.
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5.6.2 Assessment on specific time windows
Figure 5.4 shows in a representative test time series the prediction obtained with the
compared models during the 2 h following CHO ingestion and insulin injection (left
column) and during the night (i.e. from 23:00 to 06:00), when no CHO are ingested and
no insulin is injected (right column). Focusing on the left column, adding to CGM inputs
relative to insulin and CHO, or adding to CGM inputs relative to ingested CHO only,
improves the accuracy of prediction during the 2 h following the injection of insulin and
ingestion of CHO. Both NN I+M (red) and NN M (blue) forecast glucose concentration
more accurately than NN I (green) and NN CGM (gray) and with a lower delay. On
the contrary, plots in the right column clearly show that during night, (when glycemia is
stable and, usually, no CHO is ingested and no insulin is injected), all the models have
similar performance.
Figure 5.4 allows us also to discuss the usefulness of exogenous inputs for different PHs.
Taking into account exogenous signals does not improve prediction with a PH of 15 min
(top panel of Figure 5.4). This is reasonable, since, due to physiological delays and to the
relatively slow dynamics of the glucose insulin system, injected insulin and ingested CHO
do not affect glycemia instantaneously, thus their effects are not significant after 15 min.
Differently, with PHs of 30, 45 and 60 min, adding to CGM information also inputs
relative to injected insulin and ingested CHO, or relative, at least, to ingested CHO,
visibly improves prediction adherence to the target and time anticipation. However, with
a PH of 60 min all the models perform quite poorly, suggesting that inferring relationships
between the current inputs and future glucose concentration 60 min ahead in time is too
challenging with the models we adopted and information used.
Figure 5.5 shows graphically the performance of the compared algorithms in terms of
RMSE, TGnorm and ESODnorm, computed both in the 2 h window following the ingestion
of CHO and injection of insulin and during the night. For the 2 h window following
CHO and insulin, for PHs greater than 15 min NN I+M and NN M have a RMSE
visibly lower than the other models (top left panel). Also TGnorm is visibly higher for
NN I+M and for NN M, compared to NN I and NN CGM (central left panel). Finally,
the value of ESODnorm is comparable for all the NNs (bottom left panel). During the
night, differences are not so evident and all the models obtain similar RMSE, TGnorm
and ESODnorm values.
Table 5.2 summarizes average results obtained for the compared models for the
analyzed PHs. Performance are computed separately, in the 2 h time window following
CHO ingestion and insulin injection and during the night. Statistically significant
differences between results obtained with NN I+M and results obtained by the other
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Figure 5.4: Representative subject. Prediction performance in the 2 h time window following
CHO ingestion and insulin injection (left column) and during the night (right column). Vertical
stems represent insulin injection (green) and CHO ingestion (blue).
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Figure 5.5: Boxplots summarizing the performance of the models in terms of RMSE, average
TGnorm and ESODnorm during the 2 h time window following CHO ingestion and insulin
injection (left column) and during the night (from 23:00 to 06:00) (right column).
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NNs are indicated by an asterisk and are computed using the sign test1 [106].
For what concerns RMSE computed on the time window following CHO ingestion
and insulin injections, with a PH of 15 min NN I performs significantly worse than
all the other models; in addition, NN M performs significantly better than NN CGM.
With a PH of 30 min NN I+M significantly improves on NN M, NN I and NN CGM;
NN M significantly improves on NN I and NN CGM. With a PH of 45 min NN I+M
significantly outperforms all the other NNs and NN M significantly improves on NN I.
Finally, with a PH of 60 min NN I+M significantly improves on all the other predictors;
while NN M improves on NN I and NN CGM. Differently, during the night, NN I+M has
a RMSE significantly worse than the other models for a PH of 15 min and significantly
worse than NN I and NN CGM for PH of 30 min. For longer PHs the differences are
no more significant. For what concerns the average TGnorm relative to time-intervals
following CHO ingestion and insulin injection, for a PH of 15 min the models show similar
performance, apart from NN I whose TGnorm is significantly worse than those of the
other NNs. For a PH of 30 min both NN I+M and NN M significantly improve on NN I
and NN CGM. For a PH of 45 min NN I+M significantly outperforms all the other NNs;
while NN M significantly improves on NN I and NN CGM. Finally, for a PH of 60 min
NN I+M again significantly improves on all the other models; NN M is significantly better
than NN I and NN CGM; in addition NN I performs significantly better than NN CGM.
During the night, for PH of 15 min, NN I and NN CGM have a TGnorm significantly
higher than NN I+M, while, for longer PHs, no statistically significant difference is
present. For what concerns ESODnorm, results seem to not depend on ingestion of CHO
and injection of insulin and are acceptable for all the NNs.
From the above results we can conclude that when inputs relative to ingested CHO
and injected insulin are added to CGM information, the NN ability of predicting glucose
concentration after CHO ingestion and relative insulin injections is significantly improved
for PHs longer than, or equal to, 30 min. Adding only injected insulin to CGM information
is not beneficial for the NN. However, when we add to CGM both, injected insulin and
ingested CHO, the forecasted signals obtained with PHs of 45 and 60 min are more
accurate and have a higher TG than those obtained when we add to CGM only ingested
CHO information.
Difficulties of the NN in taking advantage of the input relative to injected insulin
may be due to many factors including the intra- and inter-individual variability of delay
in insulin action and absorption [111,114]. Interestingly, during the night, when effects of
CHO ingestion and insulin injection are negligible, (only a quasi-constant basal insulin is
1The sign test is a paired, two-sided test of the hypothesis that the difference between the matched
samples in the two vectors of results comes from a distribution whose median is zero.
5.6 Results 85
T
a
b
le
5
.2
:
A
v
er
a
g
e
re
su
lt
s
(m
ea
n
±s
d
)
fo
r
th
e
1
5
te
st
ti
m
e
se
ri
es
co
m
p
u
te
d
se
p
a
ra
te
ly
,
d
u
ri
n
g
th
e
2
h
ti
m
e
w
in
d
ow
fo
ll
ow
in
g
C
H
O
in
g
es
ti
o
n
a
n
d
in
su
li
n
in
je
ct
io
n
a
n
d
d
u
ri
n
g
n
ig
h
t.
A
st
er
is
k
(∗
)
in
d
ic
a
te
s
st
a
ti
st
ic
a
l
d
iff
er
en
ce
,
co
m
p
u
te
d
w
it
h
th
e
si
g
n
te
st
,
b
et
w
ee
n
N
N
I+
M
a
n
d
th
e
co
n
si
d
er
ed
N
N
.
2h
ti
m
e
w
in
d
ow
fo
ll
ow
in
g
N
ig
h
t
C
H
O
in
ge
st
io
n
a
n
d
in
su
li
n
in
je
ct
io
n
ti
m
e
w
in
d
ow
P
H
N
N
C
G
M
N
N
I
N
N
M
N
N
I+
M
N
N
C
G
M
N
N
I
N
N
M
N
N
I+
M
R
M
S
E
[m
g/
d
L
]
15
m
in
3.
6±
1.
6*
3.
6
±1
.6
*
3
.3
±1
.6
3
.5
±1
.7
1
.0
±0
.4
*
1
.0
±0
.4
*
1
.0
±0
.4
*
1
.0
±0
.3
30
m
in
7.
5±
3.
4*
7.
4
±3
.0
*
7
.0
±3
.3
*
6
.8
±3
.2
1
.5
±0
.6
*
1
.6
±0
.6
*
1
.6
±0
.5
1
.7
±0
.6
45
m
in
11
.0
±4
.6
*
11
.0
±4
.5
*
1
0
.5
±4
.7
*
9
.5
±4
.4
2
.2
±0
.8
2
.0
±0
.7
2
.2
±0
.6
2
.1
±0
.6
60
m
in
14
.2
±6
.0
*
14
.2
±5
.9
*
1
3
.2
±5
.9
*
1
2
.0
±5
.6
2
.6
±1
.0
2
.5
±0
.9
2
.6
±0
.8
2
.6
±0
.8
T
G
n
o
rm
[-
]
15
m
in
0.
35
±0
.1
3
0.
29
±0
.2
1*
0
.3
7±
0
.1
8
0
.3
9
±0
.2
2
0
.4
6
±0
.3
1
*
0
.4
0
±0
.3
1
*
0
.3
8±
0
.3
8
0
.3
2
±0
.3
2
30
m
in
0.
14
±0
.1
4*
0.
16
±0
.1
7*
0
.2
8±
0
.2
1
0
.3
2
±0
.2
7
0
.3
7±
0
.3
0
0
.3
1
±0
.2
5
0
.3
7
±0
.3
5
0
.3
7
±0
.3
5
45
m
in
0.
07
±0
.1
8*
0.
09
±0
.1
7*
0
.1
5±
0
.2
1
*
0
.2
1
±0
.2
7
0
.4
0±
0
.3
9
0
.3
1
±0
.2
9
0
.3
1
±0
.3
4
0
.3
3
±0
.3
4
60
m
in
0.
04
±0
.1
6*
0.
07
±0
.2
1*
0
.0
9±
0
.1
6
*
0
.2
1
±0
.2
6
0
.5
1±
0
.4
3
0
.3
9
±0
.3
9
0
.3
7
±0
.4
0
0
.4
0
±0
.4
1
E
S
O
D
n
o
rm
[-
]
15
m
in
4.
3±
1.
9*
3.
5
±1
.7
*
4
.3
±2
.1
*
3
.0
±1
.5
6
.5
±3
.4
*
5
.8
±3
.0
*
3
.7
±2
.4
*
4
.2
±1
.9
30
m
in
7.
3±
4.
4
5.
9
±4
.1
*
8
.2
±5
.3
7
.8
±5
.6
1
0
.4
±6
.3
1
0
.3
±5
.8
7
.4
±5
.0
*
9
.6
±7
.2
45
m
in
9.
4±
10
.7
8.
7
±6
.0
1
4
.7
±1
7
.9
1
1
.9
±1
4
.9
1
8
.4
±1
5
.1
*
1
2
.2
±9
.5
*
1
1
.5
±7
.4
8
.9
±6
.3
60
m
in
13
.0
±1
5.
0
6.
9
±7
.4
*
1
5
.3
±1
8
.6
2
3
.1
±5
6
.9
2
6
.1
±2
3
.5
*
1
0
.6
±9
.2
1
9
.4
±1
4
.9
*
1
2
.8
±1
1
.4
86 Inclusion of insulin information
present), the NN using only CGM information is the most accurate. In fact NN CGM
has less parameters to tune during training and learns more accurately the relationship
between current and future glycemia, when no other disturbance influences glucose time
course.
5.6.3 Results interpretation in terms of prediction sensitivity to
inputs
Results shown and commented above suggest that the information on ingested CHO is
the most useful for improving prediction results, while the information relative to injected
insulin only slightly helps when added to the information on ingested CHO and is not
sufficient to ameliorate prediction when used alone. In addition, the difference between
NNs using, in addition to CGM, information on insulin injection and CHO ingestion, or
on CHO ingestion only and the other two NN models becomes more evident when PHs
equal or longer than 30 min are considered.
To quantify the individual usefulness of the various input signals in determining the NN
output we performed a sensitivity analysis by Partial Derivative (PaD) method [115,116].
This method starts by computing, analytically, the partial derivative of the NN output
with respect to each input
di(t) =
∂yˆ(t+ PH|t)
∂xi(t)
(5.4)
= ωi +
Nhn∑
j=1
ψjϕ
′
(
Nin∑
k=0
ωjkxk(t)
)
ωji
with ϕ′ derivative of the tangent hyperbolic function. di is a time series showing the
time course of the output derivative for small changes of the ith input. Then the relative
contribution of each input variable on the specific output is determined by computing
the sum of the squares of the partial derivatives
SSi =
N∑
j=1
di(j)
2 (5.5)
with N length of the time series. Finally, the relative contribution of each input variable
is given by
Si =
SSi∑Nin
k=1 SSk
(5.6)
The variable with the highest S has the most effect on the output, with respect to the
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other variables. S allows to rank the relative influence of each input on the output, with
respect to the other input signals and we can also observe how this influence changes
when different PHs are considered. Figure 5.6 shows, for every model, the relative output
sensitivity to the various inputs for the considered PHs. For what concerns NN CGM,
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Figure 5.6: Boxplots of relative output sensitivity to inputs for the various models.
(Figure 5.6, top left panel), it relies mainly on CGM information for short PHs, but the
relevance of CGM derivative increases when longer PHs are considered. For NN I (Figure
5.6, top right panel) CGM is by far the most informative input for all PHs. The output
sensitivity to CGM derivative increases as the PH increases, while the sensitivity to the
input relative to insulin is very low, even if it slightly increases as the PH increases. For
NN M, (Figure 5.6, bottom left panel), CGM is far the most significant input for PHs
of 15 and 30 min, while for PHs of 45 and 60 min the output sensitivity to the input
relative to CHO becomes non-negligible. For NN I+M, (Figure 5.6, bottom right panel),
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for a PH of 15 min current CGM is the most significant input; for a PH of 30 min CGM
is still the most informative input, however, the importance of the other signals slightly
increases; for PHs of 45 and 60 min the importance of CGM and of CHO is comparable
and visibly higher than that of insulin and CGM derivative.
This analysis confirms that glucose concentration history is the most informative
signal for predicting glycemia, especially in the short- and in the mid-term (15-30 min).
However, the future glucose concentration is sensitive to information on ingested CHO
for a PH longer than 30 min. For what concerns information relative to injected insulin,
it is more difficult to use them adequately and, in our analysis, it improves prediction
only for PHs longer than 30 min if added to information on ingested CHO.
It is of interest to note that inputs relative to injected insulin and ingested CHO
can influence glucose prediction only after CHO ingestion and insulin injections, i.e.
approximately for 25% of time considering 3 meals and associated injections of insulin per
day. This might justify the lower sensitivity of prediction to signals relative to ingestion
of CHO and injection of insulin, with respect to the CGM signal.
5.7 Conclusions and margins for future work
In this Chapter we investigated if adding information relative to insulin therapy as
additional input of the jump NN presented in Chapter 4, which uses CGM and CHO
related inputs, could improve prediction, evaluating PHs in the range 15-60 min. A major
limitation of using both, CHO and insulin information, comes from their high correlation,
since the injection of an insulin bolus in usually concomitant with the ingestion of CHO
and they are proportional. Moreover, even their simulated rate of appearance in the blood
are similar. To overcome this problem and take also into account delays in insulin action
we delayed the input relative to insulin of 60 min, as estimated in [111]. Results suggest
that adding insulin and CHO to CGM information improves prediction performance
when PHs longer than, or equal to, 30 min are considered, but only if we restrict our
attention to the 2 h time window following the ingestion of CHO and relative insulin
injection. This can be justified by the fact that effects of CHO and insulin are evident
for approximately 2 h. Indeed if we compute the results on the entire monitoring, or
during night, when exogenous disturbances should be absent or quasi-constant, all the
NNs perform similarly. Surprisingly, when insulin alone was added to CGM information,
no improvement was obtained. However, a possible justification of this result could be
a non-adequate preprocessing of insulin information, due to difficulties in modelling its
effects because of high variability of delay in its action [111] and absorption, determined
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by many, often not measurable, concurrent factors (e.g. insulin on board, injection site,
skin temperature, etc [114]). To better interpret the obtained results we performed an
analysis of prediction sensitivity to inputs and results confirmed that future glucose
concentration is mainly sensitive to past CGM history and CHO information becomes
visually relevant for PHs longer than 30 min.
In light of the finding that adding information on quantity of ingested CHO and
injected insulin improves prediction accuracy only during the limited time window that
follows the ingestion of CHO and injection of insulin, a possible future analysis could
include the implementation of several NN-based models, using different combinations of
input signals. The final prediction could be obtained as a weighted sum of the output of
all the considered models, with weights proportional to the performance of each model
and to its expected validity, in the considered time instant.
Furthermore, an additional improvement of prediction accuracy could be obtained by
incorporating, among the inputs of the NN, also signals relative to PA, as preliminarily
discussed in Chapter 6.
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Use of Physical Activity (PA) on glucose
prediction algorithms: preliminary analysis
6.1 Rationale
In Chapters 3 and 4 we demonstrated that adding information on time and quantity of
ingested CHO to CGM history as inputs of a NN predictor improves results, with respect
to models using only information on glucose concentration. Moreover, in Chapter 5 we
investigated the possibility of incorporating also information relative to insulin therapy
as input of the predictor. We pointed out that CHO quantity and insulin dose are highly
correlated, thus using both signals does not guarantee the improvement of prediction
results. Moreover, it is difficult to exploit adequately inputs relative to insulin therapy
due to physiological delays and inter- and intra-individual variability in insulin action
and absorption. In Chapter 5 we also demonstrated that CHO and insulin information
effectively improve prediction performance only in a short time frame (approximately 2 h)
following CHO ingestion and insulin injection. The improvement is no more appreciable
if performance are computed during night, when exogenous disturbances should be absent
or quasi-constant.
Additional promising inputs that could be consider are signals relative to PA. PA is
uncorrelated from meal and insulin signals and is known to have short and long term
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effects on glucose dynamics. However, although effects of PA on glucose metabolism are
qualitatively quite well developed, their quantification and incorporation into mathemati-
cal models, for scopes including e.g. glucose prediction and T1D simulation, is still an
existing problem.
As a preliminary analysis, we investigated [117], quantitatively, the short-term corre-
lation between variations of glucose concentration dynamics and the PA related signal
returned by Physical Activity Monitoring System (PAMS), a system comprising ac-
celerometers and inclinometers, able to detect and quantify PA, even at low intensity
that mimic activities of daily living [118].
6.2 Database and protocol
Data used for this analysis were collected in the Clinical Research Unit at Mayo Clinic,
(Rochester, MN) as part of an in-patient study designed to detect glycemic patterns and
postprandial insulin sensitivity in control and T1D subjects, in presence of mild PA [119].
20 control and 19 T1D individuals were studied for 88 hours. Each day they were fed
with 3 meals, each one containing 80 grams of CHO, similar macronutrient and calories
compositions, without differences between meals or between days. C-peptide negative
T1D subjects were on insulin pump and administered an insulin bolus with meals. Each
day subjects took part to 4 to 6 consecutive sessions of low intensity PA in which they
alternated 26.5 min of walking on a treadmill at 1.2 mph with 33.5 min of sitting. The
distance covered daily varied from 3.5 to 4.2 miles. It is worth noting that the walking
velocity was chosen to be consistent with median free living walking velocity, since the
protocol wanted to mimic activities of daily living.
PA data were collected using PAMS, a system that captures data on body posture
and movements continuously every half second for up to 10 consecutive days [118,120,121].
As shown in Figure 6.1, PAMS comprises 2 tri-axial accelerometers (each captures motion
along three orthogonal axis) and 4 inclinometers, (each captures two axis of acceleration
against the gravitational field) for recording body posture and movements. The 2
accelerometers were placed over the base of the spine; the inclinometers were attached
to the left and right outer aspect of the trunk, and left and right outer aspect of the
thigh. Specially designed underwear was used to attach the sensors. The accelerometers
measure PA data along three orthogonal axis, (x, y, z), with the dynamic range to ±2g
(with g gravitational acceleration). The outcome PAMS signal, expressed in activity units
(AU), is obtained summing the instantaneous acceleration over epochs of 1 min [121,122].
Glucose concentration was monitored continuously with the Dexcom SEVEN PLUS
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Figure 6.1: PAMS comprises 4 inclinometers (I); 2 tri axial accelerometers (A) and 2 data
loggers. The system is worn as shown in the right panel.
CGM device. Figure 6.2 shows two typical piece of data, measured in a T1D subject,
walking sessions are highlighted in gray. The top panels represent the CGM time course,
the bottom panels show the PAMS signal.
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Figure 6.2: CGM time series (top panels) and PAMS measurements (bottom panels) during
two workout sessions of a representative T1D subject. Walking sessions are highlighted in
gray.
Since we wish to assess the effects of PA on variations of glucose dynamics, quanti-
fied via first- and second-order glucose time-derivatives, only piece of data relative to
consecutive PA sessions (i.e. repetitions of active and resting time) are considered in
our analysis, without including any long sedentary period. In the rest of the chapter,
we will refer these portions of data as workout sessions. According to the protocol, for
each patient 3 to 4 workout sessions were recorded. In addition, a time alignment of
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the signals is performed: this procedure simply consists in down-sampling PAMS, whose
original sampling time was of 1 min, considering only those values measured at the same
time instants at which CGM signal, whose sampling time was 5 min, is also available.
6.3 Computation of glucose concentration
time-derivatives
Changes in glucose dynamics were quantified by computing the first- and second-order
time-derivatives of glucose concentration. In particular, a Bayesian smoothing approach,
similar to that already employed in [108, 112] to denoise CGM data, was used to face
ill-conditioning of derivatives calculation and limit artifacts due to measurement noise
affecting CGM readings.
Briefly, in a matrix-vector embedding, the N-size vector y containing the (uniformly
spaced) CGM samples is modelled as
y = Gu + v (6.1)
where u is the N-size vector containing the samples of the (unknown) time derivative, v is
the random vector of the measurement errors (assumed uncorrelated, with zero mean and
constant unknown variance), and G is an N-size lower triangular square Toeplitz matrix
having as its first column Ts[1, 1, . . . , 1] or T
2
s [1, 2, . . . , N ], respectively, if the vector of
the first-order or second-order time derivative is estimated (Ts is the sensor sampling
period). Because of ill-conditioning, LS estimation of u given y in equation (6.1) is
unreliable, and a Bayesian regularization approach [108,112] similar to that applied by
Guerra et al. [123] for glucose trend estimation from CGM data, is used. According to
this approach, the estimated uˆ is computed as
uˆ = (GTG + γFTF)−1GTy (6.2)
where γ is the regularization parameter, whose value is determined according to a
maximum likelihood/consistency criterion, and F is a squared N-size lower triangular
Toeplitz matrix that, according to considerations on CGM data explained in detail by
Facchinetti et al. [108,112] has a first column equal to [1, 2, 1, 0, . . . , 0].
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6.4 Partial correlation analysis
For each workout session, the relationship between PAMS and glucose concentration
time derivatives was quantified by partial correlation computed at various time shifts (τ)
in the range 0-60 min. We could not choose time shifts greater than 60 min because of
constraints of our protocol: indeed the subject starts a PA session (walking on treadmill
plus resting) every hour, thus restricting our analysis to time shifts shorter than or equal
to 60 min is essential to avoid superimposition of effects of consecutive PA sessions.
Partial correlation measures the degree of association between two signals, removing the
effect of a set of controlling signals. Specifically, the controlling signals were CGM, meal
and insulin (the last one only for T1D patients) related information. In particular, meal
intakes were preprocessed to generate glucose rate of appearance in the blood [103], while
insulin dosages were used to calculate the so-called insulin on board with the formulas
described in [124]. Using partial instead of conventional correlation guarantees that
results are not affected by any collateral effects of either glucose concentration value,
CHO ingestion or insulin injections and they quantify exclusively the correlation between
PAMS and glucose derivatives.
Mathematically, the partial correlation between X (in our case PAMS) and Y (in our
case first- or second-order glucose time derivative), given a set of n controlling variables
Z = {Z1,Z2, ...,Zn} (in our case CGM, glucose rate of appearance and insulin on board),
indicated as ρXY,Z, is the correlation between the residuals rX and rY resulting from the
linear regression of X with Z and of Y with Z, respectively. Solving the linear regression
problem requires to find the n-dimensional weight vectors
w∗X = arg min
w
{
N∑
i=1
(xi − 〈w, zi〉)2
}
(6.3)
w∗Y = arg min
w
{
N∑
i=1
(yi − 〈w, zi〉)2
}
(6.4)
where N is the length of the time series, and 〈w, zi〉 represents the internal product
between vector w and vector zi. Given the weight vectors of (6.3) and (6.4), the residuals
can then be computed, respectively, as
rX,i = xi − 〈wX∗, zi〉 (6.5)
rY,i = yi − 〈wY∗, zi〉 (6.6)
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and the partial correlation is given by the formula
ρˆXY,Z =
N
∑N
i=1 rX,irY,i −
∑N
i=1 rX,i
∑N
i=1 rY,i√
N
∑N
i=1 r
2
X,i −
(∑N
i=1 rX,i
)2√
N
∑N
i=1 r
2
Y,i −
(∑N
i=1 rY,i
)2 (6.7)
6.5 Results
6.5.1 Correlation between PAMS and first order glucose time
derivative
Median results computed on the 19 T1D and on the 20 control subjects are graphically
shown in Figure 6.3. In diabetic subjects (left), there is a negative correlation between
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Figure 6.3: Median correlation curves (and 25th and 75th percentiles, dotted lines) between
PAMS and first-order CGM derivatives, computed on the 19 T1D subjects (left) and on the
20 control subjects (right).
first-order glucose concentration derivative and PAMS for τ lower than 30 min, with a
maximum, in absolute terms, for τ equals 15 min. For τ in the range (30, 60) min the
correlation becomes positive, and is maximal with τ equals 40-45 min. Results relative
to control subjects (right) are similar, however the degree of correlation is smaller (in
absolute terms), and correlation peaks are anticipated of 5-10 min compared to what
we observed on T1D. These results suggest that low intensity PA decreases glucose
concentration in the short term, with a decrease particularly evident after 10-15 min and
as exercise stops glucose tends to increase, with a maximal increase after 10-15 min.
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6.5.2 Correlation between PAMS and second order glucose time
derivative
Median results are plotted in Figure 6.4. In diabetic subjects (left) there is a negative
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Figure 6.4: Median correlation curves (and 25th and 75th percentiles, dotted lines) between
PAMS and second-order CGM derivatives, computed on the 19 T1D subjects (left) and on
the 20 control subjects (right).
correlation between PAMS and second-order glucose time derivative for τ lower than 20
min, and this correlation is maximal (in absolute terms) for τ equals 5 min, while there
is a positive correlation for τ in the interval (25, 45) min and this correlation is maximal
for τ equals 35 min. In control subjects (right) the degree of correlation is slightly lower
(in absolute value), and correlation peaks are anticipated with respect to T1D patients.
Results relative to correlation between PAMS and second-order glucose concentration
derivative suggest that, even in case glucose does not decrease during walking, at least it
increases at a lower rate; furthermore, in case glucose concentration does not increase
during rest, at least it decreases less rapidly.
6.6 Conclusions and margins for further investigations
The aim of this preliminary analysis was quantitatively assessing if PA causes measurable
variations of glucose dynamics in the short term (≤ 60 min) and if those variations
follow a typical pattern. This constitutes a necessary step before building quantitative
models of PA effects on glucose concentration, e.g. for prediction or closed-loop control
purposes. We quantified correlation between mild PA that reproduces every-day life
activity, measured using the PAMS signal, and glucose trends, quantified estimating first
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and second order glucose time-derivatives from the CGM signal.
Results obtained on 19 T1D and 20 control subjects confirm a tendency of glucose
concentration to decrease during exercise and to increase during rest periods. Interestingly,
correlation is higher, in absolute value, in T1D than in control subjects, suggesting that
in diabetic patients PA causes greater excursions of glucose concentration, as suggested
in [119]. Moreover, in diabetic subjects response to PA in terms of glucose dynamics
modification is slower than in control subjects.
The presence of short-term correlation between changes in glucose dynamics and
mild exercise suggests the potential utility of including PA information in short-time
prediction models, to infer more precisely future glucose concentration in presence of PA.
The ability of predicting exercise effects on glucose concentration could be very helpful,
since it would allow adapting insulin infusion during and after PA and it could forewarn
against hypoglycemic events, by alerting the patient before their occurrence. The effective
quantitative incorporation of PA information within glucose predictors could be matter
of in depth future investigations. For instance, PA information could be exploited to
dynamically modulate the forgetting factor typically used in low-order time varying
AR/polynomial models. Furthermore, signals relative to PA, possibly preprocessed in line
with the results of this correlation analysis, could be included as inputs of NN prediction
models.
7
Clinical usefulness of prediction for generation of
hypoglycemia alerts: a comprehensive in silico
study
7.1 Rationale
One of the major issues in diabetes management is to limit hypoglycemic events. Indeed
hypoglycemia has threatening short-term consequences, since, if not quickly detected and
treated, it could progress from measurable cognition impairment, to aberrant behavior,
seizure, coma and even death [12]. Commercial CGM devices generate visual/acoustic
alarms in real time when measured glycemia crosses critical thresholds (e.g. 70 mg/dL
for hypoglycemia) [125]. Preventing rather than simply detecting critical events when
they occur would be preferable and, to do so, short-term (30-45 min) glucose prediction
methods could be exploited [126,127].
In the literature, the benefit deriving from the exploitation of prediction methods to
prevent/ mitigate hypoglycemia by soliciting appropriate treatments (e.g. sugar intake
and/or pump basal suspension) has been assessed from real data in [65,80,81,128,129], as
described in Section 1.6 of the present thesis. However, it would be of interest to compare
different scenarios occurring for the same patient and starting from the very same patient
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conditions, which is not possible in clinical studies, where every action has an effect on
glycemia and, unavoidably, exclude the possibility of seeing what would have happened if
different decisions were made, as explained in Section 1.7. Thus, the aim of this analysis
is to use an in silico environment to quantify the potential benefits, in terms of number
and duration of hypo-events, coming from the use of predicted, rather than measured,
glucose for hypoglycemic alert generation in 50 synthetic subjects [130]. Virtual patients
were created by the UVA/Padova type 1 diabetic simulator [73, 84], described briefly
in Appendix A. The synthetic patients were virtually monitored in horizons of 54 h
(including 2 lunch, 2 dinner and 3 breakfast events per patient), in presence of additive
white noise with realistic variance corrupting CGM data, and of sources of uncertainty
on the quantity of ingested CHO and injected insulin. Three parallel scenarios were
considered:
1. the subject was unaware of hypoglycemia, no alert was generated and no counter-
measures were taken when blood glucose concentration fell below the hypoglycemic
threshold (worst case);
2. a hypo-alarm was triggered based on CGM measurements and 15 g of CHO were
ingested by the patient;
3. a hypoglycemic alert was given on the basis of the 30-min ahead-of-time predicted
glycemia, obtained via the NN-based algorithm described in Chapter 3, and 15 g
of CHO were ingested by the patient, as in Scenario 2.
7.2 Creation of simulated realistic data
The database consists of 50 type 1 diabetic virtual patients, extracted from the UVA/Padova
simulator [73, 84]. For each subject, one CGM time series has been simulated, consisting
of about 2 days and a half of monitoring and sampling time of 5 minutes. The choice of
this specific sampling time is due to the fact that it coincides with that of the majority of
currently used CGM devices. Each simulated time series consists of 54 h of monitoring,
from 03:00 of day 1 to 09:00 of day 3. The monitoring interval was chosen in order to
be long enough to observe at least one hypoglycemic event for each subject. Moreover,
since breakfast is administered between 06:00 and 08:00, termination of the monitoring
interval at 09:00 allows patients to complete the recover from an eventual nocturnal
hypoglycemia. Ten of the patients were further simulated for 4 additional days, and the
relative profiles were used to train the NN prediction algorithm. Three meals per day
were considered in the simulated scenario. To render the profiles more realistic, CHO
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intake quantities and meal timings were differentiated from meal to meal and from day
to day. Breakfast was randomly located in the time interval 06:00-08:00 h and consisted
of 35-55 g of CHO, lunch was in the interval 12:00-14:00 h and consisted of 60-90 g of
CHO, finally dinner was in the interval 19:00-21:00 h and consisted of 70-100 g of CHO.
For what concerns insulin, a basal-bolus infusion scheme was adopted, with boluses
computed to counterbalance the effect of the concomitant meals. To obtain additional
hypoglycemic events in the simulated profiles, overdosed insulin was administered. In
particular, every day basal insulin was increased twice for 30 min of a random amount
sampled from a uniform distribution in (0-3) U/h. This action has also an effect on
glucose similar to an increase of insulin sensitivity or to a mild PA. Furthermore, for
half of the patients randomly chosen, one insulin bolus was augmented once a day of
a random percentage sampled from a uniform distribution in (0-30)%. For the other
half of the patients, the size of one of the meals was simulated to be wrongly estimated
and the amount of CHO effectively ingested was decreased of a percentage randomly
chosen in the interval (0-30)%. Finally, in order to mimic the random measurement error
affecting CGM, a white noise sequence whose samples were extracted from a Gaussian
distribution with zero mean, and variance equal to 4 (in line with [131,132]) was added
to each time series.
To quantify the benefits coming from the exploitation of prediction-based hypo alerts,
we compared the three scenarios described in the introduction of the present chapter.
In Scenario 1, no hypo-alerts were generated and hypoglycemia was thought to be not
recognized and dealt with. This corresponds to a sort of worst case situation for the
diabetic patient, though possible especially during the night [133]. In Scenario 2, the alert
was triggered on the basis of the measured CGM readings. In Scenario 3, the alarm was
generated on the basis of predicted glycemia, obtained through the algorithm described in
Chapter 3. Alert generation obeyed the simple strategy explained in Section 7.3. In both
scenarios 2 and 3, a bolus of 15 g of CHO was ingested in the 5 min following the alert.
Scenario 2 and Scenario 3 were assessed also in presence of randomly delayed/absent
ingestion of CHO. Results are quantified in terms of number of hypoglycemic events,
their duration and total time in hypoglycemic range. In addition we computed also the
distribution of glucose concentration and the Low Blood Glucose Index (LBGI) and
High Blood Glucose Index (HBGI) [113], two commonly adopted indicators of the risk of
hypoglycemia and hyperglycemia, respectively. The highest the value of these indexes,
the highest the associated risk.
Remark. In the spirit of keeping the protocol as simple as possible, the action
associated with hypo alert was standardized to the ingestion of 15 g of CHO. According
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to [134] such a measure is commonly adopted by diabetic patients and has the effect of
raising glycemia of about 50 mg/dL in approximately 15 min. In addition, basal insulin
infusion was neither suspended, nor attenuated (differently from [65,80,81]), also because
this would be expected to have delayed effect.
7.3 Hypoglycemic alert generation strategy
The prediction strategy adopted is the one described in Chapter 3. For what concerns
the generation of hypo alerts, we consider a basic procedure which generates an alert
when the glucose profile (measured by the CGM sensor in Scenario 2, forecasted by the
prediction algorithm in Scenario 3) crosses 70 mg/dL, and is lower than this threshold
for at least 2 consecutive sampling times (checking for the presence of two consecutive
samples in the hypoglycemic range delays the alarm by 5 min but limits the problem of
dealing with false alerts). After 30 min from the first hypo-alert, if the subject is still in
the hypoglycemic range, a second alarm is generated and other 15 g of CHO are ingested
by the patient. The adopted strategy for alert generation is elementary, since the focus of
the present conceptual work is on benefits of considering predicted rather than measured
glucose for triggering hypo alarms.
7.4 Results
Figure 7.1 shows graphically results relative to two simulated subjects. For what concerns
the upper panel of Figure 7.1 in Scenario 3 (glucose concentration denoted by dashed
red line), the nocturnal hypoglycemia is avoided (the lowest glucose concentration
results 72 mg/dL) thanks to the generation of the alert (followed by CHO ingestion)
at time 03:25. In Scenario 2, the alarm is given at time 04:05 and the hypoglycemic
event can be only mitigated: in fact, the subject spends 60 min in the hypoglycemic
range, reaching a lowest glycemia of 63 mg/dL (glucose concentration denoted by dotted
blue line). Without hypo-alert generation (Scenario 1), the virtual subject experiences
a threatening nocturnal hypoglycemia, with a minimum glucose concentration value
of 53 mg/dL (glucose concentration denoted by dotted green line), which lasts for
255 min (approximately more than 4 h). The bottom panel of Figure 7.1 shows another
representative test subject. In Scenario 3 (glucose concentration denoted by dashed red
line), the prediction based alert (followed by CHO ingestion) is generated 20 min ahead
in time, however hypoglycemia in this case is not totally avoided, but mitigated: the
subject spends 20 min in the hypoglycemic range, (lowest glycemia equals 67 mg/dL). In
Scenario 2 and 1 the time spent in the hypoglycemic range is 50 and 55 min, respectively,
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Figure 7.1: Two representative subjects. Continuous black line represents glucose concen-
tration till CGM crosses the hypoglycemic threshold, continuous magenta line identifies the
30 min ahead-of-time glucose prediction till a prediction alert is generated). Scenario 1: (dotted
green line), no hypo-alert; Scenario 2: (dotted blue line), CGM-based hypo alert (blue alarm
bell). Scenario 3: (dashed red line), prediction-based hypo alert (red alarm bell). Note that
the value reported for the prediction at time t is the estimate of the glycemic concentration at
time t+PH obtained, at time t itself, by using data available until time t. PH is 30 min.
(lowest glycemia equals 64 mg/dL and 59 mg/dL, respectively), with recovers from the
event only after dinner.
Results computed on the 50 virtual subjects dataset considering the entire period of
monitoring (54 h) are given in terms of median and 5th and 95th percentiles. Table 7.1
and Figure 7.2 summarize number of hypoglycemic events, their duration and total
time in hypoglycemic range. In Scenario 1 (unawareness of hypoglycemia, no alerts),
patients experience, in median 4, (5th and 95th percentiles equal 2-7) hypoglycemic
episodes, of median duration of 120 (10-330) min. The total time spent in hypoglycemic
range is 9h30min (4h05min-20h30min) over 54 h of monitoring, which corresponds to 17.7%
(7.6%-38.0%) of the total time of monitoring. In Scenario 2, the number of hypoglycemic
events is similar to that of Scenario 1. This is expected, since, in Scenario 2 the alarm is
CGM-based, thus it is triggered when the subject is, de facto, already in hypoglycemia.
However, the severity of hypo-events is significantly mitigated (p<0.01), with a median
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duration of 40 (10-70) min, for a total time in hypoglycemia of 2h35min (1h35min-5h00min),
corresponding to 4.7% (2.9-9.2%) of the total time. In Scenario 3 patients could potentially
avoid, or at least mitigate, many hypoglycemic events by assuming CHO in advance. In
fact, the number of hypoglycemic events is 1 (0-4), 75% lower than Scenario 2 and Scenario
1, (p<0.01). In addition, in Scenario 3 the median duration of hypo-events is 15 (10-45)
min, significantly shorter than in Scenario 2 (-62.5%, p<0.01) and Scenario 1 (-87.5%,
p<0.01). Furthermore, in Scenario 3, the percentage of time spent in hypoglycemic range
is 1.2% (0.0-2.9%), corresponding to 0h35min (0h0min-1h35min), with a reduction of 74.5%
and 93.2% with respect to Scenario 2 and Scenario 1, respectively.
Figure 7.2 graphically summarizes the results of Table 7.1. In the top panel the his-
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Figure 7.2: Top panel shows the histogram of the number of hypoglycemic episodes per
subject, observed during the period of monitoring in the three scenarios. Bottom panels show
the boxplot of duration (in min) of hypoglycemic events (left panel) and of total time (in h)
spent in hypoglycemic range (right panel) in the three scenarios (green, blue, red for Scenario
1, 2, and 3 respectively).
togram of the count of number of hypoglycemic events per patient, during the monitoring
period, clearly shows that in Scenario 3 the majority of patients experience only from 0
to 3 hypoglycemic events, while in Scenario 2 and in Scenario 1 the majority of patients
experience from 2 to 4 hypoglycemic events. In addition, as shown in the boxplots in
the bottom panels of Figure 7.2, hypoglycemia duration (left panel) and total time in
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hypoglycemic range (right panel) considerably decrease moving from Scenario 1 and
Scenario 2 to Scenario 3.
Table 7.2 reports, for each scenario, the median and 5th and 95th percentiles of the
distribution of glucose concentration values and of LBGI and HBGI in the 50 virtual
patients. As expected, the 5th percentile of the distribution of glucose concentration
gradually increases in moving from Scenario 1 to Scenario 3. At the same time, the 95th
percentile of glucose concentration distribution does not significantly change between
Scenario 1 and Scenario 3, indicating that hypo treatments do not significantly increase
the highest hyperglycemic value. This is confirmed also by the estimated distribution
of glycemic values, in the three scenarios, plotted in the top panel of Figure 7.3. In
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Figure 7.3: Top panel shows the distribution of glycemia in the three scenarios. Bottom
panels show the boxplot of LBGI (left) and HBGI (right) in the three scenarios (green, blue,
red for Scenario 1, 2, and 3 respectively).
fact the percentage of glycemic values in hypoglycemic range is 19% in Scenario 1, and
decreases to 5% in Scenario 2, and to 1% in Scenario 3. The percentage of glycemic
values in hyperglycemic range is 14% in Scenario 1, and 17% in both Scenario 2 and
Scenario 3. Also the analysis of LBGI and of HBGI, summarized in Table 7.2, confirm
that the risk of hypoglycemia is significantly reduced (p<0.01), without any increased
risk of hyperglycemia (p>0.5), in moving from Scenario 1 to Scenario 2 and to Scenario
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3. This can be deduced also by visual inspection of the boxplots of the distribution of
LBGI and HBGI values in all the 50 subjects (bottom panels of Figure 7.3).
7.5 Robustness: delayed/ absent patient’s response to
alerts
In the previous Section we simulated the virtual patients responding to alerts in no more
than 5 min in both Scenario 2 (CGM-based alerts) and Scenario 3 (prediction-based
alerts). However, in real life conditions, subjects could be unable to promptly ingest
CHO, or to hear the alarm. For example, in the real case studies documented in [127]
young patients did not respond to 34% of the alerts. In [135] patients did not respond to
hypoalerts in 4.2% of the cases, and it took them on average 17 min during day-time,
and 60 min during night-time, to take countermeasures in case of hypoglycemia.
To assess the effect of delayed/absent responses to alerts, we did additional simulations
introducing delays in CHO ingestion and the possibility of no CHO ingestion at all, both
in Scenarios 2 and 3. In particular, every time an alarm is triggered (either on the basis
of CGM either of prediction), with probability 0.85 the subject ingests 15 g of CHO after
a delay uniformly distributed in the time interval (0-30) min, while with probability 0.15
no ingestion of CHO at all occurs. In the case of absent response, if the subject is still in
hypoglycemia, a new alert is triggered after 30 min. In the case of delayed response, the
new alert is generated 30 min after the subject has effectively ingested CHO, if he/she is
still in hypoglycemia. Every time an alert is given, the same procedure just described is
repeated (i.e. the patient ignores the alert, either ingests CHO with a certain delay).
Figure 7.4 and Table 7.3 summarize the results in terms of number of hypoglycemic
events per patient, their duration and total time in hypoglycemic range during the
monitoring period. By comparing results with those of the best case scenario of
Figure 7.2 and Table 7.1, we can clearly note a deterioration of the benefits of CGM-
based and prediction-based alerts coupled with CHO ingestion. There is still a visible
and significant reduction of number of hypoglycemic events and of their duration passing
from Scenario 2 to Scenario 3 (p<0.01). In Scenario 2, as expected, the number of
hypoglycemic events in Table 7.3 cannot worsen with respect to Table 7.1 because in both
cases the CGM-based alerts are generated when the subject is already in hypoglycemia.
In Scenario 3 the number of hypoglycemic events in Table 7.3 increases with respect to
Table 7.1 and a median of 3 (1-5) hypoglycemic events per subject was observed. In
particular, moving from Scenario 2 to Scenario 3, the number of hypoglycemic events
significantly decreases of the 25% (p<0.01). Hypoglycemia duration in Table 7.3 is longer
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Figure 7.4: As in Figure 7.2, but in presence of delays in answering to alerts.
than in Table 7.1 and is equal to 50 (10-149) min in Scenario 2, and to 25 (10-112) min
in Scenario 3. In fact in Scenario 3 the duration of hypoglycemic events decreases of
the 50% with respect to Scenario 2 (p<0.01). The total time in hypoglycemic range is
equal to 3h35min (1h55min-10h35min) in Scenario 2, and to 1h30min (0h20min-5h45min) in
Scenario 3, (significant reduction of 59%, p<0.01).
The distribution of glycemic values is reported in Table 7.4 and in Figure 7.5, top
panel. The shape of the distribution of glucose shows a mild increase in the percentage
of values in hypoglycemic range in Scenario 2 and 3, with respect to Table 7.2 and to
Figure 7.3, top panel. However, as confirmed by p-values, ingestion of CHO on the basis
of predicted glycemia, even if delayed or sometimes ignored, still significantly increases
the lowest glycemic concentration experienced by patients. In fact the percentage of
glycemic values in hypoglycemic range is equal to 8% in Scenario 2 and to 4% in Scenario
3. Analysis of LBGI and HBGI values, reported in Table 7.4 and in Figure 7.5 (bottom
panels), confirms that, moving from Scenario 2 to Scenario 3, a significant decrease of
the risk of hypoglycemia occurs, without any parallel increase of the hyperglycemia risk.
In conclusion, delays in responding to hypo alerts, or absence of response, obviously
worsen the results obtained in scenarios 2 and 3 in Section 7.4. However, since de-
layed/absent ingestion of CHO affects in a similar way Scenario 2 and Scenario 3, the
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Figure 7.5: As in Figure 7.3, but in presence of delays in answering to alerts.
relative difference between these two scenarios remains significant: in fact, passing from
Scenario 2 to Scenario 3, the total time in hypoglycemic range decreases of the 59%, the
hypoglycemia duration decreases of the 50% and the number of hypoglycemic events
decreases of the 25%.
To conclude, we remark that this simulated analysis cannot capture all the aspects of
reality, but any bias equally affects results observed in Scenario 2 (CGM-based alert) as
well as in Scenario 3 (prediction-based alert). Thus, on one hand, the absolute results
presented in this manuscript could be considered an upper bound of what could be
observed in real life. On the other hand, the relative difference between the results
obtained in Scenario 2 (CGM-based) and Scenario 3 (prediction-based alert) would
probably not change significantly.
7.6 Conclusions and margins for future works
CGM-based short-term glucose prediction algorithms could allow the patient to take
appropriate countermeasures to avoid/mitigate hypo-events before their occurrence. By
generating data for 50 virtual subjects, in this work we compared occurrence and duration
of hypoglycemic events in three scenarios occurring in the same patient, i.e. hypoglycemia
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unawareness and no countermeasure (Scenario 1), ingestion of 15 g of CHO as glucose
concentration measured by CGM sensor crosses the hypoglycemic threshold (Scenario 2)
and ingestion of 15 g of CHO as glucose concentration predicted 30-min ahead-of-time
crosses the hypoglycemic threshold (Scenario 3). Results show that, by generating
hypo-alerts based on prediction, hypoglycemia occurrence could be mitigated and almost
totally avoided (in median 1 hypoglycemic event in 54 h of monitoring), and time spent
in hypoglycemia could be reduced to 1.2% of the period of monitoring, corresponding to
35 min in 54 h. For what concerns the generation of false alerts, in Scenario 3 we had,
on average, 1 false alert every 39 h. However, in this analysis we have not considered the
problem of how to generate alerts and have limited ourselves to using a simple threshold
comparison strategy. In fact, generating alerts from CGM profiles is a critical issue
because of data noise and should be matter of in depth investigation.
The in silico environment, although realistic and widely used to preliminarily test new
algorithms, has some limitations. For example, diurnal variation of model parameters is
not yet taken into account in the model due to lack of quantitative knowledge of this
phenomena. Moreover, there is no model for the various factors that influence glycemia
in real life, as, for example, stress and illness. These issues have been partially dealt
with by simulating a large number of patients (50 synthetic subjects) for a short period
of time (54 h), rather than simulating a few patients for longer periods. Furthermore,
it is worth underlying that any bias due to simplifications of the in silico environment
equally affects results observed in Scenario 2 (CGM-based alert) as well as in Scenario 3
(prediction-based alert). Thus, the relative difference between the results obtained in the
two scenarios would probably not change significantly.
To complete the analysis of the effective clinical usefulness of the use of prediction
for generation of hypoglycemic alerts, our promising results obtained in silico should
be confirmed in vivo. To this purpose, a clinical trial should start in the first quarter
of 2014, in collaboration with Dexcom Inc (San Diego, CA). The protocol design of
the study was optimized using both results obtained retrospectively, on data collected
by Dexcom during Pivotal trials, and results obtained in simulation, on a population
of virtual subjects whose parameters had been optimized to reproduce closely glucose
dynamics observed on the real patients participating to the pivotal trials [136]. 30 to 40
T1D should be enrolled in the trial, for a duration of 8 weeks and the primary outcome
should be a significant reduction in the number of severe hypoglycemic events when alerts
and relative therapy are triggered on the basis of the predicted glucose profile, obtained
with the strategy jointly developed by our research group and Dexcom [137].
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8
Conclusions
In diabetes management, tight monitoring of glucose concentration is essential for limiting
short and long term complications due to hypo- and hyperglycemic events. Short-time
prediction (30-60 min ahead in time) of glucose concentration might improve T1D therapy
by allowing the patient to tune the therapy on the basis of future, instead of current,
glycemia, possibly avoiding, or at least mitigating, critical events. Accurate prediction of
glucose concentration, in every glycemic range, is important in closed loop applications
based on model predictive control, and also in open loop therapy, to allow diabetic subjects
to anticipate therapeutic decisions, based on expected future glycemia and planned daily
life activities. Not least important is the use of prediction in open loop therapy for
generating preventive alerts, when glucose concentration is expected to cross pre-set
risky thresholds in the short term, potentially allowing diabetics to avoid the majority
of critical hypo and hyperglycemic events. Most of the prediction methods proposed
in the literature in the last decade are based on models that use only CGM history as
input. Recently, various attempts of using also insulin, CHO and PA information have
been proposed, mainly by incorporating these additional inputs in simple linear ARX
and ARMAX models. However, exploiting these supplementary sources of information
is not easy since their effects are affected by physiological delays and inter- and intra-
individual variability is high. NN based models appear to be suitable candidates to
forecast future glucose concentration. Indeed NNs are intrinsically non-linear, can learn
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complex functions and extract, relatively easily, relevant information from input signals
with different characteristics and nature. Despite these appealing features, NNs have
been scarcely utilized, so far, for prediction of glucose concentration.
Starting from the observation that feedforward NN described in the literature [66,77]
did not significantly outperform linear time series models, we firstly proposed a paradigm
composed by a feedforward NN in parallel with a linear model [102] so that the nonlinear
behaviour of the NN could be better exploited. Inputs of this model are signals derived
from glucose concentration, measure by the CGM sensor and signals derived from
information on timing and quantity of ingested CHO, simulated with a physiological
model of oral glucose absorption. The proposed architecture outperformed the NN
of [66] and the AR model of [59] both on simulated and real data. Moreover, we proved
its robustness against errors in the estimation of timing and CHO content of meals.
Afterwards, we demonstrated, using the same input signals, that a different architecture,
i.e. a jump NN, which is able to separately deal with linear and nonlinear relationships
between inputs and output, had performance statistically comparable with the previously
proposed model, despite its simpler structure [107]. This is a major novelty, since,
to the best of our knowledge, jump NNs had never been proposed before for glucose
concentration prediction. In addition, the simplicity of the chosen structure, once trained,
renders it potentially implementable also in a CGM device, where computational power
is limited and shared between several algorithms. Finally, we incorporated among the
inputs of the jump NN a signal derived from information on timing and quantity of
injected insulin boluses, preprocessed with a physiological model of insulin absorption
and sensitivity. Our analysis assessed, comparing NN models with different combination
of input signals, how much prediction was effectively improved when information on
CHO ingestion and/ or insulin injection was added to information on CGM and included
among the NN inputs. We showed that exogenous inputs relative to CHO and insulin
significantly improve prediction in the 2 h time window that follows the ingestion of CHO
and the injection of insulin, while their benefits are no visible, for example, during night
periods [109, 110]. This fact, previously unnoticed in the glucose prediction literature,
could be justified, physiologically, by the fact that CHO and insulin effects are particularly
evident for about 2 h and become scarcely relevant after a longer time interval.
A future development of our prediction paradigm could be the inclusion, among
the inputs of the NN, of signals relative to PA and energy expenditure. Indeed we
demonstrated [117] that even mild PA is significantly correlated, in the short-term, with
changes in glucose dynamics. These results suggest that the NN ability of accurately
predicting glucose time course would benefit by the inclusion of this additional source
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of information. Even if, so far, some attempts of exploiting signals related to PA for
prediction of glucose concentration have been made, this field is still rather unexplored
and there are no widely accepted models of PA effects on glucose time course. How to
adequately preprocess and utilize this information is a challenging issue that is worth
future in depth investigation.
One of the natural applications of short-time prediction is the generation of preventive
hypoglycemic alerts. In the literature, some contributions assessed, on real data of
hospitalized subjects, the reduction and mitigation of induced hypoglycemia obtained
when therapeutic actions were triggered on the basis of prediction of glucose concentration.
However, these analysis could not be exhaustive, since, on real data, once an action is
taken, there is no possibility of knowing what would have happened if different decisions
were made. To overcome these limitations we used the in silico environment of [73],
which is widely accepted to preliminarily test new algorithms, given its high realism. In
particular, we quantified how much hypoglycemia could be reduced if hypoglycemic alerts
and relative therapy (ingestion of CHO) were triggered based on prediction, instead of
CGM [130]. Results showed a significant reduction of hypoglycemia and an improvement
of the management of glucose concentration, when alerts were generated based on
prediction. Furthermore, we demonstrated that hypoglycemia was reduced even if the
T1D virtual subject responded with a certain delay to the alerts, or even ignored some
of them. Such a comprehensive analysis and comparison between alternative scenarios
had never been performed and, to confirm our promising and encouraging results in vivo,
an extensive clinical study should start in the first quarter of 2014, in collaboration with
Dexcom Inc. (San Diego, CA). Indeed our research group optimized, using simulation and
analysing retrospectively real data, the design and protocol of a clinical trial [136]. The
aim of the study is demonstrating, in vivo, that prediction based [137] hypoglycemic alerts,
incorporated in a research prototype of the Dexcom G4 PLATINUM CGM sensor [31],
allow a significant reduction of the natural occurrence of hypoglycemia in every-day life
conditions.
Further possible future works include the investigation of specifically formulated
objective functions that quantifies the goodness of glucose concentration prediction,
e.g. [100], for optimizing the NN weights and the design of the NN for predicting
specifically hypo- and hyperglycemia, instead of the entire range of glucose values,
as done e.g. in [65] with different models, transforming the prediction problem in a
classification issue.
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A
Glucose-insulin meal model
The mathematical model providing the base for the in silico subjects of the simulation
environment is the glucose-insulin meal model of Dalla Man et al. [103,104,138], whose
equations are reported in this Appendix. In particular, the model has 26 free parameters,
whose joint distribution has been computed from real individuals’ data. The simulator
allows generating a large cohort of virtual “subjects”, characterized by key metabolic
parameters spanning the variability observed in the population of people with T1D.
The model was shown to represent adequate glucose fluctuations in T1D observed
during meal challenges and was thus accepted by FDA as a substitute to animal trials
in preclinical testing of closed-loop control strategies [73, 84]. For these reasons, the
simulator has been widely used to preliminarily test new algorithms, given its sufficient
realism, e.g. [124,139–141].
A.1 Glucose absorption model
The rate of appearance of glucose in plasma is obtained through the physiological model
of glucose intestinal absorption reported in [103] and graphically shown in Figure A.1.
The model describes the glucose transit through the stomach and intestine by representing
the stomach with two compartments, (one for solid and one for triturated phase), while
the gut is described with a single compartment. The differential equations system that
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Figure A.1: Glucose absorption model, which assumes two compartments for the stomach
(one for the liquid and one for the solid phase) a gastric empting rate (kempt) dependent on
the total amount of glucose in the stomach (qsto), a single compartment for the intestine (qgut)
and a constant rate of intestinal absorption (kabs).
characterizes the three compartment model is
qsto(t) = qsto1(t) + qsto2(t) qsto(0) = 0;
q˙sto1(t) = −k21 qsto1(t) +D δ(t) qsto1(0) = 0;
q˙sto2(t) = −kempt(qsto) qsto2(t) + k21 qsto1(t) qsto2(0) = 0;
q˙gut(t) = −kabs qgut(t) + kempt(qsto) qsto2(t) qgut(0) = 0;
RaG(t) =
f kabs qgut(t)
mBW
RaG(0) = 0.
(A.1)
where qsto1 [mg] and qsto2 [mg] represent the amount of CHO in the stomach (solid and
liquid phase), D [mg] is the amount of ingested CHO, qgut [mg] is the CHO mass in
the intestine, k21 [min
-1] represents the rate of grinding, kempt(qsto) [min
-1] is the rate
constant of gastric emptying, which is a nonlinear function of qsto, as reported in equation
(A.2), kabs [min
-1] is the rate constant of intestinal absorption, f the fraction of the
intestinal flux that appears in plasma, mBW the body weight, RaG [mg/kg/min] is the
rate of appearance of glucose in plasma.
kempt(qsto) = kmin + k{tanh[α(qsto − bD)]− tanh[β(qsto − cD)] + 2} (A.2)
where
k =
kmax − kmin
2
(A.3)
α =
5
2D(1− b) (A.4)
β =
5
2Dc
(A.5)
with kmax, kmin, b and c parameters.
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In Chapters 3, 4 and 5 RaG was simulated using the population parameter values
estimated in [104]. The model was validated in [103], and parameters were estimated with
coefficients of variation ranging from 6% to 46%. Parameters kgri=0.0558 min
−1 and
c=0.00236 mg−1 were fixed, while the remaining parameters were estimated: kmax=0.0558
min-1, kmin=0.008 min
−1, kabs=0.057 min−1, f=0.9 (adim) and b=0.82 (adim).
A.2 Insulin absorption model
The physiological model used for describing subcutaneous insulin kinetics is described
in [138] and graphically shown in Figure A.2. Mathematically, it is represented by the
Figure A.2: Insulin absorption model, which assumes a compartment for nonmonomeric
insulin and a compartment for monomeric insulin.
following system of equations:
i˙sc1(t) = −(kd + ka1)isc1(t) + IIR(t) isc1(0) = isc1ss;
i˙sc2(t) = kdisc1(t)− ka2isc2(t) isc2(0) = isc2ss;
RaI(t) = ka1isc1(t) + ka2isc2(t) RaI(0) = 0.
(A.6)
where isc1 is the amount of nonmonomeric insulin in the subcutaneous space, isc2 is the
amount of monomeric insulin in the subcutaneous space, IIR(t) (pmol/kg/min) is the
exogenous insulin infusion rate, kd (min
−1) is the rate constant of insulin dissociation, and
ka1 and ka2 are the rate constants of non-monomeric and monomeric insulin absorption,
respectively. For what concerns parameters value, in analogy with the approach adopted
with the glucose absorption model we used the population parameters estimated in [104],
whose values are: kd=0.0164 min
−1, ka1=0.0018 min−1, ka2 = 0.0182 min−1.
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B
Real database (from the DIAdvisor project)
The DIAdvisor was a large-scale integrating project, running in the period 2008-2012,
aiming at the development of a device which uses CGM and vital signs to optimize T1D
therapy, funded under the Framework Program 7 (FP7) by the European Commission.
Data used in this thesis were collected in two different data acquisition sessions of the
DIAdvisor project. Notably, two different CGM sensors were used: during the first data
acquisition session, (the DAQ trial), the FreeStyle Navigator device was used, which has
a sampling time of 1 min. During the following data acquisition sessions, the Dexcom
SEVEN PLUS sensor was utilized, whose sampling time is equal to 5 min. The reasons
for adopting a different CGM device were the greater accuracy of the SEVEN PLUS,
compared to the FreeStyle Navigator, the easier procedure for downloading data and
last but not least important, the fact that the majority of commercial CGM devices
had implemented a sampling time of 5 min. This was relevant, since the purpose of the
DIAdvisor platform was to be independent from a particular device, thus developing it
on CGM data measured every 5 min made it, potentially, more portable.
In total 60 patients, (male or female), diagnosed with T1D or T2D were enrolled into
the study. Inclusion criteria comprised being between 18 and 70 years old, having been
diagnosed with T1D or T2D (according to WHO criteria [142]) for at least one year prior
to study entry and following a basal-bolus insulin therapy using an external pump or
multiple-daily injections. A standard GMS mobile phone with camera was used by the
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study participants for capturing pictures of all the food and beverages they ingested. For
each picture, the timing and the estimated amount of CHO were extracted and added to
the data relative to meals. Information on insulin therapy (timing, dose and type) was
manually recorded by the patients.
C
Assessment metrics
The quality of prediction obtained with the proposed algorithms is quantitatively assessed
by computing three metrics commonly used in the glucose prediction literature. As
discussed in [79], using different metrics is necessary for a comprehensive evaluation of
glucose prediction performance. Let us define y(t) measured signal, yˆ(t|t− T ) predicted
signal relative to time t, obtained using data available until time t− T , N length of y(t),
Ts sampling time of y(t), PH Prediction Horizon in min, T = PH/Ts, i.e. T prediction
horizon in number of steps. The indexes we use are:
• The RMSE (mg/dL) between the predicted time-series and the original glucose
time-series measured by the CGM sensor, calculated as
RMSE =
√√√√( 1
N
N∑
k=1
(yˆ(k|k − T )− y(k))2
)
(C.1)
• The TG
TG = PH− delay (C.2)
and the normalized TG
TGnorm =
PH− delay
PH
(C.3)
124 Assessment metrics
with the delay quantified as the temporal shift that minimizes the distance between
y(t) and yˆ(t|t− T )
delay = arg min
k∈[0, T ]
{
1
N − T
N−T∑
i=1
(yˆ(i+ k|i+ k − T )− y(i))2
}
Ts (C.4)
• The ESOD (i.e. the sum of the squared second order differences) of the predicted
time series, normalized by the ESOD of the target time series [59]
ESODnorm =
ESOD(yˆ)
ESOD(y)
(C.5)
where
ESOD(yˆ) =
1
T 4s
N∑
k=3
(yˆ(k|k − T )− 2yˆ(k − 1|k − 1− T ) + yˆ(k − 2|k − 2− T ))2
(C.6)
ESOD(y) =
1
T 4s
N∑
k=3
(y(k)− 2y(k − 1) + y(k − 2))2 (C.7)
The RMSE is a widely used metric in the CGM literature, e.g. [59, 60, 66, 67, 143],
however it has some limitations: it does not penalize spurious oscillations around the
target and it is unable to penalize differently under- and over- estimation of the target.
TG is one of the most important indexes from a practical perspective, since it
quantifies the average anticipation with which events could be, in theory, detected and
can have, thus, a clinical value. The higher the TG and the closer to 1 the TGnorm, the
better the prediction, since the patient could decide therapeutic actions ahead in time
and, likely, avoid critical events. Notably, the definition of the delay given in equation
(C.4) is consistent with those of [58,105].
ESODnorm reflects how (possibly spurious) oscillations are amplified in the predicted
time series. Thus it roughly quantifies the risk of generating false hypo/hyper alerts. The
closer to 1, the better the predicted time series.
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